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Abstract 
 
S. pneumoniae is a genetically diverse species which complicates attempts to associate a 
given clonal lineage or serotype with propensity to cause disease; as well as in the 
identification of specific molecular determinants of distinct virulence phenotypes. 
Formation of biofilms is an important step in pneumococcal pathogenesis, as they serve 
as reservoirs of infection and organisms within biofilms are resistant to antimicrobials 
and host immune defences.  
The aim of this work was to extend our understanding of the correlation between 
biofilm formation in clinical isolates of S. pneumoniae and factors that could influence 
their invasive disease potential, namely isolate source, pH and Fe(III) supplementation. 
Firstly, the formation of biofilms of clinical isolates belonging to serotypes/groups 3, 6, 9, 
14 and 19 isolated from blood and ear revealed marked inconsistencies in biofilm 
formation capacity. However, upon MLST typing distinct biofilm phenotypes were 
identified between blood and ear isolates belonging to the same serotype/group and ST 
type. Further in vivo investigations on blood and ear isolates of serotype 3 ST180, ST232, 
ST233 and serotype 14 ST15 revealed distinct pathogenic profiles, which clearly 
demonstrated the adaptation of the strains to the host niches from which they were 
isolated. The in vivo co-infection experiment of ST15 isolates further suggested the 
possibilities of induction of distinct host immune responses, or secretion of a virulence 
factor by the blood isolate, that prolonged survival of the ear isolate, which would 
otherwise have been cleared from the lung when challenged in isolation. Investigation of 
early immune response in the lungs of mice challenged by blood and ear isolates revealed 
strain-specific differences in gene expression and provided insight into how the immune 
response may vary from strain to strain, resulting in distinct patterns of infection from 
two closely related strains. 
The observed consistent differences suggested the existence of fundamental 
genomic, methylomic, transcriptomic, proteomic or metabolomic differences between 
clonally-related blood and ear isolates, which allows them to adapt to, and survive in, 
distinct host niches. Nevertheless, transcriptomic analysis of the in vitro grown ST180, 
ST232 and ST15 strains using RNA-Sequencing did not identify any genes that were 
ix 
 
consistently differentially expressed between the blood and ear isolates of a given ST.    
This suggests that there may be differences in expression patterns of key virulence-related 
genes between bacteria growing in different in vivo niches, as well as between in vivo 
niches and the in vitro cultures.  
The findings of this study constitute a significant paradigm shift, in that we have 
found multiple examples of clonally-related strains that consistently and reproducibly 
exhibit distinct virulence phenotypes in mice that directly correlate with the original site 
of isolation from human patients (in this case, ear vs blood). Thus, strains within a clonal 
lineage can exhibit stable niche adaptation. Moreover, our data suggest differential 
capacity to trigger early host innate immune responses may underpin this adaptation and 
influence the course of disease. These findings provide a robust platform for future 
studies aimed at identifying critical bacterial and host determinants of pneumococcal 
virulence phenotype. 
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Chapter 1:  Introduction  
1.1 Burden of pneumococcal disease 
 Streptococcus pneumoniae (the pneumococcus) is a Gram positive, aerotolerant, 
facultatively anaerobic bacterium belonging to the pneumoniae-mitis-pseudopneumoniae 
cluster of the Streptococcus genus, along with S. mitis, S. oralis, S. infantis and S. 
pseudopneumoniae (Kilian et al., 2008). Diseases caused by S. pneumoniae include 
localized infections such as otitis media (OM), sinusitis and focal pneumonia, as well 
invasive diseases such as bacteraemic pneumonia, septicemia and meningitis. Individuals 
at increased risk of pneumococcal disease include children with immature immune 
responses, adults with immunodeficiency disorders (particularly HIV infection) and 
elderly people with waning immunity and other co-morbidities such as heart and lung 
problems (Naucler et al., 2013; O'Brien et al., 2009). 
 Despite significant reductions in child mortality between 2000 and 2012, the 
status of S. pneumoniae as the world’s leading bacterial pathogen remains unchallenged. 
A 2007 World Health Organization (WHO) report estimated 1.6 million deaths occur 
annually due to pneumococcal disease. In 2000, global estimates of pneumococcal deaths 
were 826,000 in children between 1-59 months of age, of which 735,000 were HIV-
negative (O'Brien et al., 2009). In 2008, WHO reported approximately 500,000 
pneumococcus-related deaths of children in this age group. From 2010-2011, 120 million 
episodes of pneumococcal pneumonia were estimated to have occurred, of which 14 
million cases progressed to severe disease (Walker et al., 2013). Of these, 1.3 million 
fatalities were reported, with 1 million deaths occurring in children under 2 years old 
(Walker et al., 2013). In a study on global burden of pneumococcal diseases by O’Brien 
et al, of the 735,000 deaths occuring in HIV-negative children, 61%  occurred in ten 
African and Asian countries (India 27%, China 12%, Nigeria 5%, Pakistan 5%, 
Bangladesh 4%, Indonesia 3%, Ethiopia 3%, Congo 3%, Kenya 2%, and the Philippines 
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2%). Out of the estimated 14·5 million cases of pneumococcal disease, 95·6% were due 
to pneumonia, 3·7% non-pneumonia, non-meningitis invasive pneumococcal syndromes, 
and 0·7% meningitis (O’ Brien et al., 2009). In Australia, indigenous Aborigines show 
one of the highest invasive pneumococcal disease (IPD) burdens in the world (Torzillo et 
al., 2007). 
 The World Health Organization (WHO) reported that the majority of deaths due 
to pneumococcal disease that occur in developing countries of Africa and South East 
Asia, is due to the limited availability of pneumococcal conjugate vaccines. While 
pneumococcal diseases are mainly treated by antibiotics in these regions where vaccines 
are not readily available, the flagrant use of antibiotics has resulted in the emergence of 
antibiotic resistant strains which further complicates treatment to pneumococcal diseases; 
(Rutebemberwa et al., 2015; Kim et al., 2012). As Africa and South East Asia also 
present the highest HIV incidences in the world, immunodeficiency is a further 
significant contributing factor to fatalities in these regions. Other related factors include 
poor hygiene, overcrowding and inadequate housing, which facilitate transmission of 
pneumococci. S. pneumoniae is also one of the major pathogens implicated in OM, a non-
invasive but significant disease associated with hearing loss, social disadvantage and high 
medical costs. In the US, the total costs for OM treatment exceed USD 5 billion per year 
(Klein, 2000). Closer to home, the prevalence and severity of OM is highest amongst 
Australian Indigenous children. A study by Morris et al reported 91% of 914 participating 
Indigenous children were found to have OM (Morris et al., 2005). OM in Indigenous 
Australians can be almost universal in some communities (Leach et al., 1994). 
1.2 Pneumococcal colonisation and disease 
A paradoxical feature of S. pneumoniae is that despite its ability to cause life-
threatening diseases, it is also a common commensal inhabitant of the human 
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nasopharynx. Indeed, humans are the primary reservoir for pneumococci, which resides 
particularly in the upper respiratory tract of small children. In general, global 
pneumococcal  carriage was estimated to occur in 25 to 40% of healthy children and 10 to 
15% adults at any given time without any symptoms of disease (Crook et al., 2004). 
 The peak incidence of colonisation in the nasopharynx of children occurs around 
the age of 2-3 years, followed by a decrease where stable prevalence can be observed 
after the age of 10 years (reviewed by Bogaert et al. (2004)). Various other potentially 
pathogenic bacterial species also co-reside in the human nasopharynx, such as Moraxella 
catarrhalis and Haemophilus influenzae, and multiple serotypes/strains of S. pneumoniae 
may colonize the nasopharynx simultaneously (Shiri et al., 2013; Xu & Pichichero, 
2014). Spread or transmission of pneumococci to a new host primarily occurs via 
contaminated respiratory secretions (droplet infection), usually among close family 
contacts. Crowding that frequently occurs in child day care centers, hospitals and prisons 
facilitates spread (Hoge et al., 1994; Mandigers et al., 1994; Pessoa et al., 2013). There 
are three possible outcomes of pneumococcal carriage: elimination of the pneumococci 
by host immune responses soon after acquisition, asymptomatic persistence for weeks or 
months in the nasopharynx, or invasion of the pneumococci into deeper tissues and 
progression to disease. Longitudinal studies (Weiser, 2010) have shown that although 
nasopharyngeal colonisation by itself is insufficient for progression to invasive disease, it 
is a necessary first step in pneumococcal pathogenesis.  
 Adherence of pneumococci to the epithelial cells lining the upper respiratory tract 
is the first important step for colonisation. The interactions between bacteria and host 
occur by specific binding of ligands (e.g. adhesins) to receptors, for example some 
members of the choline binding protein family of surface proteins (CBPs) adhere 
specifically to host cell glycoconjugates (Rosenow et al., 1997). Colonisation is also 
facilitated by non-specific physico-chemical interactions (e.g. hydrophobic or surface 
charge interactions) between the bacterial cell and host mucosa (Swiatlo et al., 2002). 
Several other factors reported to be important for colonisation include phosphorylcholine 
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(choP) present in the pneumococcal cell wall, which has affinity for the platelet activating 
factor receptor (rPAF) (Cundell et al., 1995), while neuraminidase (NanA), β-
galactosidase (BgaA) and β N-acetylglucosaminidase (SrtH) may unmask adhesin 
receptors by cleaving terminal sugars from human cell surface glycoconjugates (Kadioglu 
et al., 2008). The capacity of pneumococci to switch between colony opacity phenotypes 
(“opaque” or “transparent”) also impacts on nasopharyngeal colonisation (discussed 
further in 1.2.2.2) (Weiser et al., 1994). 
 Intraspecies competition between pneumococci has also been suggested to be an 
important driving factor in pneumococcal colonisation. Dawid et al. (2007) reported that 
the bacteriocins encoded by blpM and blpN genes of a type 6A strain inhibited the growth 
of a type 4 strain in vitro. Furthermore, when blpMN mutants were constructed in a type 
19 background and used to challenge mice intranasally along with a type 4 strain or its 
wild type parent, the mutant strain was not able to compete with the parent type 19 strain 
or the type 4 strain (Dawid et al., 2009).  
 Another important factor modulating bacterial adherence to host cells is the 
pneumoccocal capsule. Capsule expression repels sialic acid contained in the mucus  
allowing access to epithelial surfaces (Nelson et al., 2007). This is due to the net negative 
charge of the capsular polysaccharides (CPS) produced by the vast majority 
pneumococcal serotypes. They also demonstrated the important role of capsule in 
enhancing colonisation in vivo by showing that unencapsulated mutants were less able to 
stably colonize the mouse nasopharynx compared to the encapsulated strains (Nelson et 
al., 2007). Levels of pneumococcal capsular expression was also shown to be 
differentially regulated in the first stages of pneumococcal infections. Using a lysine-
ruthenium-red fixation procedure in conjunction with electron microscopy, 
Hammerschmidt et al visually demonstrated total loss of capsular material in 
pneumococci when they were in close proximity with A549 cells (type II pneumocytes) 
and HEp-2 epithelial cells and in the process of invasion. This study also went on to show 
a significant loss of capsular material in invasive pneumococci recovered from the host 
cells compared to their wild type (WT) counterparts; the occurrence of which possibly 
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further promotes adherence by exposure of other virulence factors located beneath the 
capsule layer  (Hammerschmidt et al., 2005).  
 
1.3 Transition from asymptomatic colonisation to disease   
 The spectrum of diseases caused by the pneumococcus reflects its ability to 
survive in, and adapt to, distinct ecological niches within the human host (Weiser, 2010). 
Translocation of pneumococci from the nasopharynx to other tissues may follow various 
routes, and may result in distinct pathogenic outcomes. For example, spread that occurs 
from the nasopharynx to the middle ear cavity via the Eustachian tubes results in OM, 
while aspiration into the lungs may cause pneumonia (Bogaert et al., 2004). Pneumococci 
can also spread from the lungs via the pleural cavity into the blood, resulting in 
septicemia. In some instances the pneumococcus then crosses the blood brain barrier to 
cause meningitis; alternatively it can invade the brain directly from the nasopharynx, via 
olfactory neurons (van Ginkel et al., 2004). The transition from asymptomatic carriage to 
invasive or non-invasive disease has been a focal point of research for many decades. 
Studies have so far indicated that the transition event is multifactorial, involving a 
complex interplay of genetic and environmental elements of both bacterium and host. 
Although still poorly understood, some molecular mechanisms behind pneumococcal 
disease progression have been identified. These are briefly described below. 
1.4 Mechanisms of pneumococcal colonisation and disease  
1.4.1  Virulence factors  
 Virulence factors are molecules expressed by pathogenic bacteria that facilitate 
their ability to cause disease. S. pneumoniae produces a myriad of virulence factors, and 
for many of these their role in disease is only partly understood. Generally, pneumococcal 
virulence factors facilitate evasion of host defense mechanisms to allow for persistence 
and invasion of host tissues. Brief descriptions of some of the more important 
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pneumococcal virulence factors which have been identified as potential vaccine 
candidates (Kadioglu et al., 2008) are provided below. 
 
 
1.4.1.1  Capsular Polysaccharides (CPS) 
 The capsule is arguably the most important virulence factor of the pneumococcus. 
Initially reduced during colonisation, capsule expression significantly increases during 
invasive disease (Hammerschmidt et al., 2005). The capsule facilitates evasion of 
phagocytosis and complement activity (Hyams et al., 2010). It prevents complement 
factor C3b and the Fc portion of antibodies bound to deeper cell wall structures from 
interacting with surface receptors on phagocytic cells, as well as inhibiting complement-
mediated adaptive immunity. CPS also has negative impact on the occurrence of 
spontaneous autolysis in stationary phase in an autolysin dependent manner (Fernebro et 
al., 2004). This study also highlighted the role of CPS in reducing vancomycin- and 
penicillin-induced lysis in encapsulated strains. 
 Capsular serotype is known to influence disease type and severity, and the distinct 
CPS structures differ in anti-phagocytic efficacy (Kadioglu et al., 2008). Although > 93 
serotypes have been described, a relatively small subset of types accounts for the majority 
of disease. Certain serotypes (e.g. types 1, 4, 5, 7F and 14) have been found to have a 
high invasive capacity, as they are rarely isolated from asymptomatic carriers, but are 
frequent causes of invasive disease. Conversely, certain other serotypes (e.g. types 3, 6A 
and 19F) are more commonly isolated from carriers although they are also able to cause 
invasive disease (Sandgren et al., 2004). Various factors influence the distribution of 
serotypes among disease-causing pneumococci, including age and immune status of the 
host, type of disease and geographical region. The incidence of pneumococcal disease is 
greatest in the young, the elderly, the poor and those living in institutional settings 
(Levine et al., 1999; Pastor et al., 1998; Takala et al., 1995). Since children are more 
commonly colonized with pneumococci than adults, exposure to young children appears 
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to increase the risk of adults acquiring pneumococcal infection. A diagram showing 
cellular location of pneumococcal capsule is as depicted in Figure 1.1. 
 
 
1.4.1.2  Pneumolysin 
 One of the earliest described protein virulence factors, pneumolysin (Ply) is a 53-
kDa multifunctional cytotoxin that form pores in cells leading to tissue damage and cell 
death. It is a member of the cholesterol-dependent cytolysin (CDC) family of bacterial 
toxins (Gonzalez et al., 2008), but it initially binds to target cell surfaces via glycan 
(particularly sialyl-LewisX) receptors, followed by interaction with membrane 
cholesterol, enabling the toxin to oligomerize and form membrane pores leading to lysis 
(Shewell et al., 2014). The role of pneumolysin (Ply) in pathogenesis has been examined 
in many studies, which report that ply deficient pneumococci cause significantly reduced 
injury in the lungs compared to their isogenic wild type strains (Rubins et al., 1995), 
increased survival times (Berry et al., 1989), reduced bacterial recovery in the 
nasopharynx (Kadioglu et al., 2008) and lungs (Rubins et al., 1995), as well as 
significantly delayed bacteremia and lung damage (Canvin et al., 1995). More recently it 
was demonstrated that circulating Ply is a potent inducer of cardiac tissue damage 
(Alhamdi et al., 2015). A strong activator of the classic complement pathway (Mitchell et 
al., 1991; Paton et al., 1984; Yuste et al., 2010), Ply also acts as a double-edged sword in 
the activation of immune responses, where it is involved in the bacterial activation of 
macrophage apoptosis (Bewley et al., 2014). It also stimulates the production of tumor 
necrosis factor and interleukins by activating phagocytes, thereby facilitating bacterial 
clearance (Houldsworth et al., 1994). A diagram showing cellular location of 
pneumolysin is depicted in Figure 1.1. 
 
1.4.1.3  Pneumococcal surface protein A (PspA) 
 PspA is a member of the choline binding protein (CBP) family of surface proteins, 
which are non-covalently attached to phosphoryl choline moieties on the cell wall 
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teichoic acid and membrane lipoteichoic acid via a binding domain comprising roughly 
ten copies of a conserved 20 amino acid repeat sequence (Gosink et al., 2000). There are 
roughly 12 distinct CBPs encoded on the pneumococcal genome with a diverse range of 
functions (Frolet et al., 2010). PspA was one of the first CBPs to be characterized; it is a 
highly immunogenic (Ren et al., 2003) virulence factor that provides protection against 
complement activation (Tu et al., 1999) by preventing the attachment of C3 to the 
pneumococcal cell surface, as well as protecting against apolactoferrin, which is 
bactericidal towards pneumococci (Shaper et al., 2004).  A diagram showing cellular 
location of PspA is depicted in Figure 1.1. 
 
1.4.1.4  Autolysin (LytA) 
 LytA, another CBP family member, is an amidase that breaks down the N-
acetylmuramoyl-L-alanine bonds in the peptidoglycan backbone of S. pneumoniae, 
resulting in autolysis. This releases highly inflammatory cell wall degradation products, 
as well as cell-associated virulence factors such as Ply (Berry et al., 1992; Canvin et al., 
1995; Mosser & Tomasz, 1970). LytA also mediates penicillin-induced lysis (Tomasz & 
Waks, 1975), and along with other CBPs with cell wall hydrolase activity (CbpD and 
LytC), plays an important role in the phenomenon of fratricide, whereby genetically 
competent pneumococci are able to lyse non-competent pneumococci in their immediate 
environment (Eldholm et al., 2009). A diagram showing cellular location of LytA is 
depicted in Figure 1.1. 
 
1.4.1.5  Pneumococcal surface protein C (PspC) 
 PspC (also known as CbpA and SpsA) is another CBP whose functions include 
specifically binding to the complement regulatory protein factor H, contributing to 
protection against complement action and opsonophagocytosis (Dave et al., 2004a; Dave 
et al., 2004b). It also is able to bind to the secretory component of secretory IgA 
(Hammerschmidt et al., 1997) and thereby mediates binding to the polymeric 
immunoglubulin receptor on the surface of respiratory epithelial cells, triggering 
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internalization of pneumococci (Zhang et al., 2000). A separate domain of PspC mediates 
binding to the laminin receptor on endothelial cells, triggering translocation across the 
blood brain barrier to cause meningitis (Orihuela et al., 2009).  A diagram showing 
cellular location of  virulence factor PspC is depicted in Figure 1.1. 
 
1.4.1.6  Pneumococcal surface antigen A (PsaA) 
 PsaA is a lipoprotein tethered to the outer face of the pneumococcal cell 
membrane. Although originally thought to function as an adhesin, it is actually the solute 
binding protein (SBP) component of the highly conserved ABC transport system essential 
for uptake of Mn2+ by S. pneumoniae. Capacity to scavenge Mn2+ is essential for survival 
of the pneumococcus in host tissues, as it is a cofactor for numerous important cellular 
proteins, including Mn-superoxide dismutase, which mediates resistance to oxidative 
killing mechanisms of the host (McAllister et al., 2004; Rajam et al., 2008). A diagram 
showing cellular location of PsaA is depicted in Figure 1.1. 
 
1.4.1.7  Pneumococcal Iron Uptake A (PiuA) and Pneumococcal Iron 
Acquisition A (PiaA) lipoproteins 
 PiuA and PiaA are the solute binding protein (SBP) components of two distinct 
ABC transporters deployed by the pneumococcus to scavenge iron in the host 
environment. The PiaA system is responsible for the transport of hydroxamate 
siderophores such as ferrichrome and ferrioxamine B, whereas the PiuA system is 
responsible for uptake of heme from hemoglobin (Whalan et al., 2006). A diagram 
showing cellular location of PiuA and PiaA is depicted in Figure 1.1. 
 
1.4.1.8  Neuraminidases  
 Pneumococci produce up to three neuraminidases (NanA, NanB and NanC) 
capable of cleaving the terminal sialic acid residues from host glycoconjugates (Taylor, 
1996; Lock et al., 1988; Camara et al., 1994; Berry et al., 1996 ). Neuraminidases 
promote virulence by altering the function of host glycoproteins including immune 
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defense proteins (King et al., 2004) and unmask potential binding receptors for adherence 
(Andersson et al., 1983; Linder et al., 1994; McCullers & Bartmess, 2003). Sialic acid 
released by neuraminidases from host mucosal glycoconjugates can also be taken up and 
metabolized by pneumococci (Burnaugh et al., 2008; King et al., 2006). Of the three 
neuraminidases, NanA is the most highly expressed at the transcriptional level (Manco et 
al., 2006) and is most highly conserved in all strains (King et al., 2005; Pettigrew et al., 
2006). Mutational studies have shown the importance of NanA in nasopharyngeal 
colonisation and middle ear infection in a chinchilla model, where mutation of nanA 
significantly reduced persistence of S. pneumoniae in the tracheal epithelia, as well as 
enhanced clearance from the middle ear of infected chinchillas (Tong et al., 2000; Tong 
et al., 2002). A diagram showing cellular location of neuraminidases is depicted in Figure 
1.1. 
 
1.4.1.9  Hyaluronate lyase (Hyl) 
 Hyaluronate lyase (Hyl) is another sortase-dependent surface protein, which may 
contribute to virulence by breaking down hyaluronan, a ubiquituous host extracellular 
matrix component, potentially enhancing access to host cell surfaces. It also enables the 
pneumococcus to utilize hyaluronan, which is present in the upper respiratory tract, as a 
carbon source (Marion et al., 2012). Mutagenesis of the hyl gene in S. pneumoniae D39 
did not have a significant impact on virulence on its own, but resulted in significant 
additional attenuation of a ply deletion derivative of D39 (Berry & Paton, 2000). A 
diagram showing cellular location of Hyl is  depicted in Figure 1.1. 
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Figure 1.1: Diagram showing cellular location of selected S. pneumoniae virulence 
proteins:   Taken from Kadioglu et al. (2008). 
 
1.4.2 Phase variation  
 In 1994, Weiser and colleagues observed distinct colonial morphologies in 
isolates of S. pneumoniae based on opacity when viewed on a transparent agar surface 
under oblique, transmitted light, referred to as “transparent” and “opaque” (Weiser et al., 
1994). Isolates were able to spontaneously and reversibly switch between these 
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phenotypes at frequencies between 10-3 and 10-6 per generation, depending on the strain.  
Such a phenomenon, termed phase variation, has previously been described in other 
pathogenic bacteria (Swanson, 1982; Weiser et al., 1990). Analyses by Weiser and others 
revealed marked distinctions between the opaque and transparent phenotypes. When 
compared with the opaque variant, electron micrographs of the transparent variant 
showed less well-defined surface structures, cytoplasm separation from the cell and the 
presence of extracellular debris, suggesting that it was more prone to autolysis. The 
transparent variant was also found to show reduced levels of PspA and CPS. Conversely, 
the opaque variants showed decreased teichoic acid (a component of the cell wall) but 
increased amounts of CPS and PspA (Kim & Weiser, 1998; Weiser et al., 1994). By 
sandwich ELISA, the CPS content of the opaque phenotype was up to 5.6-fold higher 
than the transparent variant. Conversely, the teichoic acid content of the transparent strain 
was up to 3.8-fold higher than the opaque phenotype.  
 In vivo studies also revealed distinct differences in virulence phenotype between 
the two variants (Weiser et al., 1994). When equal doses of transparent and opaque 
variants were separately introduced into the nasopharynx of infant rats, the transparent 
variant displayed higher levels of colonisation at all time points (days 1, 3, and 7) 
compared to the opaque variant. By day 7, no opaque colonies were identified from nasal 
washes of animals given the opaque phenotype. Transparent variants were also found to 
show greater adherence to buccal epithelial cells in vitro (Cundell et al., 1995). When the 
two phenotypes of the type 2 strain D39 were compared in an intraperitoneal mouse 
challenge model (which bypassed the nasopharynx), the opaque phenotype showed 
significantly higher mortality rates then their transparent counterparts (Kim & Weiser, 
1998). In an analysis of 304 pneumococcal clinical isolates from cases of invasive disease 
belonging to over 10 serotypes, Serrano et al. (2006) found that 52% of the isolates were 
of the opaque phenotype, while only 26% were transparent. The remaining 22% 
comprised either mixtures of different phenotypes or an intermediate phenotype. This 
study also confirmed the animal model predictions that isolates recovered from human 
13 
 
invasive infections predominantly display the opaque phenotype, but also demonstrated 
that the recovery frequencies of each phase variant was heterogeneous between serotypes 
and further suggested that distinct variant phenotypes may be preferentially expressed by 
some serotypes.  The differential prevalence of the transparent and opaque variants in the 
nasopharynx versus invasive sites highlights the importance of phase variation in 
pneumococcal pathogenesis, as both variants reflect adaptations to distinct host niches 
that the pneumococcus is exposed to during the transition from carriage to disease. 
Increased CPS expression in the opaque variants confers higher resistance to 
complement-mediated opsonophagocytosis, as described in Section 1.4.1.1 above. In 
contrast, transparent variants with higher teichoic acid content are better able to adhere to 
the nasopharyngeal mucosa. Teichoic acid, a major component of the pneumococcal cell 
wall is decorated with phosphorylcholine (choP), which mediates bacterial attachment to 
the receptor for platelet activating factor on respiratory epithelial cells (Kadioglu et al., 
2008).  
 The precise molecular basis for pneumococcal phase variation remains poorly 
understood. Weiser et al. reported that differences in colony opacity were not directly 
attributable to either environmental conditions, expression and type of CPS, or 
differences in the function or expression of the major amidase  lytA (Weiser et al., 1996). 
Repetitive intergenic box elements A and C, which were located immediately 3’ to the 
glpF termination codon, were later identified by Weiser’s group to be important for a 
high frequency of phase switching, but not for the opacity phenotype itself (Saluja & 
Weiser, 1995). Recently it was demonstrated that pneumococcal opacity phenotype was 
influenced by a Type I restriction-modification (RM) system (SpnD39III). Spontaneous 
genetic rearrangements at the SpnD39III locus generate six alternative sequence target 
specificities resulting in distinct genome-wide DNA methylation patterns, as determined 
by single-molecule, real-time (SMRT) methylomics (Manso et al., 2014).  A series of 
mutants that were each locked in one of the six alternative SpnD39III arrangements 
exhibited marked differences in expression of several virulence-associated genes 
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including luxS and the cps operon (encodes CPS biosynthesis). This was associated with 
differences in colony opacity in vitro, as well as virulence in mouse models. However, 
such SpnD39III-locked strains do not exist in nature. Rather, the rate of SpnD39III 
switching in vivo is sufficiently high that pneumococci exist as mixed populations with 
heterologous genomic methylation patterns. In parallel with the observations relating to 
selection for opaque vs. transparent phase variants in one host niche vs. another, changes 
in SpnD39III allele frequencies were observed during the course of experimental 
pneumococcal infection, and between host niches (Manso et al., 2014).  
1.4.3 Host immune responses in colonisation and disease 
 Defense of a eukaryotic host against pathogen invasion is achieved via a 
combination of physico-chemical barriers such as skin or chemical secretions, innate 
immunity which involves the response of a defined population of cells in a non-specific 
manner, and adaptive immunity which is mediated by B- and T- lymphocytes following 
exposure to a specific antigen, and is characterized by immunological memory. Upon 
breaching physical barriers, innate immunity firstly comes into play against the 
pneumococcus by recognition of a variety of pneumococcal surface structures and 
virulence factors, via the host’s pattern recognition receptors (PRRs). PRRs include the 
transmembrane Toll-like receptors (TLRs), the cytosolic NOD-like receptors (NLRs) and 
DNA sensors; these are critical for pneumococcal clearance as they initiate and control a 
range of host defense mechanisms. This includes inflammatory response molecules such 
as TNFα and IL-1β, which mediate migration of immune cells such as macrophages and 
neutrophils to the site of infection and initiate the adaptive immune response (reviewed 
by Opitz et al. (2010)).  The importance of these PRRs has been demonstrated in a 
number of studies in which mutation and genetic defects in various types of TLR resulted 
in increased susceptibility to bacteremia (Currie et al., 2004) and reduced survival in mice 
even after low-dose challenge (Branger et al., 2004). 
 The complement system is critical for immunity against pneumococcal infections, 
as activation of one or more of the 3 major pathways: the classical, alternative and 
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mannan-binding pathways mediates bacterial clearance. The classical complement 
pathway is activated by antibody-mediated opsonisation and is thought to be the most 
important means of host protection against pneumococcal infections. Brown et al., used a 
variety of complement-deficient mice to demonstrate the importance of the classical 
pathway of complement activation, loss of which significantly increased disease severity 
(Brown et al., 2002). The importance of complement mediated immunity is also reflected 
in the vast numbers of factors produced by S. pneumoniae to resist or evade complement 
activity, including CPS, Ply, PspA and CbpA, as discussed above, as well as the surface 
exoglycosidases NanA, BgaA (a beta-galactosidase gene encoding a putative 2,235-
amino-acid protein ) and StrH (a β-N-acetylglucosaminidase  required to process the 
termini of host complex N-linked glycans) (Dalia et al., 2010; Hyams et al., 2010; Yuste 
et al., 2005).  
1.4.4 Associations with viral infections 
 The lethal synergy between influenza A viruses (IVA) and pneumococci was 
identified as early as 1918, with a significant proportion of the 50 million deaths during 
the Spanish influenza pandemic attributable to secondary bacterial infections, 
predominantly with S. pneumoniae (Morens et al., 2008).  Analyses by Shrestha et al. 
(2013) indicated a 100-fold higher risk of pneumococcal pneumonia following influenza 
infection. Given the morbidity and mortality associated with recent major influenza 
outbreaks around the world, as well as 4 pandemics over the last 120 years, much 
attention has been focused on understanding mechanisms of co-pathogenesis between 
respiratory viruses and pneumococci. These studies have revealed a complex and 
multifactorial synergy between both pathogen classes and host. For example, viral-
induced epithelial cell damage brought about by the host immune response (i.e. 
inflammation) allows better access of bacteria to underlying sterile sites. Such damage 
also causes surface sloughing, resulting in exposure of additional host sites for adherence 
of pneumococci, mediated by various virulence factors such as PspA, CbpA and 
pneumococcal serine-rich repeat protein (PsrP). These virulence proteins can bind to the 
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basement membrane or elements of the extracellular matrix such as fibrin, fibrinogen and 
collagen (reviewed by McCullers & Tuomanen (2001)). The production of viral proteins 
such as the influenza virus non-structural protein 1 (NS1) was also found to hamper early 
host immune responses (Hale et al., 2008) allowing easier access of the pneumococci to 
the host. Furthermore, the cleaving of host terminal sialic acid residues by the influenza 
virus increases sialic acid availability for bacterial metabolism, thereby facilitating 
pneumococcal proliferation in the host (Siegel et al., 2014). 
 
1.5 Genomic diversity of S. pneumoniae   
 S. pneumoniae is naturally competent, in that it has the ability to take up genetic 
material from the environment and incorporate it into its chromosome. Such horizontal 
gene transfer (HGT) is the backbone of its genetic diversity (Gogarten & Townsend, 
2005). HGT occurs through interactions and competition between neighboring 
populations of bacteria from the same or other species. Active DNA uptake by the natural 
process of transformation is common in pneumococcal biofilms, facilitated by “fratricide” 
in which genetically competent S. pneumoniae cells are able to take up DNA by the 
induction of cell lysis in non-competent neighboring cells (Hall-Stoodley et al., 2008). 
Hiller et al. (2010) have also reported the generation of genetic diversity by HGT in 
pneumococcal isolates during chronic polyclonal pediatric infection. Novel DNA 
acquisition due to recombination has resulted in a species-level supragenome (pan-
genome) in pneumococci wherein between 46% (Hiller et al., 2007) and 74% (Donati et 
al., 2010) of genes in the genome are conserved in all strains.  
 Genomic diversity of S. pneumoniae is reflected by the 93 distinct CPS serotypes 
recognized to date, superimposed on >5,000 clonal lineages or sequence types (ST) 
distinguished on the basis of multi-locus sequence typing of seven house-keeping genes 
(Enright & Spratt, 1998).  Additional genomic differences also occur within a given 
serotype and ST (Silva et al., 2006). Genetic diversity facilitates host niche adaptation 
strategies and antibiotic resistance, and presumably determines invasive disease potential. 
S. pneumoniae isolates exhibit diverse virulence phenotypes within as well as across 
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capsular serotypes (McAllister et al., 2011). Of the 93 known CPS serotypes, 20 types 
account for roughly 85% of pneumococcal disease, while some STs are more associated 
with invasive disease than others (Sjostrom et al., 2006). Marked serotype-independent 
variation in complement activation, a critical factor mediating bacterial clearance, was 
also observed in genetically distinct S. pneumoniae strains (Hyams et al., 2011), further 
supporting the contribution of genetic diversity towards differences in invasive disease 
potential (Hiller et al., 2010; McAllister et al., 2011). 
 
1.6 Pneumococcal vaccines and serotype replacement 
 In order to combat the serious burden of pneumococcal disease, polyvalent 
vaccines have been developed based on the CPS, either alone or conjugated to protein 
carriers. Purified CPS vaccines were the first to be licensed for general use in about 1980. 
The initial formulation (Pneumovax®) was 14-valent, with coverage expanded to 23 
serotypes a few years later (White, 1988). However these CPS vaccines are T-cell 
independent and were poorly immunogenic in young children – a principal high-risk 
group (Douglas et al., 1983). This prompted development of more immunogenic 
polysaccharide-protein conjugate vaccines, which elicit strong, T-cell dependent antibody 
responses and immunological memory, even in infants. A 7-valent conjugate vaccine 
(PCV7) (Prevnar®, Wyeth), first licensed in 2000, included the seven serotypes known to 
be the most prevalent causes of invasive pneumococcal disease in USA at the time 
(serotypes 4, 6B, 9V, 14,18C, 19F and 23F).  
 The widespread use of the PCV7 vaccine in young children in USA led to a 
significant decrease in nasopharyngeal carriage and invasive pneumococcal disease due 
to the 7 “vaccine types” (VT) in vaccine recipients, as well as a marked herd immunity 
effect in non-recipients, particularly the elderly (Miller et al., 2011). However, it also 
introduced strong selection for the emergence of non-vaccine types (NVT) resulting in 
“serotype replacement” in both carriage and disease. This was unsurprising, as the 
phenomenon of serotype replacement was observed in one of the earliest clinical trials of 
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PCVs conducted in Gambia (Obaro et al., 1996), and has since been observed to varying 
extents in virtually all regions where PCVs have been deployed (Weinberger et al., 2011). 
Serotype replacement can result from two distinct scenarios. Firstly, NVT pneumococci 
already present in a vaccine recipient in low numbers, or in the vaccinated community at 
large at lower frequency, are able to expand in number once competition from more 
“successful” VT strains is eliminated by the PCV. The second, and perhaps more 
concerning scenario involves “capsule switching” whereby one of the more “successful” 
VT strains may acquire a NVT cps locus by genetic recombination with a NVT strain co-
occupying the nasopharynx. The retention of the “successful” genetic background in such 
“vaccine escape mutants” may confer higher virulence, and/or transmissibility and/or 
drug-resistance on a previously “less successful” serotype. 
 Regardless of scenario, increased NVT levels in the nasopharynx increase the 
likelihood of progression to disease, as well as the rate of transmission of NVT 
pneumococci in the community. In a study of Aboriginal people in Western Australia it 
was found that although a significant decrease in IPD incidence in young children and the 
elderly was observed with PCV7, a marked increase in incidence of NVT IPD was also 
observed in young adults (Lehmann et al., 2010). In non-invasive pneumococcal diseases 
such as otitis media, NVT serotype 3 otitis media involving the ST180 complex was 
reported to increase from 3% of total cases in 1999 to 11% in 2002 (McEllistrem et al., 
2005). A 13-valent vaccine (PCV13) covering all serotypes in PCV7 as well as serotypes 
1, 3, 5, 6A, 7F and 19A is now replacing PCV7 in an attempt to address serotype 
replacement (Gaviria-Agudelo et al., 2016).  
1.7 Bacterial biofilms  
 Bacteria had long been assumed to exist principally as individual organisms, 
which adopt a strictly unicellular, independent lifestyle. However, bacteria exhibit an 
alternative mode of growth similar to eukaryotic organisms, as organised communities 
(biofilms) that are either single species, or more commonly, multispecies in nature 
(Costerton, 1999). The occurrence of heterogeneous, sessile bacterial populations, as 
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opposed to independent planktonic organisms, has since been recognized to be a 
predominant feature of bacterial growth in various natural, clinical and industrial 
environments (Costerton et al., 1995). Biofilms, which occur in both bacteria and fungi, 
can be defined as highly structured and intricate microbial populations, which are densely 
aggregated and adhere to various biological or inert surfaces, or each other. Biofilm-
forming bacteria extrude and become embedded in an extracellular matrix comprising 
polysaccharides, DNA and proteins, which is responsible for the cohesion and three 
dimensional structure of biofilms (Costerton et al., 2003; Domenech et al., 2013; 
Moscoso et al., 2009).  
 Bacteria in biofilms engage in activities and respond as single or multispecies 
populations and biofilm formation is an adaptation strategy for survival in hostile 
environments (Hall-Stoodley et al., 2004). Bacterial biofilms have been shown to be 
phenotypically distinct from their homogenous planktonic counterparts with regard to 
growth rate and gene transcription (Costerton et al., 2003; Fux et al., 2003). This 
distinction has been brought about by the exposure to different microenvironments as a 
consequence of living in dense populations. The modified microenvironments involve, 
among other parameters, nutrient limitation, higher cell density and high osmolarity 
conditions. Other significant features of bacterial biofilms include increased resistance to 
desiccation, biocides and radiation, which facilitate persistence in adverse environments 
(Hall-Stoodley & Stoodley, 2002).  
1.7.1 Industrial and environmental significance of biofilms 
 Biofilms were first reported over 70 years ago, when bacteria from sea water were 
observed to grow tenaciously on solid surfaces (Zobell, 1943). Although biofilms may be 
beneficial in applications such as bioremediation of contaminated soil, wastewater 
treatment and microbial leaching for recovery of metals, they are still a major cause of 
concern across a variety of sectors, particularly in industry, medicine and the environment 
(Maukonen et al., 2003; Sihorkar & Vyas 2001).  
 In the dairy industry, biofilm development on equipment leads to contamination 
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and spoilage of milk and other dairy products due to the resistance to cleaning agents and 
disinfectants (Gibson et al., 1999). Metal corrosion has also been shown to occur as a 
result of bacterial biofilms via the catalysis of chemical and biological reactions, leading 
to billions of dollars’ worth of damage annually for the replacement of parts in piping 
systems, etc. Sulphate reducing bacteria (SRB) such as Desulfovibrio gigas have been 
implicated in the corrosion of ferrous metals in various aquatic and terrestrial habitats. 
The key mechanisms of SRB-influenced metal corrosion involve dehydrogenase enzymes 
and the presence of iron sulphide bacteria. 
1.7.2 Clinical significance of biofilms 
 The adaptability of bacteria in biofilms to harsh environments poses significant 
challenges in clinical and hospital settings, particularly their inherent resistance to 
antimicrobial agents, and as well as their capacity to evade host immune defense 
mechanisms. Biofilms act as infection reservoirs (Fux et al., 2003) and facilitate 
colonisation of new niches by various dispersal mechanisms (Hall-Stoodley & Stoodley 
2005; Mai-Prochnow et al., 2008). According to estimates by the Centers for Disease 
Control and Prevention (Costerton et al., 1999), approximately 65% of all human 
bacterial infections involve biofilm growth by pathogens, including Pseudomonas sp, 
Haemophilus sp, staphylococci and streptococci. Clinical diagnosis of biofilm infections 
is complicated by the replicative inactivity of bacteria within biofilms, which may delay 
or inhibit growth in diagnostic cultures. Biofilms are also the preferred bacterial 
phenotype adopted for chronic persistence (Ehrlich et al., 2002). They facilitate the 
growth and spread of microorganisms by providing a stable protective environment for 
persistence (Post et al., 2004). 
 The use of antibiotics is currently the mainstay of treatment for bacterial diseases, 
especially for the management of acute infections. Single or combinatorial antibiotic 
therapy has been found to be effective against many pathogenic bacteria such as P. 
aeruginosa and S. pneumoniae, but resistance is not uncommon. Generally the clearance 
of bacteria by antibiotics is achieved more efficiently when the bacteria are in planktonic 
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form and exponentially growing. Biofilm infections are a bane to resolve, as 
combinations of increased doses and prolonged courses of antibiotics are usually required 
to eradicate them. Several hypotheses have been postulated to explain enhanced 
antimicrobial resistance in biofilms. Biofilms are sessile communities and the bacteria 
therein exhibit stationary phase characteristics (Anderl et al., 2003; Xu et al., 2001) with 
MBC (minimal bactericidal concentration) values three to four logs higher than those of 
exponentially growing planktonic cells (Anderl et al., 2000; Ceri et al., 1999). Given the 
nature of biofilms as clusters of bacteria embedded in extracellular matrix, it has been 
hypothesized that antibiotic resistance in biofilms is directly attributable to the restricted 
penetration of these agents. In P. aeruginosa biofilms, penetration of positively charged 
aminoglycosides was significantly hindered by binding of these antibiotics to the 
negatively charged matrix polymers (Walters et al., 2003). The production of 
extracellular slime in coagulase-negative staphylococci was also observed to reduce 
glycopeptide activity even in planktonic cultures (Konig et al., 2001; Souli & 
Giamarellou 1998).  
 Starvation-induced stationary phase in biofilm bacteria is another contributor to 
resistance. Due to the high number of cells in the population, bacteria in biofilms are 
constantly exposed to nutrient limitation, which along with waste product accumulation, 
may result in dormant metabolic and reproductive activity in biofilm bacteria. Nutritional 
starvation has been documented in deep layers of endocarditis vegetations by means of 
radiolabeled amino acids (Durack & Beeson, 1972). Antimicrobial action has been found 
to be more effective against exponentially growing cells as opposed to those in the 
stationary phase. Indeed for β-lactams such as penicillin and ampicillin, cell growth is a 
prerequisite for effective bactericidal action (Eng et al., 1991). When mechanically 
dispersed from biofilms and transferred to fresh medium (Williams et al., 1997), bacteria 
will then regain nutrients initially accessible only to bacteria at surface layers and thus 
will also become antibiotic susceptible due to their switch from stationary to exponential 
growth phase. This observation shows that antibiotic resistance within biofilms is an 
important survival mechanism, which is not obtained through mutation.  
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 The ability of bacterial biofilms to escape elimination by host immune defenses is 
increasingly being identified as another key factor behind the persistence of many chronic 
infections. Polymorphonuclear leucocytes (PMNs) have been identified to be the most 
prominent immune cells encountered by bacterial biofilms as evident in studies of 
infections in cystic fibrosis patients caused by P. aeruginosa. The interaction between 
neutrophils and P. aeruginosa biofilms explored in vitro via scanning electron 
microsocopy (SEM) and confocal scanning laser microscopy (CSLM) analysis revealed 
unstimulated neutrophil morphology (Jesaitis et al., 2003). P. aeruginosa biofilms were 
also found to down-modulate leukocyte functions, with elastase observed to inhibit 
human monocyte function (Kharazmi & Nielsen 1991). The activation of complement is a 
typical host response against many Gram positive and negative bacteria. However, 
complement activation analyses carried out in P. aeruginosa biofilms exhibited less 
complement activation than their planktonic counterparts (Jensen et al., 1993). Some 
examples of bacterial biofilm-associated diseases are listed in Table 1. 
 
Table 1.1 Partial list of human infections involving biofilms (adapted from (Costerton, 
JW, Stewart & Greenberg 1999)) 
Infection or disease Common biofilm bacterial species 
Dental caries Acidogenic Gram-positive cocci 
Periodontitis Gram-negative anaerobic oral bacteria 
Otitis media S. pneumoniae, Nontypable strains of H. 
influenzae, M. catarrhalis, etc. 
Musculoskeletal infections Gram-positive cocci (e.g. staphylococci) 
Necrotizing fasciitis Group A streptococci 
Biliary tract infections Enteric bacteria (e.g. Escherichia coli) 
Osteomyelitis Mixed bacterial and fungal species 
Bacterial prostatitis E. coli and other Gram-negative bacteria 
Native valve endocarditis Viridans group streptococci 
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Cystic fibrosis pneumonia Burkholderia cepacia and P. aeruginosa 
Melioidosis Pseudomonas pseudomallei 
Nosocomial infections:  
   ICU pneumonia Gram negative rods 
   Sutures S. epidermidis and S.aureus 
   Exit sites S. epidermidis and S.aureus 
   Arteriovenous shunts S. epidermidis and S.aureus 
   Endovascular catheter infections Staphylococci 
    Intra Uterine Devices (IUDs) Actinomycetes israelii and others 
1.7.3 Stages of biofilm formation 
 The formation of biofilms can be divided into distinct stages comprising 
attachment, growth and maturation, and detachment, and represents a survival strategy 
where microorganisms can form mature, single or multiple species biofilms, and then 
disseminate to new surfaces (Hall-Stoodley & Stoodley 2005). 
 
1.7.3.1 Attachment and proliferation 
 Biofilm formation is a dynamic process that begins with weak and reversible 
attachment of a small number of bacteria to either each other, or onto a surface, primarily 
by Van der Waals forces. When sufficient numbers of bacteria have attached, bacterial 
signaling or ‘quorum sensing’ (QS) is then initiated. This leads to a cascade of changes in 
gene expression, including those encoding species-specific adhesins, as well as other 
proteins and polysaccharides, which firmly attach the cells to the substratum and to each 
other as they undergo exponential binary division (Vandecasteele et al., 2003). Upon cell 
division, spread of the daughter cells occurs outward and upward from the attachment 
point, forming cell clusters. Exopolysaccharides (EPS) or "slime" are produced, which 
embeds the aggregating cells to form microcolonies, which are typically composed of 
10% to 25% cells and 75% to 90% EPS matrix, with a consistency similar to a viscous 
polymer hydrogel (Costerton, W et al., 2003) (see Figure 1.2).  
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Figure 1.2. Illustration of biofilm development, including initial attachment, the growth 
and maturation, and detachment events, seeding dispersal either via clumps or individual 
planktonic bacteria (Image credit : P. Dirckx; Adapted from Hall-Stoodley et al; 2004). 
 
1.7.3.2 Growth and maturation 
 Biofilms continue to form according to the biochemical and hydrodynamic 
conditions, as well as the availability of nutrients in the immediate environment (Cappelli 
et al., 2005). The hormone-like regulatory QS signals produced by the biofilm cells 
themselves influence structural organization in reaction to growth conditions. QS allows 
for communication among the cells, not only controlling colony formation, but also 
regulation of growth rate, species interactions, toxin production, invasive properties, etc. 
(Costerton, 1999). There is structural and metabolic heterogeneity in the cell clusters and 
both aerobic and anaerobic processes occur simultaneously in different parts of the 
multicellular community. Depending on the species and local environmental conditions, 
increases in cell density lead to the formation of complex 3-D structures, such as tower- 
and mushroom-shaped cell clusters within 1-2 weeks of growth, with aqueous channels 
that connect adjacent microcolonies and serve as a primitive circulatory system for 
delivery of nutrients and removal of wastes. Biofilm thickness varies (between 13-60 µm) 
depending on the balance between growth of the biofilm and detachment of cells (see 
Figure 1.2). 
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1.7.3.3 Detachment 
 Detachment and dissemination is a critical step for colonisation of new surfaces 
and to prevent density-mediated starvation within the mature biofilm, and is 
accomplished by shedding, detachment, or shearing. Shedding occurs when increased cell 
density induces cell-cell signaling to direct chemical degradation of the EPS, releasing 
bacteria from cell clusters and sending clumps of biofilm into the circulation (Donlan, 
2002). Detached biofilm clumps contain thousands of cells and leave behind an adherent 
layer of bacteria on the surface for the biofilm to be regenerated (Fux et al., 2004). 
Biofilm cells, which disseminate into the systemic circulation may result in bloodstream 
infection. Antimicrobial therapy and/or the host's immune system may eliminate shedded 
single cells, as they are more susceptible to antibiotics. However, the released clumps of 
biofilm can still retain resistance to antibiotics and immune clearance (see Figure 1.2).  
1.8 S. pneumoniae biofilms and virulence  
           In S. pneumoniae, all invasive isolates and commensal strains investigated to date 
have been found to be capable of producing biofilms in vitro, using static or continuous 
cultures, albeit to varying extents (Allegrucci et al., 2006). In a study by Reid et al. 
(2009), bacterial biofilms were detected in the middle ear of infected chinchillas. The 
presence of structures resembling biofilms in the lungs, trachea, and nasopharynx of mice 
infected with S. pneumoniae has also been reported (Sanchez et al., 2010). Bacterial 
biofilms have also been demonstrated on the middle ear mucosa of children with chronic 
OM (Hall-Stoodley & Stoodley, 2005).   
 Microscopic evidence of pneumococcal biofilms in children (Hall-Stoodley et al., 
2006) and animal models (Reid et al., 2009) suggests a complex role for biofilms in 
pneumococcal disease pathogenesis. Associations between biofilm phenotype in clinical 
isolates of different origin, or site of isolation, and a specific clinical outcome have also 
been reported (Garcia-Castillo et al., 2007; Oggioni et al., 2006; Tapiainen et al., 2010). 
In a study by Garcia-Castillo, biofilm formation and increased antimicrobial resistance 
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was found to occur significantly more frequently in pneumococcal isolates from cystic 
fibrosis bronchial secretions than non-cystic fibrosis blood isolates (Garcia-Castillo et al., 
2007). Oggioni and colleagues reported that pneumococci resemble planktonic growth 
during bacteremia, while during tissue infection, such as pneumonia or meningitis, 
pneumococci are in a biofilm-like state (Oggioni et al., 2006). However, Tapiainen et al. 
(2010) did not find any observable differences in biofilm formation capacity between 
isolate source for 204 nasopharyngeal, middle ear effusion and blood isolates.  
 To date many investigations have been carried out on pneumococcal biofilm 
formation in clinical isolates, particularly with respect to antimicrobial resistance and 
examination of any link between high biofilm formation, serotype and source of clinical 
isolate. A higher degree of antimicrobial resistance has been detected in biofilm versus 
planktonic cells (Hoyle & Costerton, 1991), perhaps due to close proximity of cells 
facilitating horizontal transfer of resistance genes. However, a study into links between 
high biofilm formation and isolate source or serotype has revealed marked inter-strain 
variations (Camilli et al., 2011; Tapiainen et al., 2010).  
1.8.1 Resistance of pneumococcal biofilms to host immune responses 
 Resistance of pneumococcal biofilms to specific immune responses has only 
recently been investigated. By means of flow cytometry and confocal laser scanning 
microscopy, Domenech et al. (2012) demonstrated that the deposition of C3b, the key 
component in complement-mediated innate immunity, was impaired on S. pneumoniae 
biofilms. In addition, binding of C-reactive protein and the complement component C1q 
to the pneumococcal surface was reduced in biofilm bacteria, indicating that 
pneumococcal biofilms can resist activation of the classical complement pathway 
(Sanchez et al., 2010). Recruitment of factor H, a down-regulator of the alternative 
pathway, was also enhanced in S. pneumoniae growing as a biofilm. These results also 
show that biofilm formation attenuates alternative complement pathway activation by a 
PspC-mediated mechanism (Sanchez et al., 2010). Phagocytosis of pneumococci in 
biofilms was also impaired. The study cited above also confirms that biofilm formation 
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by S. pneumoniae is an efficient means of evading both the classical and the PspC-
dependent alternative complement pathways of the host innate immune system. Sanchez 
et al.  (2011) also reported that planktonic pneumococci elicited stronger adaptive 
immune responses during invasive disease compared to cells growing in biofilms, which 
showed weaker antibody responses against planktonic cell lysates and did not confer 
protection against virulent pneumococci belonging to another serotype.  
 
1.8.2 Mechanisms of pneumococcal biofilm formation in colonisation and disease 
 The presence of pneumococcal biofilms has been reported in disease states (Hoa 
et al., 2010; Reid et al., 2009) and more recently in asymptomatic colonisation of the 
murine nasopharynx (Blanchette-Cain et al., 2013; Marks et al., 2012). Several proteins 
and sugars such as LytA, LytC (lysozyme), LytB (glucosaminidase), CbpA, PcpA (a 
putative adhesion) (Moscoso et al., 2006), NanA (Parker et al., 2009) and sialic acid 
(Trappetti et al., 2009), as well as the cellular processes associated with iron-dependent 
competence and fratricide (Trappetti et al., 2011c) have been implicated in biofilm 
formation.  
 A recent study which compared the gene expression profiles in early biofilms of 
S. pneumoniae with that in planktonic cells via cDNA microarray analysis (and 
subsequently confirmed by RT-PCR) reported that 89 genes were significantly 
differentially expressed in biofilm versus planktonic cells (Yadav et al., 2012). Genes that 
were preferentially expressed in biofilms included those involved in cell wall and 
isoprenoid biosynthesis, cell wall biosynthesis, translation and purine and pyrimidine 
nucleotide metabolic pathways. For planktonic cells, the transcriptional regulator genes 
ccpA, rr13 and marR were exclusively upregulated. Differences in gene expression and 
virulence determinant production between planktonic and biofilm bacteria reported in 
other studies include pneumococcal serine-rich repeat protein (PsrP), CbpA, Ply and 
PspA, indicating growth mode-dependent alterations in the antigenic profile of 
pneumococci (Moscoso et al., 2006; Oggioni et al., 2006; Orihuela et al., 2009; Sanchez 
et al., 2010). Microarray analysis of planktonic and sessile pneumococci by Trappetti et 
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al demonstrated the role of the two-component system CiaRH in the formation of 
extracellular matrix, a characteristic feature of biofilms (Trappetti et al., 2011b). In a 
study by Blanchette-Cain et al. (2013), biofilm formation was investigated in nasal septa 
of the murine nasopharynx, which also showed that the two-component system CiaR/H 
responsible for competence and virulence was critical for colonisation of mice and 
biofilm formation. 
 Ply, the pneumococcal pore-forming toxin, was also revealed to play a novel role 
in biofilm formation (Shak et al., 2013), independent of its haemolytic activity; ply 
knockout mutants  in D39 and TIGR4 strains produced significantly lesser biofilm 
biomass than their wild-type counterparts. These findings contradicted those of Lizcano 
et al. (2010), which revealed that ply knockout mutants were able to form biofilms 
normally like the wild type. These differences in findings may be related to differences in 
culture conditions Furthermore, different strains have been used between these studies; 
therefore resulting in differences in biofilm phenotypic observations. 
 The last five years have seen an increase in investigations of pneumococcal 
biofilms at the structural and genetic level (Domenech et al., 2012), facilitated by 
technological advances, such as Real-Time PCR and next generation sequencing.  
However the role of biofilm formation in disease pathogenesis is still incompletely 
understood. A recent study by Pettigrew et al. (2014) found significant differences in 
transcriptomic profiles between planktonic bacteria and bacteria dispersed from biofilms.  
 Hyaluronic acid (HA), an important component of the extracellular matrix of host 
epithelial cell apical surfaces, has also been recently recognized to play a role in biofilm 
formation (Yadav et al., 2013). This study reported hyaluronic acid derived from 
Streptococcus equi gave rise to enhanced biofilm formation in S. pneumoniae. Biofilm 
biomass was higher compared to controls when cultures were stained with crystal violet. 
Subsequent SEM analysis also showed biofilms grown in HA-supplemented Yeast 
Extract (YE) medium as adherent cells which were interconnected in thick organized 
structures, as opposed to non-supplemented YE medium which showed no detectable 
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biofilm formation. Gene expression in planktonic cells and biofilms grown in HA was 
also assessed and it was found that luxS, nanA, ugl, hysA and PTS-EIIA encoding genes 
(genes implicated in HA degradation) were significantly up-regulated at least 2-fold in 
biofilms. This study indicated that HA supports pneumococcal biofilm growth and up-
regulated some virulence and biofilm-related genes. 
 Colony opacity phenotypic (phase) variation has also been reported to influence 
biofilm formation. In a 4 day static biofilm assay of opaque and transparent variants of a 
serogroup 19F clinical isolate, Trappetti et al. (2011b) observed the presence of 
extracellular matrix, a characteristic feature of biofilms, on opaque variants but not on 
transparent variants. This study went on to show that opaque bacteria were able to 
translocate from the nasopharynx to the lungs and brains of mice; as well as an observed 
100-fold greater in vitro adherence to A549 cells than the transparent counterpart. 
Differential gene expression of the ciaRH two-component system and the choline uptake 
lic operon between the two phenotypes was confirmed via microarray analysis. It was 
proposed that the production of extracellular matrix by the opaque phase variants 
enhanced the ability of pneumococci to cause invasive disease. 
1.8.3 Social interactions in pneumococcal biofilm formation and virulence  
 Various signalling pathways have been shown to be involved in the switch from 
the planktonic mode of growth to the biofilm state. The term ‘quorum sensing’ (QS) was 
first coined by Tomasz et al. (1964) to describe intercellular concentration-dependent 
microbial communication in microorganisms. QS is a widespread phenomenon and is a 
social networking channel for both Gram-positive and Gram-negative bacteria. It involves 
the production, secretion and detection of diffusible chemical signals when cell density 
reaches a threshold. The term ‘signal’ indicates the chemical compound is produced 
explicitly to invoke a response from other organisms (or itself) to coordinate activities 
between signal producers and the responder (Platt & Fuqua 2010). This mechanism 
enables bacteria to ‘count’ their local population and monitor external environmental 
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parameters such as pH, osmolarity and nutrient availability. Once a quorum is reached, 
bacteria are able to modify their group behavior through changes in gene expression.  
 The most common QS system found among Gram-negative bacteria such as P. 
aeruginosa, E. coli and Vibrio spp. employs acylated homoserine lactones as 
autoinducers, while in Gram-positive bacteria processed oligopeptides are used (Miller & 
Bassler, 2001). In Gram positive bacteria including streptococci, QS systems comprise 
three components: a peptide signal, and a two component regulatory system comprising a 
histidine kinase sensor (HK) and an intracellular response regulator (RR) (Cvitkovitch et 
al., 2003). In S. pneumoniae, the QS signalling molecule is a 17-amino acid (aa) 
competence-stimulating peptide (CSP) processed from a 41-amino acid precursor 
(Havarstein et al., 1995).  
 Biofilm formation is one of many physiological processes or phenotypes regulated 
through the QS mechanism, with others including luminescence, swarming motility, 
antibiotic and virulence factor production, pigment production, plant-microbe interactions 
and motility. The involvement of QS in biofilm formation by streptococci was first shown 
by Loo et al. (2000), who recovered a biofilm defective mutant of S. gordonii following 
transposon mutagenesis which had inactivated the comD gene encoding the HK receptor 
that detected the QS autoinducer peptide. Gilmore et al. (2003), later demonstrated that 
two S. gordonii genes, comD and comE encoding the HK and RR of the QS two-
component signal transduction system were upregulated in the biofilm phase.  
 In S. pneumoniae biofilm formation involves a variety of factors, including QS 
peptides (Costerton et al., 2003). Oggioni et al. (2006) revealed a relationship between 
biofilm formation and the S. pneumoniae CSP QS system that mediates genetic 
competence. Biofilm formation was dependent on CSP, and CSP receptor (comD) 
mutants could not form biofilms. They went on to show that CSP induced in vitro biofilm 
formation, and increased virulence in pneumonia and meningitis models in mice. They 
also showed that a comD receptor mutant that did not form biofilms showed decreased 
virulence in mice.  
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1.8.4 The LuxS – Autoinducer 2 QS system 
 An additional QS system used by both Gram-positive and Gram-negative bacteria 
has been identified, which represents a “universal language”. This involves synthesis of a 
signaling molecule called autoinducer-2 (AI-2) by the metabolic enzyme LuxS (S-
ribosylhomocysteine lyase), as a by-product of the activated methyl cycle (see Fig. 1.3).  
 
 
 
 
Figure 1.3 Activated methyl cycle. In the first instance, methylation reactions result in 
conversion of S-adenosylmethionine (SAM) to a toxic intermediate S-
adenosylhomocysteine, which is then catalayzed by MtnN to form S-ribosylhomocysteine 
(SRH). LuxS then converts SRH to homocysteine and 4,5-dihyroxy 2,3-pentanedione 
(DPD). DPD is the precursor to AI-2, an unstable compound that spontaneously cyclises 
to form several furanone ring formations including AI-2.  [Credit image: A. Potter] 
  
Homologues of LuxS have been found in almost all bacterial species, suggesting a 
key role in interspecies communication. In Vibrio species, AI-2 binds to the periplasmic 
protein LuxP forming a complex that interacts with LuxQ, a membrane bound histidine 
kinase, and the signal is transduced inside the cell (Freeman & Bassler 1999; Reading & 
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Sperandio 2006). Other bacterial species lack LuxPQ homologues and sense AI-2 in a 
different manner. In Salmonella and Escherichia coli the ABC transporter encoded by the 
Lsr operon (LuxS regulated) is responsible for AI-2 uptake into the cell. AI-2 is then 
phosphorylated inside the cell and interacts with the LsrR regulator (Taga et al., 2001; 
Xavier & Bassler, 2005). The actual structure of AI-2 was determined by co-
crystallization with its receptor LuxP (a periplasmic protein that resembles the ribose-
binding protein RbsB). Using electron density analysis the AI-2 structure was identified 
as a furanosyl-borate diester with a molecular mass of 192.9 Da (Chen et al., 2002).  
 The involvement of LuxS in biofilm formation has been demonstrated by 
mutational analysis in many Gram-negative bacteria such as Shewanella oneidensis 
(Bodor et al., 2011), Klebsiella pneumoniae (De Araujo et al., 2010) and P. aeruginosa 
(Parveen et al., 2001), as well Gram positive bacteria such as Staphylococcus epidermidis 
(Lin-Xu et al.,, 2005), S. mutans (Merritt et al., 2005) and S. suis (Wang et al., 2011).  
 
1.8.4.1 The role of LuxS/AI-2 QS in S. pneumoniae 
 Initial studies of the role of the LuxS/AI-2-mediated QS in S. pneumoniae focused 
on its contribution to disease pathogenesis. Stroeher et al. (2003) reported that a luxS 
mutation significantly reduced virulence in a mouse sepsis model, and also resulted in 
multiple changes in protein expression patterns. In a separate study, LuxS was also shown 
to be necessary for persistent carriage and expression of virulence-associated genes such 
as ply, as well as other cellular processes (Joyce et al., 2004). More recent studies have 
focused on the role of LuxS/AI-2 QS in biofilm development. Trappetti et al. (2011c) 
showed that a luxS-deficient mutant of S. pneumoniae D39 failed to form a biofilm. 
Interestingly, genetic competence and fratricide, functions known to be regulated by the 
CSP QS system, were also massively impacted. Thus, the two QS systems in S. 
pneumoniae interact, resulting in close linkage of several critical pathophysiological 
parameters, with luxS proposed as a central regulator (Trappetti et al., 2011c). A study by 
Vidal et al. also demonstrated a role for the luxS system in regulating S. pneumoniae 
biofilms, where at 24 h post-inoculation, two different D39ΔluxS mutants produced 
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∼80% less biofilm biomass than the wild-type (WT) strain. When these strains were 
complemented with luxS, either on a plasmid or integrated as a single copy in the 
chromosome, their biofilm formation capacity was restored to that of the WT.  
Supplementation with a soluble factor secreted by WT D39 or purified AI-2 restored the 
biofilm phenotype of D39ΔluxS. Thus, the LuxS/AI-2 QS system is a key regulator of 
biofilm formation by S. pneumoniae (Vidal et al., 2011). 
 
1.8.5 Role of iron in biofilm development in S. pneumoniae 
 S. pneumoniae utilizes a high-affinity iron uptake mechanism to overcome iron 
restriction in the host environment. ABC transporter systems Pia (pneumococcal iron 
acquisiton) and Piu (pneumococcal iron uptake) have been shown to mediate iron uptake 
in S. pneumoniae (Brown et al., 2001) and are necessary for full virulence of S. 
pneumoniae. Trappetti et al. (2011c) established a positive association between iron 
(Fe[III]) concentration in the growth medium, luxS expression and biofilm development 
in S. pneumoniae D39.  
 
 
1.9  Project Hypothesis and Aims 
 From the aforementioned studies, it is clear that S. pneumoniae is a genetically 
diverse bacterium capable of causing a broad spectrum of infections, spanning 
asymptomatic carriage, localized infections and life-threatening invasive disease. Biofilm 
formation also appears to be an important component of pneumococcal disease 
pathogenesis. Our central hypothesis is that differences in virulence phenotype between S. 
pneumoniae strains belonging to diverse serotypes and STs will be related in some way to 
biofilm formation capacity. Thus, the overall aim of this research project is to identify 
any correlation between biofilm formation in clinical isolates of S. pneumoniae and 
factors that would influence their invasive disease potential. Specific research objectives 
are as follows: 
34 
 
Aim 1. Investigate the biofilm formation capacity of a collection of clinical isolates of S. 
pneumoniae belonging to serotypes/serogroups 3, 6, 9, 14 and 19 in relation to site of 
isolation (clinical isolate source) and environmental factors including medium pH and 
Fe(III) supplementation. 
Aim 2. Examine the virulence profiles of clonally-related blood and ear isolates 
exhibiting distinct in vitro biofilm phenotypes. 
Aim 3. Examine differences in host immune responses to infection with S. pneumoniae 
isolates with distinct virulence profiles. 
Aim 4. Identify transcriptomic differences between closely-related S. pneumoniae strains 
that exhibit distinct biofilm and/or virulence phenotypes. 
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Chapter 2: Materials and Methods 
2.1 Bacterial strains 
 The S. pneumoniae strains used in this study are listed in Table 2.1.  
Table 2.1   S. pneumoniae strains 
Strain Description Source 
4482 Capsular serotype 3 blood isolate 
Women’s and Children’s 
Hospital, Adelaide (WCH) 
4499 Capsular serotype 3 blood isolate WCH 
4522 Capsular serotype 3 blood isolate WCH 
4529 Capsular serotype 3 blood isolate WCH 
5065 Capsular serotype 3 blood isolate WCH 
5234 Capsular serotype 3 blood isolate WCH 
5258 Capsular serotype 3 blood isolate WCH 
5267 Capsular serotype 3 blood isolate WCH 
4483 Capsular serotype 3 blood isolate WCH 
4521 Capsular serotype 3 blood isolate WCH 
5272 Capsular serotype 3 blood isolate WCH 
5060 Capsular serotype 3 blood isolate WCH 
9706840 Capsular serotype 3 ear isolate WCH 
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61887 Capsular serotype 3 ear isolate WCH 
22318 Capsular serotype 3 ear isolate WCH 
54833 Capsular serotype 3 ear isolate WCH 
57934 Capsular serotype 3 ear isolate WCH 
68872 Capsular serotype 3 ear isolate WCH 
62139 Capsular serotype 3 ear isolate WCH 
75100 Capsular serotype 3 ear isolate WCH 
58497 Capsular serotype 3 ear isolate WCH 
53203 Capsular serotype 3 ear isolate WCH 
79725 Capsular serotype 3 ear isolate WCH 
5069 Capsular serotype 3 ear isolate WCH 
5268 Capsular serotype 3 ear isolate WCH 
4501 Capsular serogroup 6 blood isolate WCH 
4519 Capsular serogroup 6 blood isolate WCH 
4526 Capsular serogroup 6 blood isolate WCH 
4550 Capsular serogroup 6 blood isolate WCH 
53034 Capsular serogroup 6 ear isolate WCH 
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61888 Capsular serogroup 6 ear isolate WCH 
87765 Capsular serogroup 6 ear isolate WCH 
50397 Capsular serogroup 6 ear isolate WCH 
4531 Capsular serogroup 9 blood isolate WCH 
4539 Capsular serogroup 9 blood isolate WCH 
5055 Capsular serogroup 9 blood isolate WCH 
62195 Capsular serogroup 9 ear isolate WCH 
66919 Capsular serogroup 9 ear isolate WCH 
9723173 Capsular serogroup 9 ear isolate WCH 
40502 Capsular serogroup 9 ear isolate WCH 
4484 Capsular serotype 14 blood isolate WCH 
4495 Capsular serotype 14 blood isolate WCH 
4524 Capsular serotype 14 blood isolate WCH 
4534 Capsular serotype 14 blood isolate WCH 
4511 Capsular serotype 14 blood isolate WCH 
4538 Capsular serotype 14 blood isolate WCH 
4545 Capsular serotype 14 blood isolate WCH 
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4549 Capsular serotype 14 blood isolate WCH 
4559 Capsular serotype 14 blood isolate WCH 
51742 Capsular serotype 14 ear isolate WCH 
53705 Capsular serotype 14 ear isolate WCH 
67456 Capsular serotype 14 ear isolate WCH 
73363 Capsular serotype 14 ear isolate WCH 
9725201 Capsular serotype 14 ear isolate WCH 
50582 Capsular serotype 14 ear isolate WCH 
76547 Capsular serotype 14 ear isolate WCH 
9-47 Capsular serotype 14 ear isolate WCH 
9-5133 Capsular serotype 14 ear isolate WCH 
5210 Capsular serogroup 19 blood isolate WCH 
5219 Capsular serogroup 19 blood isolate WCH 
5239 Capsular serogroup 19 blood isolate WCH 
5221 
 
Capsular serogroup 19 
blood isolate WCH 
4507 Capsular serogroup 19 blood isolate WCH 
5027 Capsular serogroup 19 blood isolate WCH 
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5058 Capsular serogroup 19 blood isolate WCH 
5074 Capsular serogroup 19 blood isolate WCH 
5030 Capsular serogroup 19 blood isolate WCH 
5054 Capsular serogroup 19 blood isolate WCH 
24190 Capsular serogroup 19 ear isolate WCH 
51862 Capsular serogroup 19 ear isolate WCH 
53685 Capsular serogroup 19 ear isolate WCH 
48498 Capsular serogroup 19 ear isolate WCH 
61884 Capsular serogroup 19 ear isolate WCH 
63748 Capsular serogroup 19 ear isolate WCH 
64051 Capsular serogroup 19 ear isolate WCH 
74434 Capsular serogroup 19 ear isolate WCH 
74951 Capsular serogroup 19 ear isolate WCH 
79213 Capsular serogroup 19 ear isolate WCH 
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2.2 Growth Media and Bacterial Cultures 
 S. pneumoniae strains were routinely grown in a semisynthetic casein hydrolysate 
medium with 0.5% yeast extract (C+Y) according to the recipe of Lacks and Hotchkiss 
(1960), Todd–Hewitt broth (Oxoid, Hampshire, UK) with 1% Bacto yeast extract 
(Becton, Dickinson and Company (BD), New Jersey, USA) (THY), on blood agar (BA) 
(39 g/l Columbia base agar [Oxoid], 5% (v/v) defibrinated horse blood), or for challenge 
of mice, in serum broth (SB) (10% [v/v] heat-inactivated horse serum [Gibco®, 
Auckland, New Zealand], 10 g/l peptone [Oxoid], 10 g/l Lab Lemco powder [Oxoid] and 
5 g/l NaCl).  
 BA was routinely supplemented with gentamicin (5 μg/ml) to inhibit background 
bacteria from in vivo samples, or with erythromycin (0.2 μg/ml), for the selection of 
suitable transformants for competitive index experiments in ST15/4495 blood and 
ST15/9-47 ear isolates. 
 For examination of colony opacity phenotype (opaque vs transparent), strains 
were grown on THY agar (THY with 1.5 % (w/v) agar [Merck, Darmstadt, Germany]) 
supplemented with 200 U/ml catalase (Sigma, NSW, Australia). After incubation at 37°C 
with 5% CO2 overnight, the colony phenotype was viewed under oblique transmitted 
light, as described by Weiser et al. (1994). For storage of pneumococci, opaque colonies 
selected from THY/catalase plates were grown in C+Y medium to a final A600 of 0.4, 
20% (v/v) glycerol was then added and the culture was stored at −80°C until use. Opaque 
colonies were used in all experiments. 
 
2.3 Oligonucleotide primers 
 The oligonucleotide primers and plasmids used in this study are listed in Table 
2.2. 
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Table 2.2: Oligonucleotide primers and plasmids 
 
Target gene and 
primer/plasmid name Sequence (5’-3’) Purpose (reference) 
recP (transketolase) 
recP F (forward) GCCAACTCAGGTCATCCAGG 
MLST typing  
(Enright & Spratt, 1998) 
recP R (reverse) TGCAACCGTAGCATTGTAAC MLST typing  (Enright & Spratt, 1998) 
aroE (shikimate 
dehydrogenase) 
aroE F 
GCCTTTGAGGCGACAGC MLST typing  (Enright & Spratt, 1998) 
aroE R TGCAGTTCA(G/A)AAACAT(A/T)TTCTAA MLST typing  (Enright & Spratt, 1998) 
ddl (D-alanine ligase) 
ddl F TGC(C/T)CAAGTTCCTTATGTGG 
MLST typing  
(Enright & Spratt, 1998) 
ddl R CACTGGGT(G/A)AAACC(A/T)GGCAT MLST typing  (Enright & Spratt, 1998) 
gdh (glucose-6-phosphate 
dehydrogenase) 
gdh F 
ATGGACAAACCAGC(G/A/T/C)AG(C/T)TT MLST typing  (Enright & Spratt, 1998) 
gdh R GCTTGAGGTCCCAT(G/A)CT(G/A/T/C)CC MLST typing  (Enright & Spratt, 1998) 
gki (glucokinase) 
gki F GGCATTGGAATGGGATCACC 
MLST typing  
(Enright & Spratt, 1998) 
gki R TCTCCCGCAGCTGACAC MLST typing  (Enright & Spratt, 1998) 
spi (signal peptidase I) 
spi F TTATTCCTCCTGATTCTGTC 
MLST typing  
(Enright & Spratt, 1998) 
spi R GTGATTGGCCAGAAGCGGAA MLST typing  (Enright & Spratt, 1998) 
xpt (xanthine phospho-
ribosyltransferase) 
xpt F 
TTATTAGAAGAGCGCATCCT MLST typing  (Enright & Spratt, 1998) 
xpt R AGATCTGCCTCCTTAAATAC MLST typing  (Enright & Spratt, 1998) 
16S rRNA F CATGCAAGTAGAACGCTGAA Q-PCR for 16S rRNA 
16S rRNA R TGTCATGCAACATCCACTCT Q-PCR for 16S rRNA 
luxS F CCCTATGTTCGCTTGATTGGGG Q-PCR for luxS 
luxS F AGTCAATCATGCCGTCAATGCG Q-PCR for luxS 
trpF F GGCTGTGCAGGTAGATGGAA Q-PCR for trpF 
trpF R TTCATTAAGGCCACCTGCGA Q-PCR for trpF 
trpG F GCGGTCATGCGTTATCACAG Q-PCR for trpG 
trpG R TCTGGCGTTCCAATGCTCTC Q-PCR for trpG 
nanA F CGGAGAGCGCCTCAAGATATTACTC Q-PCR for nanA 
nanA R GCCCATTCCGAAGTACAATTCC Q-PCR for nanA 
spxB F CAACATGTGCTACCCAGACG Q-PCR for spxB 
spxB R CGAGCATCGATGACAACAGT Q-PCR for spxB 
pAL2 plasmid pAL2 plasmid containing erythromycin resistance gene (Biswas et al., 2008) 
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2.4. Biofilm assay 
 Frozen stocks of opaque isolates were firstly grown on BA overnight at 37°C in 
5% CO2 and pre-cultured in 1.0 ml C+Y medium at pH 7.4 or pH 6.8 to a final A600 of 
0.3. The cultures were then diluted 1/100 in fresh C+Y medium and two-fold dilutions of 
the suspensions were transferred into consecutive wells of a flat-bottomed 96 well 
microtitre plate (Costar, Corning Corporation), with or without 100 μM Fe(III). Assays 
were carried out in triplicate and repeated for three biological replicates. 
2.4.1 Quantification of bacteria 
 For the quantification of attached bacteria, the incubated microtitre plates were 
washed in Luria Bertani (LB) medium three times. A volume of 100 μl of fresh LB 
medium was then added to the wells. The plates were then sealed with parafilm and 
sonicated at 35 kHz for 3 sec in a Transonic 460/H sonicating water bath. The dispersed 
biofilm-derived bacterial suspension was then serially diluted two-fold before being 
plated on to BA plates and incubated at 37°C in 5% CO2 overnight. Total CFU counts 
emanating from the biofilm for each well were then calculated. 
2.4.2 Microscopic examination of biofilms 
 For microscopic examination of biofilms, wells of microtitre plates were washed 
three times in LB medium to remove planktonic bacteria. The wells were dried at 37°C 
for 30 min and stained with 0.5 % crystal violet (w/v) for 30 min at 37°C. Crystal violet 
was then removed from each well and the plate was left at room temperature for 10 min. 
The wells were then washed three times in phosphate-buffered saline (PBS) pH 7.4 and 
observed under transmitted light using an AMG Evos inverted microscope with a 40 × 
objective.  
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2.4.3 Quantitation of biofilm density 
 For quantitation of biofilm density, 50 μl absolute ethanol was dispensed into the 
wells of the crystal violet-stained microtitre plates and Absorbance at 570nm was 
measured using a Spectramax M2 Microplate Reader (Molecular Devices). All assays 
were performed in duplicate and repeated for three biological replicates. 
 
2.5 Growth curves of clinical isolates 
 Strains were grown overnight on BA at 37°C in 5% CO2 and then grown in C+Y 
medium (pH 7.4) from an initial inoculum of A600 = 0.05 to a final A600 = 0.2. Cultures 
were then diluted 1/100 in C+Y and 180 µl of bacterial suspension was then added to 
each well of a 96 well flat bottom microtitre plate (Costar, Corning Corporation) with a 
minimum of three replicates per sample. A breathable film cover was then placed over the 
plate. A600 was measured every 30 min for 18h, at 37°C in a Spectramax M2 Microplate 
Reader (Molecular Devices, California, USA). Data obtained were analysed using 
Softmax Pro® software v 4.6 (Molecular Devices). 
 
2.6 SDS-PAGE and Western blotting  
2.6.1 SDS-PAGE 
 Selected clinical isolates were grown to A600 = 0.15 and 0.3 at 37°C in C+Y (pH 
7.4 or pH 6.8), with or without additional 100 µM Fe(III). 1 ml of the culture was then 
placed in a centrifuge tube and spun for 5 min at 8,000 × g. The pellet was then 
resuspended in 50 μl PBS and lysed in 0.1% (w/v) sodium deoxycholate (DOC) at 37°C 
for 30 min. The protein concentrations of the lysates were then measured using the 
Pierce™ BCA Protein Assay Kit according to the manufacturer’s instructions. Samples 
containing approximately 30 μg of protein solubilised in LUG buffer (5% [v/v] β-
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mercaptoethanol, 62.5 mM Tris-HCl, 2% [w/v] sodium dodecyl sulphate [SDS], 10% 
[v/v] glycerol and 0.05% [w/v] bromophenol blue, pH 6.8), together with a BenchmarkTM 
prestained protein ladder (Thermo Fisher Scientific), were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) at 200V for 20 min using a 12% 
NuPage Bis-Tris mini gel (Invitrogen). 
2.6.2 Western Blotting  
 Upon completion of electrophoresis, separated proteins were electrophoretically 
transferred onto a nitrocellulose membrane using an iBlot Dry Blotting System 
(Invitrogen) according to the manufacturer’s instructions. The membrane was blocked by 
incubation in Tris-buffered saline containing 0.02% Tween 20 (TTBS) and 1% skim milk 
powder, at room temperature (RT) for 30 min and washed twice for 5 min in TTBS. The 
proteins were then labeled with the appropriate primary polyclonal mouse antiserum 
overnight at 4°C at a dilution of 1:1000 in TTBS supplemented with 0.05% (w/v) skim 
milk powder. The membrane was then washed three times for 5 min in TTBS and 
incubated with secondary antibody (IRDye800-labeled anti-mouse IgG [LI-COR 
Biosciences, Nebraska, USA]) diluted 1:50,000 in TTBS for 60 min at RT in the dark. 
Finally the membrane was washed three times for 5 min in TTBS and once in PBS for 5 
min. Blots were dried at 37°C and scanned using an Odyssey Infrared Imaging System 
(LI-COR Biosciences). Relative quantification of protein expression between the strains 
was determined by the Odyssey Infrared Imaging System application software v 3.0.21 
by comparing units of fluorescence (LI-COR Biosciences). 
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2.7 Quantitation of Pneumococcal Capsular Polysaccharide  
2.7.1 Capsular Polysaccharide (CPS) Preparation 
 Pneumococci were grown overnight on BA at 37°C in 5% CO2 and then harvested 
and suspended in 20 ml PBS to A600 = 0.5. A 10 ml aliquot was pelleted via 
centrifugation at 3,000 × g for 30 min. Pellets were resuspended in Eppendorf tubes 
containing 500 μl 150 mM Tris-HCl (pH 7.0), 1 mM MgSO4. Five μl 10% (w/v) DOC 
was then added and the tubes were incubated for 30 min at 37°C. 100 U of mutanolysin, 
50 U DNase I and 50 μg RNase A were added to each tube and incubated at 37°C 
overnight. After incubation, 100 μg Proteinase K was added to each tube and tubes were 
then incubated at 56°C for 4 h. The CPS preparation was then spun briefly in a microfuge 
to pellet debris and stored at -20°C until use. 
2.7.2 Uronic Acid Assay 
 CPS serotypes containing glucuronic acid in the repeat units were quantitated by 
uronic acid assay, as described by Morona et al. (2006). CPS samples were diluted two-
fold, in duplicate, to a final volume of 100 μl in ultrapure H2O in Eppendorf tubes, 
including blanks comprising 100 μl ultrapure H2O. The samples were then cooled on ice. 
600 μl H2SO4 /0.0125 M Na2B4O4 was added, vortexed and heated at 100oC for 5 min 
before being cooled on ice. 10 μl of 3-phenylphenol solution (0.15% (w/v) 3-
phenylphenol in 0.5% (w/v) NaOH) was added to one sample tube, while 10 μl 0.5% 
NaOH was added to the respective duplicate control tube. The tubes were mixed and 200 
μl of each sample and control were then transferred into wells of a 96-well flat-bottomed 
microtitre plate (Costar, Corning) and A520 was read within 5 min in a SpectraMax M2 
Microplate Reader. The difference in the amount of uronic acid was determined by 
subtracting the NaOH-only control A520 from that for the respective test sample. 
 
46 
 
2.7.3 CPS ELISA  
 For S. pneumoniae serotype 14 (and other serotypes that do not contain uronic 
acid in the CPS repeat unit), CPS was quantitiated by ELISA using a modification of the 
method described by Trappetti et al. (2011). Serial two-fold dilutions in sterile normal 
saline of either purified CPS standard (American Type Culture Collection, USA) (starting 
concentration 10 μg/ml) or CPS preparations (Section 2.12.1) were used to coat poly-L-
lysine-treated Nunc MaxiSorp®  flat-bottom 96-well plates overnight at 4oC. After 
blocking with 1% foetal calf serum (FCS) for 1 h at room temperature, the samples were 
reacted with a 1:10,000 dilution of serotype 14 pneumococcal typing serum (Statens 
Seruminstitut, Copenhagen, Denmark) for 4 h. The plates were washed five times (0.05% 
Tween in PBS) and then reacted with a 1:20,000 dilution of goat anti-rabbit IgG alkaline 
phosphatase conjugate ( Sigma-Aldrich) overnight at 4°C. The plates were then developed 
using alkaline phosphatase substrate (p-nitrophenyl phosphate solution (PNPP) (Sigma)) 
(1mg/ml) in diethanolamine buffer (1.0 M diethanolamine with 0.5 mM MgCl2), and the 
absorbance at 405 nm was read in a Spectramax M2 spectrometer (Molecular Devices, 
California, USA).    
 
2.8 Manipulation and analysis of DNA 
2.8.1 Preparation of genomic DNA 
 To obtain genomic DNA for use in PCR for MLST typing and other 
investigations, strains were grown overnight on BA at 37°C in 5% CO2 and then 
harvested and suspended in an Eppendorf tube containing 1 ml sterile PBS to an A600 of 
0.2. The suspension was then microfuged for 5 min at 8,000 × g and the supernatant was 
removed. The bacterial pellet was then resuspended in 300 μl 0.1% DOC in PBS and 
incubated at 37°C for 30 min. The suspension was then microfuged for 3 min and the 
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supernatant was then transferred to a new Eppendorf 1.5 ml tube. Purification of DNA 
was then carried out using the QIAGEN DNeasy Blood and Tissue Kit according to the 
manufacturer’s instructions. DNA was then quantitated by A260/A280 using a Nanodrop 
spectrophotometer (Thermo Scientific).  
2.8.2 PCR, agarose gel electrophoresis and DNA sequencing 
 PCR was performed using Phusion Flash High Fidelity PCR Master Mix (Thermo 
Fisher) according to the manufacturers’ instructions. For overlap PCR in which one large 
product was to be amplified from multiple smaller fragments, equimolar amounts of each 
fragment were used as template, with approximately 100 ng of template DNA used in 
total.   
Agarose gel electrophoresis was performed using gels composed of 0.8 - 1.5% 
(w/v) agarose dissolved in TBE (44.5 mM Tris, 44.5 mM boric acid, 1.25 mM EDTA, pH 
8.4). These were immersed in TBE and electrophoresed at 180 V. DNA samples were 
mixed with 1/10th volume of loading buffer (15% [w/v] Ficoll, 0.1% [w/v] bromophenol 
blue, 100 ng/ml RNAse A) prior to loading. Staining was performed using GelRedTM 
(Biotium, California, USA) according to the manufacturer’s instructions and DNA was 
visualised by trans illumination with short wavelength ultraviolet light using the Gel Doc 
XR system (Bio-Rad, NSW, Australia).  
 For sequencing, DNA was purified from PCR reactions using a QIAquick PCR 
purification kit (Qiagen) according to the manufacturer’s instructions. Purified DNA was 
submitted to the Australian Genome Research Facility for sequencing. 
2.8.3 Multi Locus Sequence Typing of clinical isolates  
 MLST typing involved PCR amplification and sequence analyses of portions of 
the conserved but polymorphic housekeeping genes aroE, gdh, gki, recP, spi, xpt and ddl, 
using primers listed in Table 2.2. Sequencing of PCR products was carried out as 
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described in Sections 2.7.1 and 2.7.2 above. Sequence data for the 7 genes were then 
compared against the MLST database (http://www.pubmlst.org) and sequence type (ST) 
was assigned on the basis of allelic profile.  
2.8.4 Overlap-extension PCR 
 Site-directed mutagenesis of target genes was carried out using overlap-extension 
polymerase chain reaction (OE-PCR) (Ho et al., 1989) to amplify the products required 
for S. pneumoniae transformation. Primers used to amplify the respective fragments are 
specified in Table 2.2. 
2.8.5 Transformation of S. pneumoniae 
 S. pneumoniae strains were grown overnight on BA at 37°C in 5% CO2, and then 
inoculated into 1 ml C+Y medium at an initial A600 = 0.05 and then incubated at 37°C to 
a final A600 = 0.2. The cultures were then diluted 1/10 in fresh C+Y medium in a total 
volume of 1.0 ml. Competence was induced by addition of 50 ng of competence 
stimulating peptides CSP1 or CSP2 and incubation at 37°C for 15 min, followed by 
addition of 1 μg donor DNA and incubation for 2-3 h at 37°C. The culture was then 
microfuged for 1 min, 950 μl of the supernantant was removed, and then the pellet was 
resuspended and plated on BA supplemented with 0.2 μg/ml erythromycin and incubated 
overnight at 37°C in 5% CO2.  
 
2.9 RNA extraction and analysis  
2.9.1 RNA Extraction 
 Strains were grown in 5 ml C+Y medium at pH 7.4 or 6.8, with or without 100 
μM Fe(III), or in serum broth, until A600 = 0.2. Using RNase-free Eppendorf tubes, 2 
volumes of RNAProtect reagent (Qiagen) was added to 1 volume of bacterial culture, 
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mixed and left to stand for 5 min at room temperature. The culture was then microfuged 
at 8,000 × g for 5 min and the supernatant was discarded. RNA was then extracted from 
the bacterial pellet using the Qiagen RNeasy Mini Kit, according to the manufacturer’s 
instructions (Qiagen RNAprotect Bacteria Reagent Handbook).  
2.9.2 Quantitative real-time RT-PCR  
 Real-time RT-PCR was performed using the Invitrogen Superscript III Platinum 
SYBR green one-step qRT-PCR kit (Invitrogen). A primer pair specific for 16S rRNA 
was used as an internal control and diluted 1/200 in RNase-free water (Table 2.2). A 
standard 20 μl reaction mix was prepared for all the samples (10 μl 2× Phusion Flash 
PCR Mix [Phusion Flash II DNA Polymerase, 2X reaction buffer, dNTPs, and MgCl2] 
[Thermo-Fisher Scientific], 7 μl ultrapure MilliQ water, 1 μl forward primer, 1 μl reverse 
primer [Table 2.2]); followed by 1 μl of template or 16S rRNA diluted internal control. 
Amplification was performed using a Light Cycler 480 instrument (Roche) with the 
following program conditions: reverse transcription cycle at 50°C for 15 min, followed 
by 35 amplification cycles comprising denaturation at 95°C for 15 sec, annealing at 60°C 
for 30 sec and extension at 72°C for 30 sec. The relative gene expression was calculated 
by the comparative critical threshold (2-∆∆CT) method (Livak & Schmittgen, 2001), 
whereby the amount of target mRNA in one sample was compared with the amount of the 
same target mRNA in another sample, which was normalised to the 16S rRNA internal 
control concentration. Alternatively, the amount of target mRNA relative to the amount 
of the 16S rRNA was also determined in some instances. 
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2.10 Animal studies 
2.10.1 Mouse infection model 
 Animal experimentation was approved by the University of Adelaide Animal 
Ethics Committee. Groups of 5 week old outbred Swiss (CD-1) mice were first 
anaesthetized by intraperitoneal injection with sodium pentobarbitol (Nembutal [Rhone-
Merieux]) at a dose of 66 µg/g body weight. Mice were then challenged intranasally with 
a 40 µl volume containing 1 × 108 CFU of the respective clinical isolate grown to early 
exponential phase (A600 = 0.2) in SB. The mice were monitored frequently for signs of 
disease (e.g. lethargy, ruffled coat, etc.). At specified time points, the mice were 
euthanized by CO2 asphyxiation. Blood was collected from the superior vena cava and 
after perfusion via the left ventricle with sterile saline, lung, brain, nasopharynx and ear 
tissues were harvested into tubes containing 2.8 mm diameter ceramic beads and 1 ml 
PBS and homogenized with a Precellys® 24 tissue homogeniser (Bertin Technologies). 
The samples were then serially diluted in serum broth and plated onto BA supplemented 
with gentamicin (to inhibit background bacteria). Plates were then incubated at 37°C in 
5% CO2 overnight and bacterial counts were determined. 
2.10.2 In vivo competition experiments. 
  Two groups of mice were challenged with equal numbers of ST15/4495 blood 
isolate and ST15/9-47 ear isolate. In order to distinguish the strains, erythromycin-
resistant derivatives of each strain (ST15/4495:pAL2 and ST15/9-47:pAL2) were 
constructed by transformation with the plasmid pAL2, as described in Section 2.8. Two 
competition experiments were performed with 5 mice per group for each time point of 24 
h and 72 h. In one experiment, mice were challenged intranasally with a mixed inoculum 
comprising equal numbers of ST15/4495 and ST15/9-47:pAL2 (approximately 5 × 107 
CFU of each strain), in a modified protocol previously described by Harvey et al. (2011). 
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In another experiment, mice were challenged with equal numbers of ST15/4495:pAL2 
and ST15/9-47 (approximately 5 × 107 CFU of each strain). Tissue samples were plated 
on BA or BA + erythromycin to determine the numbers of sensitive and resistant 
organisms. The competitive index (CI) within nasopharyngeal, ear, lung and brain 
samples was determined at 24 h and 72 h post-challenge by calculating the ratio of 
sensitive to resistant organisms, relative to the input ratio (the ratio of sensitive to 
resistant organisms in the original inoculum). As the CI values were log transformed, a 
value close to 0 is expected if strains compete equally. For the purposes of CI calculation, 
when a given strain was not detected in a particular niche, it was assigned a CFU value 
equivalent to 50% of the detection threshold.    
2.10.3 FACS detection of Ly-6G and F4/80 positive cells in blood and 
bronchoalveolar lavage  
 Blood was collected from infected and uninfected mice by cardiac puncture into 
heparin tubes. Blood leukocytes were isolated by lysing the red blood cells with a 
hypotonic shock. Bronchoalveolar lavage (BAL) was performed using 1 ml of ice cold 
PBS. The blood leukocytes or BAL cells were washed in ice cold PBS and fixed in 
1% paraformaldehyde in PBS overnight at 4°C. Before immunofluorescence labelling, 
the leukocytes were washed with PBS and permeabilised with 0.1 ml of 0.1% Triton 
X100 in PBS for 30 sec. The cells were then washed again with PBS and were then 
incubated with monoclonal rat anti-mouse Ly-6G (BD Biosciences) or monoclonal rat 
anti-mouse  F4/80 (Santa Cruz Biotechnology) at room temperature for 1 h. Ly-6G 
(neutrophil marker) or F4/80 (monocyte/macrophage marker) was detected by incubation 
with Alexa 488-conjugated donkey anti-rat Ig (Invitrogen) at RT for 1 h. Fluorescence 
data were acquired with a BD FACSCanto (Becton-Dickinson) or BD  LSR II with high-
throughput sampler plus BD FACSDiva Software (version 5.0.3) and analyzed with 
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WEASLE v2.6 software. The fluorescence intensity of Alexa-488 is proportional to the 
expression level of Ly-6G or F4/80. The data are reported as the product of geometric 
mean fluorescence intensity and the total number of Ly-6G or F4/80 positive cells. The 
data are presented as means ± standard errors (SE), and differences were analyzed using 
Student's t test.  
2.10.4 Examination of lung tissue with HE staining or immunofluorescence labelling  
  After the blood and BAL were collected, the lungs of infected and uninfected 
mice were removed and fixed in 4% formaldehyde overnight at 4°C, embedded in 
paraffin, sectioned, stained with hematoxylin-eosin (HE), and examined by light 
microscopy. Alternatively, sections were labelled with rat anti-mouse Ly-6G or F4/80, 
followed by Alexa 488-conjugated anti-rat IgG and examined by fluorescence 
microscopy (AX 70; Olympus).  
 
2.11 Detroit 562 adherence and invasion assays  
 Detroit 562 (human nasopharyngeal carcinoma) cells were grown in a 1:1 mix of 
Dulbecco’s Modified Eagle Medium (Gibco) and Ham’s F-12 Nutrient Mixture (Gibco), 
supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 50 IU of penicillin and 50 
μg/ml streptomycin. Confluent monolayers in 24-well plates were washed with PBS and 
infected with pneumococci (approximately 5 × 105 CFU per well) in 1:1 mixture of the 
above culture medium (without antibiotics) and C+Y, pH 7.4. Plates were centrifuged at 
500 × g for 5 min, and then incubated at 37°C in 5% CO2 for 2.5 h. Monolayers were 
washed 3 times in PBS, and adherent bacteria were released by treatment with 100 μl 
trypsin/EDTA, followed by 400 μl 0.025% Triton X-100. Lysates were serially diluted 
and plated on BA to enumerate adherent bacteria. Invasion assays were carried out 
essentially as above, except that after the post-adherence washing step, cultures were 
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incubated for 1 h in fresh medium supplemented with 200 μg gentamicin and 10 μg 
benzyl penicillin per ml to kill extracellular bacteria, after which monolayers were again 
washed, lysed, serially diluted and plated on BA, as above.    
 
 
2.12 PCR Array analysis of host innate and adaptive immune responses 
2.12.1 Tissue RNA isolation using TRIzol® 
 Infected mouse tissues harvested in 1 ml TRIzol® Reagent (Ambion, Life 
Technologies) were first homogenized with 1 ml PBS in tubes containing 2.8 mm 
diameter ceramic beads tubes with a Precellys® 24 homogenizer (Bertin Technologies, 
France). The homogenate was then transferred to RNase-free tubes and incubated at room 
temperature for 5 min (or stored at -80oC). Chloroform (200 μl per tube) was then added 
and the tubes were shaken vigorously. The tubes were then incubated at room 
temperature for 3 min and centrifuged at 13,000 × g for 15 min at 4°C. The aqueous 
phase was then added to 500 μl isopropanol, inverted gently to mix, and then incubated at 
room temperature for 10 min before being centrifuged at 13,000 × g for 10 min at 4°C. 
The supernatant was then discarded and the pellet washed with 1 ml 75% (v/v) ethanol, 
vortexed and centrifuged at 10,000 × g for 5 min at 4°C. Ethanol was then removed and 
the resultant pellet was air dried and redissolved in 100 μl RNAse-free water. RNA 
purification and clean up was carried out using the RNeasy kit (Qiagen), according to the 
manufacturer’s instructions. 
2.12.2 cDNA Synthesis 
 cDNA was synthesised from RNA samples using the RT2 First Strand Kit 
(Qiagen). RNA samples were firstly treated with RNase-free DNase to remove 
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contaminating genomic DNA and then reverse-transcribed to cDNA according to the 
manufacturer’s protocols.  
2.12.3 RT2 Profiler Array 
 Mouse innate and adaptive immune responses to S. pneumoniae infection were 
examined using the Mouse Innate & Adaptive Immune Responses RT² Profiler PCR 
Array [Qiagen] according to manufacturer’s instructions. Briefly, a PCR components mix 
(2× RT2 SYBR Green MasterMix, cDNA synthesis reaction and RNAse-free water) was 
firstly prepared according to manufacturer’s instructions. The mix was then dispensed 
into the RT2 Profiler PCR Array plate, sealed tightly with optical adhesive film and 
centrifuged for 1 min at 1000 × g at RT. The array plate was then analysed for gene 
expression by quantitative reverse transcription-PCR (qRT-PCR) on a Roche LightCycler 
480 II system using the following program settings: hot-start cycle (1 cycle at 95°C for 10 
min), 45 amplification cycles (95°C for 15 sec, 60°C for 1 min) and a melt curve cycle 
(95°C for 1 min, 65°C for 2 min and 95°C continuously thereafter). Five (5) 
housekeeping genes (Actb, B2m, Gapdh, Gusb, Hsp90ab1) were included in the array to 
normalize PCR array data. In addition,  genomic DNA control primer set was included to 
detect nontranscribed genomic DNA contamination, along with reverse transcription 
controls (RTC) to determine cDNA synthesis efficiency. Positive PCR controls (PPC) 
were also included to test the efficiency of the PCR itself; while the latter two controls 
(RTC and PPC) also tested for interwell and intraplate efficiency. Data were then 
analyzed using a PCR Array Data Analysis Software provided by the manufacturer. 
 
2.13 RNA Sequencing 
 Strains were grown in serum broth at 37°C to A600 = 0.2. RNAProtect reagent 
(Qiagen) was then added and the bacterial culture was centrifuged at 3000 × g for 30 min. 
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RNA was extracted from the pellet and purified using the Qiagen RNeasy Mini Kit 
according to the  manufacturer’s instructions (Qiagen RNAprotect Bacteria Reagent 
Handbook). The purified RNA was then quantitated using the Nanodrop 
spectrophotometer (Thermo Scientific) and the integrity of the RNA (RIN number) 
determined using an Agilent 2100 Bioanalyzer, according to the manufacturer’s 
instructions (Agilent). RNA samples with a RIN integrity of ≥ 8.0 and total yield of ≥ 3 
ng were then sent to the Australian Genome Research Facility (AGRF) for ribosomal 
RNA removal, cDNA library preparation and RNA-sequencing using the Illumina Next-
Gen Sequencing platform. Initial analysis to compare the isolates’ transcriptomes was 
carried out by AGRF using the EDGE-pro (Estimated Degree of Gene Expression in 
PROkaryotes) pipeline, as described by Magoc et al. (2013) and R/Bioconductor-based 
voom and limma packages, as described by Ritchie et al. (2015). In addition to AGRF’s 
data analyses, differential gene expression analysis was also carried out using the 
R/Bioconductor DESeq (v.3.2) package, as described by Anders et al. (2010) to validate 
AGRF's analysis, as well as to examine differential gene expression analysis between 
single isolates. Firstly, sequenced reads were aligned to the CGSP14 and SPNOXC 
reference genomes using Bowtie2 (v2.0.0.0-beta6), as described by Langmead et al. 
(2012). SAMtools (v 0.0.18) (Li et al., 2009) and BEDTools (v2.24.0) (Quinlan et al.,, 
2010) were then used to obtain read counts for each transcript.  DESeq analysis was 
subsequently performed using these data. The Basic Local Alignment Search Tool 
(BLAST) (Altschul et al., 1990) and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database resource (http://www.genome.jp/kegg/genes.html) were used as 
appropriate.  
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Chapter 3: In vitro characterization of biofilm 
formation by S. pneumoniae clinical isolates. 
3.1 Introduction 
 The studies of infectious diseases initiated by Koch and colleagues over 150 years 
ago were essentially based on the development of pure culture techniques for growth and 
isolation of planktonic, individual bacterial cells (Koch, 1880). More recent studies have 
shown instead that bacteria predominantly exist in biofilms, as a preferred lifestyle in 
many natural environments (Fux et al., 2003). Analysis of human biopsy samples and 
studies in animal models have highlighted the potential importance of biofilm formation 
by S. pneumoniae during the early stages of colonisation and invasion (Hall-Stoodley et 
al., 2006; Reid et al., 2009; Sanchez et al., 2010).  
 A large number of bacterial factors have been implicated in pneumococcal biofilm 
formation in previous studies, including the competence stimulating peptide (CSP) and 
LuxS quorum sensing systems, as well as various pneumococcal surface structures and 
virulence factors (Blanchette-Cain et al., 2013; Hall-Stoodley et al., 2008; Marks et al., 
2012; Moscoso et al., 2006; Oggioni et al., 2006; Parker et al., 2009; Pettigrew et al., 
2014; Sanchez et al., 2011; Sanchez et al., 2010; Shak et al., 2013; Talekar et al., 2014; 
Trappetti et al., 2009; Trappetti et al., 2011c; Vidal et al., 2011; Yadav et al., 2013). 
However, the link between biofilms and disease has been less well defined. While some 
studies described the importance of biofilms in invasive disease (Trappetti et al., 2011b), 
others have observed that the production of biofilms attenuated disease (Blanchette-Cain 
et al., 2013; Chao et al., 2014; Sanchez, Kumar, et al., 2011). These differences may have 
been attributable to the type of experimental models used (Shak et al., 2013; Trappetti et 
al., 2011a).  
 Many studies involving different in vitro models have shown that biofilm 
formation is significantly affected by the growth medium and other environmental 
factors, including pH, temperature and osmolarity (Moscoso et al., 2006; Oggioni et al., 
2006; Trappetti et al., 2009). Moscoso et al. (2006) observed optimal pneumococcal 
biofilm development when the starting cultures were grown in a semisynthetic (C) 
57 
 
medium with pH adjusted in the range 7.0 - 8.0. A drop in pH to below 6.0 was shown to 
inhibit the activity of the major autolysin LytA, an important determinant of biofilm 
formation (Lopez et al., 1976; Moscoso et al.,  2006).  
 Despite the abundant literature on pneumococcal biofilm formation in clinical 
isolates, studies on the influence of clinical isolate source and iron availability on biofilm 
formation have been very limited. These studies include that of Trappetti et al. (2011c) 
which reported that pneumococcal biofilm formation was significantly enhanced in D39 
strains in media supplemented with 50 μM Fe(III), while Garcia-Castillo et al. (2007) 
reported that biofilm formation occurred more frequently from cystic fibrosis (CF) 
respiratory samples than among non-CF blood culture isolates.  
  Certain serotypes and ST types of S. pneumoniae have been reported to show a 
greater potential to cause invasive disease in humans than others; likewise strains differ in 
their propensity to cause otitis media (OM) (Forbes et al., 2008; Hanage et al., 2005). 
This suggests that strains may differ in their capacity to adapt to and survive or proliferate 
within distinct host microenvironments. This further implies that clinical isolates from 
cases of OM may exhibit distinct in vitro and in vivo phenotypes from blood isolates. 
Two conditions that vary significantly between different niches of the human body are 
metal ion concentrations (McDevitt et al., 2011) and pH; the pH of the blood is typically 
around 7.4, while in the (uninfected) ear cavity pH is in the range of 6.5 - 6.8 (Jahn, 
2001). The aim of the work described in this chapter was to investigate the influence of 
isolate source, pH and Fe(III) concentration on biofilm formation by clinical isolates 
belonging to five distinct capsular serotypes/groups: 3, 6, 9, 14 and 19. The strains were 
grown in C+Y medium with or without 100 μM Fe(III) supplementation, at either pH 7.4 
or 6.8, which corresponds to the environmental pH of the blood and ear cavity, 
respectively, in human hosts (Jahn, 2001). 
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3.2 Results 
3.2.1 Viable count (CFU/well) assays for influence of clinical isolate source, pH and 
Fe(III) availability on biofilm formation. 
 A total of 78 blood and OM isolates belonging to serotypes/groups 3 (n=25), 6 
(n=8), 9 (n=7), 14 (n=18) and 19 (n=20) were selected (see Section 2.1) and grown 
accordingly (see Section 2.2). Two assays were carried out in parallel. The viable count 
assay quantitated colony forming units (CFU) of bacterial biofilms dispersed by brief 
sonication after 24 h incubation (detection limit of 40 CFU/well). The assays were 
performed in four different media: C+Y pH 7.4, C+Y pH 6.8, C+Y+Fe(III) pH 7.4 and 
C+Y+Fe(III) pH 6.8. The crystal violet assay quantitated the biofilm biomass and matrix 
by measuring the A570 of stained pneumococcal biofilms after 24 h incubation (see 
Section 2.4.1) (detection limit of A570 = 0.05, which corresponds to the Absorbance after 
staining of blank wells incubated with C+Y media without bacteria). Statistical 
comparisons were performed only for isolates which showed biofilm formation in all 
tested media conditions. Firstly, as shown in Figures 3.1 – 3.8, the viable count biofilm 
assays revealed markedly variable biofilm formation capacity of the strains within a 
clinical isolate source in response to pH and the presence of Fe(III), as discussed below. 
3.2.1.1 Serotype 3  
 For the viable count biofilm assay of serotype 3 strains, a total of 12 blood (Figure 
3.1) and 13 ear isolates (Figure 3.2) were investigated in 4 media conditions, as described 
above. Biofilm CFU counts for blood and ear isolates that formed detectable biofilms 
were low compared to those for the other serotypes/groups tested, and ranged between 
5×101 and 103 CFU per well (Figure 3.1 and 3.2). For the blood isolates, two strains 
(5267 and 5272) did not form biofilms under any condition tested, while biofilm 
formation for 5258 was only evident in C+Y pH 7.4, and that was at a low level. Two 
strains (4529 and 5060) formed biofilms in all 4 media.  5065, 4482, 4499, 5234, 4483, 
formed biofilms in both C+Y and C+Y+Fe(III) at pH 7.4, but at pH 6.8, biofilm 
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formation was evident for only one of these strains (5065) and only when Fe(III) was 
supplemented. 4521 formed biofilms at both pHs when there was no Fe(III) 
supplementation.  4522 formed biofilms in C+Y+Fe(III) pH 7.4 and C+Y pH 6.8.  The 
biofilm assay suggested better overall biofilm formation of the blood isolates at pH 7.4 
compared to pH 6.8, particularly in the presence of Fe(III). Nevertheless, when statistical 
analysis was performed using the 2-tailed Student’s t-test to investigate the influence of 
pH (i.e. C+Y pH 6.8 vs. C+Y pH 7.4 and C+Y+Fe(III) pH 6.8 vs. C+Y+Fe(III) pH7.4) 
and Fe(III) supplementation (i.e. C+Y pH 6.8 vs. C+Y+Fe(III) pH 6.8 and C+Y pH 7.4 
vs. C+Y+Fe(III) pH7.4) on biofilm formation on all 12 isolates, no significant differences 
were detected.  
 For ear isolates, 6 strains (54833, 57934, 9706840, 61887, 22318, 58497) formed 
low level (<102 CFU) or no biofilms in C+Y pH 7.4, but exhibited greater biofilm 
formation at pH 6.8 with significant increases in three isolates (54833, 61887 and 58497) 
(P < 0.01). Four of the remaining strains (75100, 68872, 53203 and 79275) formed 
biofilms at densities > 102 CFU/well in both in C+Y pH 7.4 and C+Y pH 6.8, while two 
strains (5069 and 5268) formed little or no biofilms (< 102 CFU/well) under all conditions 
tested. Fe(III) had no consistent effect on biofilm formation at pH 7.4, but at pH 6.8, 
Fe(III) was inhibitory for 7 biofilm-forming strains (P < 0.01) except 57934, 9706840, 
62139 and 75100 which showed inhibition but was not significantly different. 
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Figure 3.1. Biofilm formation of serotype 3 blood isolates assessed by viable count 
(CFU/well). Biofilm formation by serotype 3 blood isolates after 24 h of growth in C+Y 
medium at either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 100 
μM Fe(III), determined by viable count (CFU/well). Data are the means ± SEM for three 
independent experiments. 
 
 
 
 
Figure 3.2. Biofilm formation of serotype 3 ear isolates by viable count (CFU/well). 
Biofilm formation by serotype 3 ear isolates after 24 h of growth in C+Y medium at 
either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 100 μM Fe(III), 
determined by viable count (CFU/well). Data are the means ± SEM for three independent 
experiments. 
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3.2.1.2 Serogroup 6 
 For the viable count biofilm assay of serogroup 6 strains, a total of 4 blood (4501, 
4519, 4526 and 4550) and 4 ear isolates (53034, 61888, 87765 and 50397) were 
investigated. CFU counts in isolates that formed biofilms ranged between 102 and 105 
CFU (Figure 3.3). 4501 did not form a biofilm in any of the conditions tested, while 4519 
formed a biofilm >102 CFU/well only in C+Y pH 7.4 with Fe(III) supplementation. The 
remaining two blood and four ear isolates formed measurable biofilms in all conditions 
tested. Whilst statistical analysis identified a number of significant differences in biofilm 
formation by individual strains between growth conditions (see Table 3.1), there was no 
consistent statistically significant effect of isolate source, pH or Fe(III) on biofilm 
formation across all strains. However, at pH 7.4, there was a consistent stimulatory effect 
of Fe(III) on biofilm formation for 7 of the 8 strains, which was significantly different in 
3 strains (4550 and 50397 (P < 0.05) and 4519 (P < 0.01)). 
 
Figure 3.3. Biofilm formation by serogroup 6 blood and ear isolates by viable count 
(CFU/well). Biofilm formation by serogroup 6 blood and ear isolates after 24 h of growth 
in C+Y medium at either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 
100 μM Fe(III), determined by viable count (CFU/well). Data are the means ± SEM for 
three independent experiments. 
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Table 3.1. Statistical analysis of biofilm formation by serogroup 6 isolates.a 
Isolates C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y+Fe(III) C+Y 
4501 NS NS NS NS 
4519 P < 0.01 NS P < 0.01 P < 0.05 
4526 NS NS P < 0.05 P < 0.05 
4550 P < 0.05 NS NS P < 0.05 
53034 NS NS NS NS 
61888 NS NS P < 0.01 P < 0.05 
87765 NS NS NS NS 
50397 P < 0.05 NS NS P < 0.05 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student t-tests. NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
 
3.2.1.3 Serogroup 9  
 For the viable count biofilm assay of serogroup 9, a total of 3 blood (4531, 4539, 
5055) and 4 ear isolates (9723173, 40502, 66919 and 62195) were investigated. CFU 
counts in isolates that formed biofilms ranged between 103 and 105 CFU (see Figure 3.4). 
For blood isolates, 4531 and 4539 formed biofilms only at pH 7.4, and was significantly 
enhanced by Fe(III) supplementation for 4539 (P < 0.05). 5055 formed biofilms in all 
media conditions and was significantly enhanced at pH 7.4 in C+Y+Fe(III). Enhanced 
biofilm formation was also observed for 5055 in C+Y pH 6.8 compared to pH 7.4 (P < 
0.05). For ear isolates, 9723173 did not form a biofilm at either pH, while 40502 and 
62195 formed biofilms similarly at both pH 7.4 and pH 6.8. 66919 formed a biofilm only 
at pH 7.4, especially with Fe(III) supplementation. Similar to serogroup 6, there was no 
consistent effect of pH, Fe(III) or isolate source on biofilm formation across all strains, 
except for the consistent stimulatory effect of Fe(III) supplementation at pH 7.4 (P < 
0.05). 
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Figure 3.4 Biofilm formation by serogroup 9 blood and ear isolates by viable count 
(CFU/well). Biofilm formation by serogroup 9 blood and ear isolates after 24 h of growth 
in C+Y medium at either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 
100 μM Fe(III), determined by viable count (CFU/well). Data are the means ± SEM for 
three independent experiments. 
 
Table 3.2. Statistical analysis of biofilm formation by serogroup 9 isolates.a 
Isolate C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
4531 NS NS P < 0.01 P < 0.05 
4539 P < 0.01 NS P < 0.01 P < 0.01 
5055 P < 0.05 NS NS P < 0.05 
9723173 NS NS NS NS 
40502 NS NS NS NS 
66919 P < 0.05 NS P < 0.01 P < 0.01 
62195 NS NS NS NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student t-tests. NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
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3.2.1.4 Serotype 14 
 For the viable count biofilm assay of serotype 14, a total of 9 blood (Figure 3.5) 
and 9 ear isolates (Figure 3.6) were investigated. From both figures it can be seen that 
serotype 14 isolates showed the highest biofilm formation capacity when compared to 
other serotypes, with all isolates forming detectable biofilms. For the blood isolates, 
although actual level of biofilm formation by individual strains varied between 
approximately 2 × 102 and 106 CFU/well, there was close agreement within a strain 
between biofilm formation at pH 7.4 vs pH 6.8. Statistical analysis of biofilm data for 
individual strains (Table 3.3) showed a significant stimulatory effect of Fe(III) for strains 
4524, 4534, 4511 and 4545 at pH 7.4, and for strain 4511 at pH 6.8 as well. Three of the 
blood isolates (4524, 4545 and 4549) also exhibited significantly higher biofilm 
formation at pH 7.4 vs pH 6.8. However, there was no significant overall effect for either 
parameter.   
 For the type 14 ear isolates, the level of biofilm formation by individual strains 
varied between approximately 5 × 102 and 106 CFU/well, but there was less agreement 
within a strain between biofilm formation at pH 7.4 vs pH 6.8. Statistical analysis of 
biofilm data for individual strains (Table 3.4) showed a significant stimulatory effect of 
Fe(III) for all strains except 9-47 at pH 7.4 (P < 0.05). Interestingly, the outlier 9-47 was 
the only strain showing a significant stimulatory effect of Fe(III) at pH 6.8. Individual 
strains also exhibited significant differences in biofilm formation at pH 7.4 vs pH 6.8 
(Table 3.3), although the direction of change (i.e. higher or lower) was inconsistent 
between strains, with no overall significant effect.  
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Figure 3.5. Biofilm formation by serotype 14 blood isolates viable count (CFU/well). 
Biofilm formation by serotype 14 blood isolates after 24 h of growth in C+Y medium at 
either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 100 μM Fe(III), 
determined by viable count (CFU/well). Data are the means ± SEM for three independent 
experiments. 
 
Table 3.3. Statistical analysis of serotype 14 blood isolate biofilm formation.a 
Isolate C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
4484 NS NS NS NS 
4495 NS NS NS NS 
4524 P < 0.01 NS P < 0.05 NS 
4534 P < 0.01 NS NS P < 0.05 
4511 P < 0.01 P < 0.01 NS NS 
4538 NS NS NS NS 
4545 P < 0.05 NS P < 0.05 NS 
4549 NS NS P < 0.01 P < 0.01 
4559 NS NS NS NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type 
respectively. 
 
66 
 
 
Figure 3.6. Biofilm formation by serotype 14 ear isolates by viable count (CFU/well). 
Biofilm formation of serotype 14 ear isolates after 24 h of growth in C+Y medium at 
either pH 7.4 or 6.8, with (light gray columns) or without (open columns) 100 μM Fe(III), 
determined by viable count (CFU/well). Data are the means ± SEM for three independent 
experiments. 
 
Table 3.4. Statistical analysis of serotype 14 ear isolates biofilm formation.a 
Isolates C+Y+Fe(III) vs C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
50582 P < 0.05 NS P < 0.005 P < 0.05 
76547 P < 0.01 NS P < 0.01 NS 
9-47 NS P < 0.01 P < 0.0005 P < 0.0005 
9-5133 P < 0.05 NS P < 0.05 NS 
51742 P < 0.005 NS P < 0.01 NS 
53705 P < 0.0005 NS P < 0.005 P < 0.005 
67456 P < 0.05 NS P < 0.05 NS 
73363 P < 0.05 NS NS P < 0.05 
9-5201 P < 0.005 NS P < 0.005 NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
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3.2.1.5 Serogroup 19  
 A total of 10 blood (Figure 3.7) and 10 ear (Figure 3.8) serogroup 19 isolates were 
investigated.  All isolates formed biofilms with counts rangingaa between 102 and 105 
CFU/well. For the blood isolates, Fe(III) supplementation had no significant impact on 
biofilm formation at either pH 7.4 or pH 6.8. However, three strains (5219, 5239 and 
5027) formed significantly greater biofilms at pH 7.4 than pH 6.8, with or without Fe(III) 
supplementation, while 5058 showed significantly greater biofilms at pH 7.4 than pH 6.8 
in C+Y+Fe(III) (Table 3.5).   
 For serogroup 19 ear isolates (Figure 3.8), six strains (24190, 51862, 53685, 
64051, 74434 and 79213) formed biofilms similarly in all conditions tested. Biofilm 
formation was significantly greater for 48498 in both C+Y and C+Y+Fe(III) at pH 7.4 
than at pH 6.8 (see Table 3.6). In contrast, 61884 and 74951 formed significantly greater 
biofilms at pH 6.8 in both C+Y and C+Y+Fe(III) than at pH 7.4, while 63748 formed 
significantly better biofilms at pH 6.8 than pH 7.4 only in C+Y+Fe(III). Fe(III) 
supplementation did not significantly impact biofilm formation of any isolate at either 
pH. 
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Figure 3.7  Biofilm formation by serogroup 19 blood isolates by viable count 
(CFU/well). Biofilm formation by serogroup 19 blood isolates after 24 h of growth in 
C+Y medium at either pH 7.4 or 6.8, with (shaded columns) or without (open columns) 
100 μM Fe(III), determined by viable count (CFU/well). Data are the means ± SEM for 
three independent experiments. 
 
 
Table 3.5. Statistical analysis of serogroup 19 blood isolates biofilm formation.a 
Isolates C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
5210 NS NS NS NS 
5219 NS NS P < 0.05 P < 0.0005 
5239 NS NS P < 0.005 P < 0.005 
5221 NS NS NS NS 
4507 NS NS NS NS 
5027 NS NS P < 0.05 P < 0.05 
5058 NS NS P < 0.01 NS 
5074 NS NS NS NS 
5030 NS NS NS NS 
5054 NS NS NS NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
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Figure 3.8.  Biofilm formation by serogroup 19 ear isolates by viable count. Biofilm 
formation by serogroup 19 ear isolates after 24 h of growth in C+Y medium at either pH 
7.4 or 6.8, with (shaded columns) or without (open columns) 100 μM Fe(III), determined 
by viable count (CFU/well). Data are the means ± SEM for three independent 
experiments. 
 
 
Table 3.6. Statistical analysis of serogroup 19 ear isolates biofilm formation.a 
Isolates C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
24190 NS NS NS NS 
51862 NS NS NS NS 
53685 NS NS NS NS 
48498 NS NS P < 0.01 P < 0.05 
61884 NS NS P < 0.05 P < 0.05 
63478 NS NS P < 0.05 NS 
64051 NS NS NS NS 
74434 NS NS NS NS 
74951 NS NS P < 0.05 P < 0.05 
79213 NS NS NS NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
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3.2.2 Crystal Violet biofilm assay. 
 Biofilm formation by the various serotype/group blood and ear isolates was also 
assessed using Crystal Violet (CV) staining assays as independent confirmation of the 
CFU assays described above. 
3.2.2.1 Serotype 3 
 Similar to the CFU data, CV assays of serotype 3 blood isolates (Figure 3.9) 
showed strain-strain variation in biofilm formation in response to pH and Fe(III) with the 
maximum observed A570 of 2, which was the highest compared to all other 
serotypes/groups. Ten of the twelve blood isolates formed biofilms similarly in all media 
conditions. However, 5234 formed significantly lesser biofilms in C+Y+Fe(III) at pH 7.4 
than at pH 6.8 (P < 0.05), while 5267 formed greater biofilms at pH 7.4 than pH 6.8, 
regardless of Fe(III) supplementation (P < 0.05 in both cases). Indeed, supplementation 
with Fe(III) did not significantly influence biofilm formation of any strain at either pH. 
 
 
Figure 3.9. Biofilm formation by serotype 3 blood isolates assessed by CV 
staining. Biofilm formation by serotype 3 blood isolates after 24 h of growth at either pH 
7.4 or 6.8, with or without 100 μM Fe(III), was assayed by CV staining and A570. Data 
are the means ± SEM for three independent experiments. 
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CV assay of the 13 serotype 3 ear isolates (Figure 3.10) indicated generally stronger 
biofilm formation at pH 6.8 than at pH 7.4. However, between assay variability resulted 
in the differences only being statistically significant for strains 75100 and 58497, with or 
without Fe(III) supplementation (P < 0.05 in all cases).  At pH 6.8, 75100 also showed 
significantly greater biofilm formation the presence of Fe(III) (P < 0.05).   
 
Figure 3.10. Biofilm formation by serotype 3 ear isolates assessed by CV staining. 
Biofilm formation by serotype 3 ear isolates after 24 h of growth at either pH 7.4 or 6.8, 
with or without 100 μM Fe(III), was assayed by CV staining and A570. Data are the means 
± SEM for three independent experiments. 
 
3.2.2.2 Serogroup 6 
 CV assays of serogroup 6 blood and ear isolates (Figure 3.11) showed variable 
biofilm formation capacity of the isolates, with a maximum A570 of 0.4, generally well 
below that observed for serotype 3 strains. For blood isolates, 4501 and 4526 formed 
biofilms similarly in all tested conditions. At pH 7.4, supplementation with Fe(III) 
significantly increased biofilm formation by 4519, while Fe(III) significantly increased 
biofilm formation by 4550 at pH 6.8 (see Table 3.7). For ear isolates, biofilm formation 
was significantly greater for 53034 and 87765 at pH 7.4 than at pH 6.8, with or without 
Fe(III). 50397 and 61888 also formed greater biofilms at pH 7.4 than at pH 6.8 in 
C+Y+Fe(III) and C+Y, respectively (Table 3.7). 
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Figure 3.11. Biofilm formation by serogroup 6 blood and ear isolates assessed by CV 
staining. Biofilm formation by serogroup 6 blood and ear isolates after 24 h of growth at 
either pH 7.4 or 6.8, with or without 100 μM Fe(III), was assayed by CV staining and 
A570. Data are the means ± SEM for three independent experiments. 
 
 
Table 3.7. Statistical analysis of serogroup 6 biofilm formation.a 
Isolates C+Y+Fe(III) vs. C+Y pH 7.4 vs. 6.8 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) C+Y 
4501 NS NS NS NS 
4519 P < 0.05 NS NS NS 
4526 NS NS NS NS 
4550 NS P < 0.01 NS NS 
53034 NS NS P < 0.01 P < 0.05 
61888 NS NS NS P < 0.05 
87765 NS P < 0.05 P < 0.005 P < 0.01 
50397 P < 0.005 NS P < 0.01 NS 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
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3.2.2.3 Serogroup 9 
 
 CV biofilm assays of serogroup 9 blood and ear isolates (Figure 3.12) showed a 
maximum A570 of 0.33. In the presence of Fe(III) blood isolates 4531, 4539 and 5055 
formed significantly greater biofilms at pH 7.4 than at pH 6.8; 4531 biofilms in C+Y 
were also greater at pH 7.4 than at pH 6.8 (Table 3.8). For the ear isolates, 40502 formed 
biofilms similarly in all conditions tested. In C+Y, 9723173 and 66919 formed 
significantly greater biofilms at pH 7.4 than at pH 6.8, while the opposite was true for 
62195 (Table 3.8).  
 
 
 
Figure 3.12. Biofilm formation by serogroup 9 blood and ear isolates assessed by CV 
staining. Biofilm formation by serogroup 9 blood and ear isolates after 24 h of growth at 
either pH 7.4 or 6.8, with or without 100 μM Fe(III), was assayed by CV staining and 
A570. Data are the means ± SEM for three independent experiments. 
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Table 3.8. Statistical analysis of serogroup 9 biofilm formation.a 
Isolates C+Y+Fe(III) vs. C+Y a pH 7.4 vs. 6.8b 
 at pH 7.4 at pH 6.8 C+Y + Fe(III) 
C+Y 
 
4531 NS NS P < 0.05 P < 0.05 
4539 NS NS P < 0.005 NS 
5055 NS NS P < 0.05 NS 
9723173 NS NS NS P < 0.05 
40502 NS NS NS NS 
66919 NS NS NS P < 0.05 
62195 NS NS NS P < 0.05 
a Differences in biofilm formation by individual strains under the indicated growth 
conditions were analysed using 2-tailed Student’s t-tests; NS denotes not significantly 
different. Significant increases and decreases are denoted in bold and normal type, 
respectively. 
 
 
3.2.2.4 Serotype 14 
CV biofilm assays of serotype 14 blood isolates (Figure 3.13) also showed strain 
variation in biofilm formation in response to pH and Fe(III). Despite high biofilm CFU 
counts of serotype 14 isolates in the CFU assay (Figure 3.5), the maximum A570 for the 
strains in the CV assay was 0.4. There were no significant effects of Fe(III) or pH on 
biofilm formation for any of the serotype 14 blood isolates, except for 4549 which formed 
significantly greater biofilms in C+Y at pH 7.4 than at pH 6.8 (P < 0.05).  
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CV biofilm assays of serotype 14 ear isolates (Figure 3.14) also showed strain variation in 
biofilm formation with a maximum A570 of 0.4. Fe(III) or pH did not significantly affect 
biofilm formation for any of the strains, except for 76547 which formed significantly 
more biofilms at pH 6.8 than pH 7.4 in C+Y (P < 0.05), and 73363 and 9-5201 which 
also formed greater biofilms at pH 6.8 than at pH 7.4 in C+Y+Fe(III) (P < 0.01 and P < 
0.05, respectively). 
 
Figure 3.13. Biofilm formation by serotype 14 blood isolates assessed by CV 
staining. Biofilm formation by serotype 14 blood isolates after 24 h of growth at either 
pH 7.4 or 6.8, with or without 100 μM Fe(III), was assayed by CV staining and A570. 
Data are the means ± SEM for three independent experiments. 
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Figure 3.14. Biofilm formation by serotype 14 ear isolates assessed by CV staining. 
Biofilm formation by serotype 14 ear isolates after 24 h of growth at either pH 7.4 or 6.8, 
with or without 100 μM Fe(III), was assayed by CV staining and A570. Data are the means 
± SEM for three independent experiments. 
 
3.2.2.5 Serogroup 19 
CV biofilm assays of serogroup 19 blood (Figure 3.15) and ear isolates (Figure 3.16) 
showed no significant effects of either Fe(III) or pH on biofilm formation by any of the 
strains.  
 
Figure 3.15. Biofilm formation by serogroup 19 blood isolates assessed by CV 
staining. Biofilm formation by serogroup 19 blood isolates after 24 h of growth at either 
pH 7.4 or 6.8, with or without 100 μM Fe(III), was assayed by CV staining and A570. 
Data are the means ± SEM for three independent experiments. 
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Figure 3.16. Biofilm formation by serogroup 19 ear isolates assessed by CV staining. 
Biofilm formation by serogroup 19 ear isolates after 24 h of growth at either pH 7.4 or 
6.8, with or without 100 μM Fe(III), was assayed by CV staining and A570. Data are the 
means ± SEM for three independent experiments. 
 
3.2.3 Microscopic analysis of CV-stained biofilms of blood and ear isolates. 
 Both viable count and CV assays revealed varied responses of blood and ear 
isolates in terms of the effects of pH and Fe(III) supplementation on biofilm formation. 
Unsurprisingly, data obtained using the separate biofilm assays did not show a close 
correlation for individual strains or serotypes/groups as a whole, as they were measuring 
distinct parameters (bacterial viability vs total biomass/matrix).  To further explore this, 
microscopic analysis of CV-stained 24 h biofilms of a high biofilm forming blood and ear 
isolate from each serotype/group was carried out after growth in C+Y at pH 7.4 and pH 
6.8, with or without 100 μM Fe(III) supplementation (see Section 2.4.2).  
3.2.3.1 Serotype 3 
 Microscopic analysis of serotype 3 blood isolate 4529 grown at pH 7.4 with 
Fe(III) supplementation showed marked bacterial aggregation (Figure 3.17(ii)) compared 
to without Fe(III) (i). At pH 6.8, in C+Y (iii) and C+Y+Fe(III) (iv) the strain showed less 
aggregation than at pH 7.4 with or without Fe(III). Conversely, biofilm formation of ear 
isolate 9706840 was enhanced at pH 6.8 (Figure 3.17 (vii)) relative to pH 7.4 (v) and the 
presence of Fe(III) enhanced biofilm formation at pH 7.4 (vi). 
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Figure 3.17.  Microscopic analysis of CV-stained 24-h biofilms of serotype 3 blood 
and ear isolates grown at pH 7.4 and 6.8 in C+Y or C+Y+Fe(III). Scale bar = 0.2 mm. 
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3.2.3.2 Serogroup 6 
 As seen in Figure 3.18 panels (i) and (ii), serogroup 6 blood isolate 4526 in C+Y 
at pH 7.4 showed more marked aggregation of bacteria than at pH 6.8 (iii). At both pHs, 
the strains formed more robust biofilms in the presence of Fe(III), with increased 
aggregation at pH 7.4 ((ii) and (iv)). Ear isolate 87765 grown in C+Y formed biofilms 
similarly at both pHs ((v) and (vii)). However, the presence of Fe(III) at pH 6.8 appeared 
to reduce biofilm formation, as seen in Figure 3.18 (viii).  
 
 
Figure 3.18. Microscopic analysis of crystal violet-stained 24-h biofilms of serogroup 
6 blood and ear isolates grown at pH 7.4 and 6.8 in C+Y or C+Y+Fe(III). Scale bar = 
0.2 mm. 
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3.2.3.3 Serogroup 9 
 Microscopic images of crystal violet stained serogroup 9 blood isolate 5055 in 
C+Y as seen in Figure 3.19 (i) appeared to show enhanced bacterial aggregation at pH 7.4 
than at pH 6.8 (iii). The presence of Fe(III) did not appear to enhance bacterial 
aggregation of the blood isolates at either pH (Figure 3.19 (ii) and (iv)). Serotype 9 ear 
isolate 66919 in C+Y appeared to show similar biofilm formation at both pHs (Figure 
3.19(v) and (vii)), but aggregation appeared to be slightly increased in the presence of 
Fe(III) at both pH ((vi) and (viii)). 
 
 
Figure 3.19 Microscopic analysis of crystal violet-stained 24-h biofilms of serogroup 
9 blood and ear isolates grown at pH 7.4 and 6.8 in C+Y or C+Y+Fe(III). Scale bar = 
0.2 mm. 
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3.2.3.4 Serotype 14 
 For serotype 14 blood isolate 4529, microscopic analysis showed the most robust 
biofilms compared to all other serotypes (Figure 3.20(i)-(iii)). Biofilm formation was 
enhanced at pH 7.4 (i) than at pH 6.8 (iii), especially in the presence of Fe(III) (ii). Fe(III) 
supplementation at pH 6.8 appeared to markedly inhibit biofilm formation of the 
blood isolate (Figure 3.20 (iv)). Ear isolate 9-5201 in C+Y at pH 6.8 (Figure 3.20(vii)) 
formed better biofilms than at pH 7.4 (v), while the presence of Fe(III) did not appear to 
positively influence biofilm formation at either pH (Figure 3.20(vi) and (viii)). 
 
 
Figure 3.20. Microscopic analysis of crystal violet-stained 24-h biofilms of serotype 
14 blood and ear isolates isolates grown at pH 7.4 and 6.8 in C+Y or C+Y+Fe(III). 
Scale bar = 0.2 mm. 
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3.2.3.5 Serogroup 19 
 Microscopic images of serogroup 19 blood isolate 5210 in C+Y appeared to show 
more marked bacterial aggregation at pH 7.4 (Figure 3.21(i)) than at pH 6.8 (iii), while 
supplementation with Fe(III) increased bacterial aggregation at only pH 6.8 (iv).  At pH 
7.4, ear isolate 24190 appeared to show increased biofilm formation in the presence of 
Fe(III) (Figure 21(vi)) compared to without Fe(III) (v).  When grown in C+Y+Fe(III) at 
pH 6.8 (viii) the strain also displayed visibly reduced aggregation compared to pH 7.4 
(vi). 
 
Figure 3.21. Microscopic analysis of crystal violet-stained 24-h biofilms of serogroup 
19 blood and ear isolates isolates grown at pH 7.4 and 6.8 in C+Y or C+Y+Fe(III). 
Scale bar = 0.2 mm. 
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 Although microscopic images of the biofilms were variable across all serotypes, a 
general trend of increased bacterial aggregation was observed in the blood isolates 
primarily at pH 7.4, regardless of Fe(III) supplementation. Ear isolates showed an 
enhanced aggregation at pH 6.8 and the presence of Fe(III) reduced biofilm formation in 
most of these isolate types. 
 
3.2.4 MLST typing of clinical isolates. 
 The highly variable biofilm phenotypes seen across all serotypes/groups indicated 
that non-capsular factors may be having a significant impact. Therefore, strains of 
serotypes/groups 3, 14 and 19, for which there were higher numbers of blood and ear 
isolates in our collection, were selected for MLST typing (see Section 2.7.2) to further 
investigate the genetic diversity of the isolates. Briefly, this involved DNA sequencing of 
internal fragments of 7 conserved, but polymorphic, pneumococcal house-keeping genes 
(aroE, gdh, gki, recP, xpt, spi and ddl) (Enright & Spratt 1998, 1999). The sequences 
were then compared with previously known sequence variants (alleles) and assigned an 
allele number for each of the 7 loci. The combination of 7 allele numbers represents an 
allelic profile for the strain, allowing it to be assigned to a sequence type (ST) derived 
from the S. pneumoniae MLST database http://pubmlst.net. Characterization of isolates 
by MLST enables strain comparisons independently of serotyping, and at a much higher 
resolution. It also may provide a more accurate picture of strain phylogeny, particularly 
since unrelated S. pneumoniae strains are known to be able to exchange capsule 
biosynthesis loci by natural recombination (Coffey et al., 1998). ST typed strains may be 
part of a larger clonal complex (CC) comprising strains with 5-6 matching loci, denoting 
a degree of genetic relatedness (Tyrrell, 2011). Strains of the same CC or indeed ST may 
belong to different serotypes. The observed variation in biofilm formation among the 
strains of the same serotype/group seen in viable count and CV-staining assays presented 
in this chapter may be due to the presence of multiple STs, which may or may not form 
part of a CC, and indicate major genetic differences between the strains.  
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3.2.4.1 Serotype 3 
 A total of 23 blood and ear isolates (12 blood and 13 ear) from the serotype 3 
collection were selected for MLST typing. As seen in Table 3.9, serotype 3 isolates 
comprised 4 STs, which were predominated by ST180 (7 blood and 6 ear isolates), ST232 
(3 blood and 4 ear isolates) and ST233 (2 blood and 1 ear isolate) while ST458 comprised 
2 blood isolates. Further detailed analysis using 
http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_spneumoniae_seqdef&page=downl
oadProfiles&scheme_id=1 and the eBURST v3 software available from 
http://spneumoniae.mlst.net/sql/burstspadvanced.asp (Feil et al., 2004) showed that 
ST232 and ST233 belonged to clonal complex CC378, while ST180 and ST458 belonged 
to CC180 and CC458, respectively. The allelic profiles of each ST are as described 
below. 
 
Table 3.9.  STs and CCs of serotype 3 strains typed by MLST. 
 
Serotype 3 strain Source ST (CC) New strain name 
5065 Blood 
ST232 (CC378) 
Allelic  profile: aroE 13;gdh 
9;gki 15;recP 14;spi 10;xpt 
16;ddl 1 
ST232/1 
4522 Blood 
ST233 (CC378) 
Allelic profile: aroE 13;gdh 9; 
gki 15;recP 14;spi 10;xpt 16;ddl 
25 
ST233/3 
4529 Blood 
ST180 (CC180) 
Allelic profile: aroE 7; gdh 15; 
gki 2; recP 10; spi 6; xpt 1; ddl 
22 
ST180/4 
4482 Blood 
ST458 (CC458) 
Allelic profile: aroE 2; gdh 32; 
gki 9; recP 47; spi 6; xpt 21; ddl 
17 
ST458/5 
4499 Blood ST233 (CC378) ST233/6 
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5234 Blood ST180 (CC180) ST180/7 
5258 Blood ST180 (CC180) ST180/8 
5267 Blood ST180 (CC180) ST180/15 
4483 Blood ST458 (CC458) ST458/20 
4521 Blood ST232 (CC378) ST232/23 
5272 Blood ST180 (CC180) ST180/24 
5060 Blood ST 232 (CC378) ST 232/25 
54833 Ear ST180 (CC180) ST180/2 
57934 Ear ST180 (CC180) ST180/9 
9706840 Ear ST180 (CC180) ST180/10 
61887 Ear ST232 (CC378) ST232/11 
62139 Ear ST180 (CC180) ST180/12 
22318 Ear ST233 (CC378) ST233/13 
75100 Ear ST180 (CC180) ST180/14 
58497 Ear ST180 (CC180) ST180/16 
68872 Ear ST232 (CC378) ST232/17 
53203 Ear ST232 (CC378) ST232/18 
79725 Ear ST232 (CC378) ST232/19 
5069 Ear ST180 (CC180) ST180/21 
5268 Ear ST180 (CC180) ST180/22 
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3.2.4.2 Serotype 14 
 A total of 18 isolates (9 blood and 9 ear) were selected for MLST typing. As seen 
in Table 3.10, the isolates belonged to 10 different STs. Two STs appeared to 
predominate: ST15 (n=5) and ST130 (n=5), both of which were similarly represented 
amongst blood (n=3) and ear (n=2) isolates. Other strains belonged to ST124 and ST129, 
or were assigned new STs by the pneumococcal MLST database curators. Each of these 
strains were represented by one isolate only and thus could not be matched with an isolate 
from the alternative niche/source. Further eBURST analysis showed that there were two 
distinct CCs in the collection; CC15, which comprised ST15 isolates (blood isolates 
4495, 4534, 4559 and ear isolates 9-47, 51742), and CC124, which comprised ST124 (ear 
isolate 9-5201), ST129 (ear isolate 9-5133) and ST130 (blood isolates 4484, 4524, 4538 
and ear isolates 76547, 67456). Other STs were not found to belong to a particular CC. 
The allelic profiles of each ST are as described below. 
 
Table 3.10. STs and CCs of serotype 14 strains typed by MLST. 
 
Serotype 14 
isolates Source ST (CC) 
New strain 
name 
4534 Blood 
ST15 (CC15) 
Allelic profile: aroE 1; gdh 5; 
gki 4; recP 5 spi 5; xpt 3; ddl 
17 
ST15/4534 
4559 Blood ST15 (CC15) ST15/4559 
4495 Blood ST15 (CC15) ST15/4495 
51742 Ear ST15 (CC15) ST15/51742 
9-47 Ear ST15 (CC15) ST15/9-47 
4484 Blood 
ST130 (CC124) 
Allelic profile: aroE 7; gdh 5; 
gki 1; recP 8; spi 14; xpt 14; 
ddl 14 
ST130/4484 
4524 Blood ST130 (CC124) ST130/4524 
4538 Blood ST130 (CC124) ST130/4538 
76547 Ear ST130 (CC124) ST130/76547 
67456 Ear ST130 (CC124) ST130/67456 
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9-5201 Ear 
ST124 (CC124) 
Allelic profile: aroE 7;gdh 5; 
gki 1; recP 8; spi 14; xpt 11; 
ddl 14 
ST124/9-5201 
9-5133 Ear 
ST129 (CC124) 
Allelic profile: aroE 7; gdh 5; 
gki 1; recP 8; spi 14; xpt 11; 
ddl 5 
ST129/9-5133 
4549 Blood 
ST9587 
Allelic profile: aroE 1; gdh 5; 
gki 4; recP 5; spi 5; xpt 3; ddl 
1 
ST9587/4549 
73363 Ear 
ST9588 
Allelic profile: aroE 50; gdh 
5; gki 1; recP 8; spi 14; xpt 3; 
ddl 14 
ST9588/73363 
4511 Blood 
ST9589 
Allelic profile: aroE 12; gdh 
5; gki 4; recP 5; spi 5; xpt 3; 
ddl 8 
ST9589/4511 
50582 Ear 
ST9590 
Allelic profile: aroE 7; gdh 5; 
gki 1; recP 5; spi 5; xpt 3; ddl 
8 
ST9590/50582 
53705 Ear 
ST9591 
Allelic profile: aroE 1; gdh 5; 
gki 4; recP 5; spi 5; xpt 88; 
ddl 8 
ST9591/53705 
4545 Blood 
ST9592 
Allelic profile: aroE 11; gdh 
5; gki 1; recP 5; spi 5; xpt 3; 
ddl 1 
ST9592/4545 
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3.2.4.3 Serogroup 19 
 A total of 17 serogroup 19 blood and ear isolates were subjected to MLST typing. 
As seen in Table 3.11, serogroup 19 blood and ear isolates showed greater genetic 
diversity compared to serotypes 3 and 14. The 17 typed isolates comprised 14 different 
STs, including 3 ST177 ear isolates, 2 ST199 blood isolates and 12 other isolates each 
belonging to a different ST. Further detailed MLST analysis carried out via 
http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_spneumoniae_seqdef&page=downl
oadProfiles&scheme_id=1 (Maiden et al., 2013) revealed that some strains were more 
closely related than others. Two common clonal complexes were identified via eBURST 
v3 software (Feil et al., 2004). Blood isolates of ST199 (5219 and 5221) and ST876 
(5210) were found to belong to CC199, while ear isolates of ST177 (51862 and 61884) 
and ST549 (58616) belonged to CC177. Blood isolate 5239 of ST186 and ear isolate 
48498 from ST2417 also comprised similar allelic profiles, but did not belong to an 
identified CC, while the other STs identified were classed as singletons. Generally the 
multiple STs found within serotype/group 3, 14 and 19 isolates in our collection showed 
high genetic diversity among the strains, which may have accounted for the highly 
variable biofilm phenotypes seen in the biofilm assays.  
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Table 3.11. Identified STs and CCs of serogroup 19 strains typed by MLST. 
Serogroup 
19 strains Source ST (CC) 
New strain 
name 
5210 Blood 
ST876 (CC199) 
Allelic profile: aroE 8; gdh 13; gki 14; 
recP 4; spi 6; xpt 4; ddl 14 
ST876/5210 
5219 Blood 
ST199 (CC199) 
Allelic profile: aroE 8; gdh 13; gki 14; 
recP 4; spi 17; xpt 4; ddl 14 
ST199/5219 
5239 Blood 
ST186 
Allelic profile: aroE 7; gdh 23; gki 1; 
recP 1; spi 14; xpt 28; ddl 31 
ST186/5239 
5221 Blood ST199 (CC199) ST199/5221 
24190 Ear 
ST1718 (CC1718) 
Allelic profile: aroE 1; gdh 5; gki 15; 
recP 5; spi 15; xpt 20; ddl 8 
ST1718/24190 
51862 Ear 
ST177 (CC177) 
Allelic profile: aroE 7; gdh 14; gki 4; 
recP 12; spi 1; xpt 1; ddl 14 
ST177/51862 
53685 Ear 
ST309 (CC309) 
Allelic profile: aroE 8; gdh 10; gki 2; 
recP 5; spi 9; xpt 48; ddl 6 
ST309/53685 
48498 Ear 
ST2417 
Allelic profile: aroE 7; gdh 13; gki 1; 
recP 1; spi 14; xpt 28; ddl 31 
ST2417/48498 
61884 Ear ST177 (CC177) ST177/61884 
4514 Blood 
ST43 (CC423) 
Allelic profile: aroE 1; gdh 10; gki 4; 
recP 1; spi 9; xpt 3; ddl 8 
ST43/4514 
4516 Blood 
ST688 (CC426) 
Allelic profile: aroE 10; gdh 5; gki 4; 
recP 1; spi 15; xpt 1; ddl 6 
ST688/4516 
4530 Blood 
ST1131 
Allelic profile: aroE 7; gdh 13; gki 4; 
recP 6; spi 25; xpt 6; ddl 8 
ST1131/4530 
4561 Blood 
ST655 
Allelic profile: aroE 18; gdh 3; gki 4; 
recP 1; spi 15; xpt 1; ddl 14 
ST655/4561 
4562 Blood 
ST462 
Allelic profile: aroE 5; gdh 42; gki 52; 
recP 1; spi 9; xpt 1; ddl 11 
ST462/4562 
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63387 Ear ST177 (CC177) ST177/63387 
58616 Ear 
ST549 (CC177) 
Allelic profile: aroE 13; gdh 14; gki 4; 
recP 12; spi 1; xpt 1; ddl 14 
ST549/58616 
60330 Ear 
ST415 (CC415) 
Allelic profile: aroE 1; gdh 5; gki 12; 
recP 5; spi 14; xpt 15; ddl 31 
ST415/60330 
 
 
3.2.5 Pooled ST-typed isolate biofilm assay (CFU) analysis. 
 MLST typing of the isolates confirmed the unsurprising genetic diversity of the 
strains exhibiting variable biofilm phenotypes. It also enabled the identification of STs 
that included both blood and ear isolates. Examining strains belonging to the same 
serotype and ST might be expected to improve the chance of identifying significant 
effects of pH, Fe(III) supplementation and isolate source on biofilm phenotype, as the 
impact of differences in genetic background has been minimized. Accordingly, 
representative blood and ear isolates of ST232, ST233 and ST180 from serotype 3 and 
ST15 and ST130 from serotype 14 were selected for reanalysis of the viable count 
biofilm data in Sections 3.2.1.1 and 3.2.1.4, respectively. Similar analysis of serogroup 19 
strains could not be undertaken, as none of the identified STs included both blood and ear 
isolates. 
 
3.2.5.1 Serotype 3 
 CFU biofilm counts for pooled blood and pooled ear isolates within a particular 
ST (ST180 (7 blood and 6 ear isolates), ST232 (3 blood and 4 ear isolates) and ST233 (2 
blood and 1 ear isolate)) were compared after growth in C+Y pH 7.4, C+Y pH 6.8, 
C+Y+Fe(III) pH 7.4 and C+Y+Fe(III) pH 6.8 to assess the influence of isolate source on 
biofilm formation within each ST. As seen in Figure 3.22, at pH 7.4, biofilm formation of 
blood isolates of ST232 and ST233 in C+Y as well as for ST232 and ST180 in 
C+Y+Fe(III) formed significantly greater biofilms than the respective ST-matched ear 
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isolates under the same conditions. Blood isolates of ST233 in C+Y+Fe(III) and ST180 in 
C+Y also had numerically greater biofilms than the respective ear isolates at pH 7.4, 
although this did not reach statistical significance. Fe(III) supplementation also 
significantly enhanced biofilm formation by ST232 blood isolates. In addition, ST233 
blood isolates in C+Y formed significantly greater biofilms than ST232. Similarly, ST233 
ear isolates in C+Y formed significantly greater biofilms than ST232 and ST180 ear 
isolates under the same conditions, while in C+Y+Fe(III), ST233 ear isolates also formed 
significantly greater biofilms than ST180 ear isolates. 
 
 
  
Figure 3.22. Biofilm formation by serotype 3 ST232, ST233 and ST180 blood and ear 
isolates at pH 7.4 (ST180 (7 blood and 6 ear isolates), ST232 (3 blood and 4 ear isolates) 
and ST233 (2 blood and 1 ear isolate)). Data are log10 CFU per well (± SEM) for 
quadruplicate assays. Significance of differences between groups was examined using a 
two-tailed Student's t-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
 
 
 
92 
 
 
 At pH 6.8 (Figure 3.23) biofilm formation by ST232, ST233 and ST180 ear 
isolates in C+Y was significantly greater than that for the respective ST-matched blood 
isolates under the same conditions. Fe(III) supplementation also caused a significant 
reduction in biofilm formation of ear isolates for all STs. Biofilm formation by ST233 ear 
isolates in C+Y+Fe(III) was also significantly greater than that for ST180 and ST 232 ear 
isolates or ST233 blood isolates in the presence of Fe(III). Fe(III) supplementation did 
not significantly affect biofilm formation by blood isolates of any ST at this pH. 
 
 
 
Figure 3.23. Biofilm formation by serotype 3 ST232, ST233 and ST180 blood and ear 
isolates at pH 6.8 (ST180 (7 blood and 6 ear isolates), ST232 (3 blood and 4 ear isolates) 
and ST233 (2 blood and 1 ear isolate)). Data are log10 CFU per well (± SEM) for 
quadruplicate assays. Significance of differences between groups was examined using a 
two-tailed Student's t-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
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3.2.5.2 Serotype 14 
 In C+Y pH 7.4 both blood and ear isolates of ST15 showed a significant (P < 
0.0001) 2 log10-fold increase in biofilm CFU counts compared to the ST130 clinical 
isolates under the same growth conditions (Figure 3.24). ST15 blood isolates in C+Y pH 
7.4 showed a five-fold increase in biofilm formation compared to the respective ear 
isolates, although this did not reach statistical significance. At pH 7.4 ST130 ear isolates 
grown with or without Fe(III) supplementation showed significantly better biofilm 
formation than ST130 blood isolates (P < 0.0005). Neither ST15 nor ST130 blood 
isolates showed significantly higher biofilm formation than their respective ear isolates at 
this pH. Fe(III) supplementation significantly enhanced biofilm formation by all isolates 
except for ST15 blood isolates.  
 
Figure 3.24 Biofilm formation by serotype 14 S. pneumoniae ST15 and  ST130 (3 blood 
and 2 ear isolates for ST15 and ST130) at pH 7.4. Data are log10 CFU per well (± SEM) 
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for quadruplicate assays. Significance of differences between groups was examined using 
a two-tailed Student's t-test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
 Similar to findings at pH 7.4, blood and ear isolates of ST15 produced 
significantly greater biofilms than the respective ST130 isolates (blood isolates, P < 
0.0005; ear isolates, P < 0.001) at pH 6.8 (Fig. 3.25). Interestingly however, ST15 blood 
isolates produced significantly greater biofilms than ST15 ear isolates in both the 
presence and absence of Fe(III), while no significant differences were observed between 
ST130 blood and ear isolates. For both ST types Fe(III) supplementation at pH 6.8 did not 
appear to influence biofilm formation for either isolate source.  
 
Figure 3.25. Biofilm formation by serotype 14 S. pneumoniae ST15 and ST130 blood 
and ear isolates at pH 6.8 (3 blood and 2 ear isolates for ST15 and ST130). Data are log10 
CFU per well (± SEM) for quadruplicate assays. Significance of differences between 
groups was examined using a two-tailed Student's t-test: *, P < 0.05; **, P < 0.01; ***, P 
< 0.001; ****, P < 0.0001. 
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3.3 Discussion 
 The formation of biofilms has been implicated in many studies as an important 
prerequisite for pneumococcal disease (Marks et al., 2013; Moscoso et al., 2006; 
Pettigrew et al., 2014). Therefore it is important to understand the molecular determinants 
that regulate pneumococcal biofilm formation, particularly in the host environment, 
where pneumococci may encounter adverse environments such as antibiotics and host 
immune responses. This study aimed to investigate the role of clinical isolate source and 
Fe(III) supplementation in biofilm formation by 80 blood and ear isolates of S. 
pneumoniae belonging to serotypes/groups 3, 6, 9, 14 and 19, which were grown at either 
pH 7.4 or pH 6.8 to reflect the respective physiological conditions in the blood and ear 
niches.  
 Biofilm formation assays (Figures 3.1- 3.16) showing that most isolates formed 
biofilms appeared to concur with the findings of Camilli et al. (2011) and others 
(Allegrucci et al., 2006; Chao et al., 2014; Domenech et al., 2014; Garcia-Castillo et al., 
2007) that biofilm formation is a common feature among pneumococcal strains. This 
study also found that in agreement with others (Allegrucci et al., 2006; Camilli et al., 
2011; Domenech et al., 2009; Hall-Stoodley et al., 2008; Tapiainen et al., 2010), 
serotypes 3 and 14 were the lowest and highest biofilm producers, respectively. Serotype 
3 pneumococci are highly encapsulated and many studies have suggested that capsule 
expression interferes with biofilm formation (Allegrucci et al., 2006; Domenech et al., 
2009; McEllistrem et al., 2007; Waite et al., 2001). Serogroup 6 pneumococci have also 
been described as significant biofilm formers, while serotype 14 are high biofilm 
producers (Allegrucci et al., 2006; Domenech et al., 2014; Domenech et al., 2012). 
 When investigating the influence of Fe(III) supplementation on biofilm formation 
some strain variations were also observed, but generally biofilm formation of most blood 
and ear isolates was enhanced in the presence of Fe(III) at pH 7.4 for all 
serotypes/groups. This agreed with Trappetti et al. (Trappetti et al., 2011) who found that 
biofilm formation of the type 2 strain D39 was significantly enhanced when 
supplemented with Fe(III) at pH 7.4. An interesting finding in this study was that at pH 
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6.8 Fe(III) supplementation did not result in significantly increased biofilm formation in 
most serotypes/groups, and actually inhibited biofilm formation in serotype 3 ear isolates. 
The reason for this is not clear. A possible contributing factor could be differences in the 
expression levels of iron transporter components PiuA (pneumococcal iron uptake) and 
PiaA (pneumococcal iron acquisition) when strains are grown at different pH. PiuA and 
PiaA transport systems are essential for iron uptake (Kadioglu et al., 2008) and the 
possibility that these lipoproteins are expressed at lower levels at pH 6.8 warrants further 
investigation. Expression levels of the luxS gene at pH 7.4 vs pH 6.8 should also be 
investigated, as this system is known to impact piuA expression as well as biofilm 
formation in strain D39 (Trappetti et al., 2011c). 
 In general, despite high strain-strain variation in biofilm formation by blood and 
ear isolates across all serotypes/groups, the viable count assays shown in Figures 3.1-3.8 
indicated that differences in niche pH could influence biofilm formation capacity of the 
blood and ear isolates. Increased biofilm formation by either blood or ear isolates, where 
apparent, occurred primarily at their respective niche pH. That is, many blood isolates of 
serotypes/groups 3, 6, 9, 14 and 19 showed significant increases in biofilm formation at 
pH 7.4 relative to pH 6.8, while type 3 and group 19 ear isolates displayed significantly 
increased biofilm formation at pH 6.8. Exceptions to these generalised observations were 
also seen; some serogroup 6 and 9 blood and ear isolates showed variable phenotypic 
responses to pH, as well as the serotype 14 ear isolates which generally showed enhanced 
biofilm formation at pH 7.4.  
 A typical feature of bacterial biofilms is the extracellular matrix which provides 
protection and structure to the cell population within it (Moscoso et al., 2009). The CV 
assay is a useful tool for rapid and simple assessment of biofilm formation differences 
between strains, as it stains the extracellular matrix as well as the aggregated bacterial 
cells (O'Toole 2011). The CV biofilm assays showed strain-strain variation in biofilm 
formation with respect to isolate source, pH and Fe(III), while some strains showed a 
general consistency with CFU observations. An example of this was seen for serotype 3 
strains, with significant increases in biofilm formation being observed when blood and 
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ear isolates were grown at their respective niche pH of 7.4 and 6.8. Nevertheless, 
discrepancies were observed between the CFU and CV data in many cases. These are 
likely to be attributable to the fact that the former assay measures viable bacteria in 
dispersed biofilms, while the latter measures staining density of both live and dead 
bacteria as well as the extracellular matrix.  
 Similar to the CFU and CV biofilm assays, in general the microscopic images of 
the biofilms confirmed that biofilm formation was enhanced in most blood isolates at pH 
7.4 in the presence of Fe(III), while on the other hand ear isolates showed enhanced 
biofilm formation at pH 6.8. Serotype 3 isolates tended to be low overall biofilm 
producers, while serotype 14 isolates generally showed high biofilm formation. These 
images also provided microscopic evidence that the presence of Fe(III) at pH 7.4 
enhanced biofilm formation in most blood and ear isolates, while at pH 6.8 the influence 
of Fe(III) was either insignificant or inhibitory for biofilm formation.  
 An important challenge in this study was the occurrence in all the 
serotypes/groups analysed of marked variability in biofilm formation between isolates, 
which complicated interpretation of findings regarding the influence of clinical source, 
Fe(III) or pH on in vitro biofilm formation. Indeed, marked variation in biofilm formation 
capacity among individual pneumococcal strains has been demonstrated by others 
(Camilli et al., 2011; Tapiainen et al., 2010). Genetic diversity is a characteristic feature 
of S. pneumoniae with 93 different serotypes superimposed on over 5000 clonal lineages 
recognizable by MLST (Enright & Spratt 1998). Thus, much of the strain-strain variation 
in biofilm phenotype might be attributable to the presence of multiple STs within a 
serotype/group. MLST typing was carried out on 63 blood and ear isolates belonging to 
serotypes/groups 3, 14 and 19. Data presented in Tables 3.9 - 3.11 confirmed marked 
diversity of STs within all three serotypes/groups tested, particularly for group 19 
isolates, with 14 distinct STs identified amongst the 17 tested strains.  Serogroup 19 
comprises several structurally-related, immuno-cross-reactive capsular types (19A, 19B, 
19C and 19F), which may further contribute to genetic diversity within this group. The 
marked variation in biofilm formation phenotype between strains from different clinical 
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sources, and the variable influence of pH and Fe(III) supplementation may well be a 
reflection of this diversity. 
 Importantly, MLST typing of serotype 3 or 14 strains in this study also identified 
multiple examples of blood and ear isolates belonging to the same ST. This enabled 
analysis of the impact of isolate source, pH and Fe(III) on biofilm formation phenotype, 
without the complication of diversity of genetic background. At pH 7.4 (the physiological 
pH of the blood (Jahn, 2001)), serotype 3 ST180, ST232 and ST233 blood isolates 
formed significantly greater biofilms than their respective ST-matched ear isolates. 
Fe(III) supplementation significantly increased biofilm formation for the ST232 blood 
isolates, but not for any of the other strains. At pH 6.8 (the physiological pH of the 
middle ear cavity (Jahn, 2001), ear isolates of all three STs tested displayed significantly 
better biofilm formation than the respective ST-matched blood isolates. Moreover, Fe(III) 
supplementation significantly reduced biofilm formation by the ear isolates, but not the 
blood isolates. These findings suggest that isolates from a given host niche have 
somehow adapted to form better biofilms at the pH commensurate with the respective 
niche. Between the three STs, isolates belonging to ST233 also showed significantly 
higher biofilm formation at both pH 7.4 and pH 6.8. This suggests that much of the strain-
strain diversity in biofilm phenotype observed within a given serotype/group may indeed 
be attributable to diversity in genetic backgrounds therein.  
 For serotype 14, the ability of ST15 isolates to form biofilms was significantly 
(10-100-fold) greater than ST130 isolates regardless of pH or Fe(III) supplementation, 
confirming the impact of genetic background on biofilm phenotype. Interestingly, at pH 
7.4, ST130 ear isolates formed significantly greater biofilms than blood isolates, while 
there was no effect of clinical isolate source for ST15 isolates. Fe(III) supplementation at 
pH 7.4 significantly enhanced biofilm formation for both ear and blood isolates for 
ST130 and ear isolates for ST15; a similar trend (albeit non-significant) was seen for 
ST15 blood isolates.  This differs from findings for type 3 strains, where only blood 
isolates were stimulated by Fe(III). At pH 6.8, Fe(III) supplementation had no effect on 
biofilm formation by any of the type 14 strains. However, in marked contrast to findings 
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for type 3 strains, ST15 blood isolates produced significantly greater biofilms than ear 
isolates. Thus, the apparent adaptation of blood and ear isolates observed for serotype 3 
ST180, ST232 and ST233 strains, whereby biofilm formation capacity is optimized at the 
pH of the respective physiological niche, is not seen in serotype 14 ST15 or ST130 
strains. 
 The work described in this Chapter has identified marked discrepancies between 
the influence of Fe(III), pH and isolate source on biofilm phenotype in the various 
serotypes/groups and ST types. Importantly, however, it has also identified distinct 
differences in behavior in the in vitro biofilm assays between blood and ear isolates 
belonging to the same serotype/group and ST type. It is therefore important to further 
investigate these differences using in vivo models to determine whether they have 
relevance in terms of pathogenesis of pneumococcal disease.  
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Chapter 4: Influence of isolate source on virulence 
phenotype of serotype 3 S. pneumoniae clinical isolates 
 
4.1 Introduction 
 The ability to form biofilms has in recent years been recognized as a necessary 
step in the pathogenesis of OM and other pneumococcal diseases, where strong 
correlations between biofilm formation and colonisation and virulence in mice have been 
reported in several studies (Munoz-Elias et al., 2008; Oggioni et al., 2006; Trappetti et 
al., 2009). More recent studies (Marks et al., 2013; Pettigrew et al., 2014) have further 
illustrated the importance of biofilms to pneumococcal virulence. These studies 
demonstrated that invasive disease was triggered by bacteria from dispersed biofilms, 
which exhibited differential genomic expression profiles for virulence-related genes, 
relative to planktonic and sessile biofilm modes.  
  In the previous chapter, the influence of isolate type, pH and Fe(III) 
supplementation on biofilm formation in 25 blood and ear isolates belonging to serotype 
3, a type that is frequently associated with both OM and invasive disease, was 
investigated (see Section 3.2.1). The primary findings in this study indicated a strong 
association between serotype 3 clinical isolate source and their optimal pH for biofilm 
formation (see Section 3.2.1.1). Microscopic examination of crystal violet-stained 
biofilms confirmed that robust biofilms were formed by blood isolates only at pH 7.4 and 
were boosted further by Fe(III), whereas ear isolates formed robust biofilms only at pH 
6.8 and in the absence of Fe(III) (see Section 3.2.2). Further analysis revealed that biofilm 
formation between clonally related serotype 3 and serotype 14 blood and ear isolates was 
markedly variable; analysis of serotype 3 ST-matched isolates indicated an influence of 
isolate source on biofilm formation (see Section 3.2.3.1), but this was not seen for ST-
matched serotype 14 isolates (see Section 3.2.3.2).  
 S. pneumoniae genetic diversity results in important phenotypic differences in 
disease potential. It has been reported that 20 of the 93 known capsular serotypes account 
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for 85% of pneumococcal infections (Kalin, 1998) and certain STs are more strongly 
associated with invasive disease than others (Brueggemann et al., 2003; Hanage et al., 
2005). The work described in this Chapter further examines the in vitro and in vivo 
phenotypes of isolates belonging to the same serotype and ST, to determine whether there 
are any associations between isolate source, biofilm formation and capacity to cause 
invasive vs localized infections.  
 
 
4.2 Results 
4.2.1 Influence of LuxS on serotype 3 biofilm formation. 
  In the previous chapter a relationship between the site of isolation and ability to 
form biofilms under different pH and Fe(III) conditions was identified in clinical isolates 
belonging to serotype 3 (see Sections 3.2.1 and 3.2.2). To test whether the iron- and pH-
dependent biofilm formation phenotype of serotype 3 strains is linked to the activity of 
the LuxS quorum sensing system, a relationship previously identified in the serotype 2 
strain D39 (Trappetti et al., 2011c), the level of luxS expression was measured using real-
time RT-PCR (see Section 2.15). For this analysis, one blood isolate and one ear isolate 
belonging to each of the three major STs (ST180, ST232 and ST233) were selected.  
  The real-time RT-PCR analysis showed differences in luxS expression levels 
between the strains and growth conditions (Figure 4.1), which closely paralleled the 
pattern of biofilm formation previously observed for the respective strains (see Figure 
3.22). In the blood isolates ST180/15, ST232/1 and ST233/3, luxS expression was 
significantly higher when cells were grown at pH 7.4 in the presence of Fe(III) compared 
to all other growth conditions (P < 0.001, P < 0.001, and P < 0.01, respectively). In 
contrast, for the ear isolates ST180/2, ST232/11 and ST233/13, luxS expression was 
significantly higher when cells were grown at pH 6.8 without Fe(III) supplementation, 
than under any of the other conditions (P < 0.001, P < 0.05, and P < 0.01, respectively).  
However, for each ST type pair, the overall level of expression of luxS in the ear isolate 
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was significantly lower than that of the corresponding blood isolate under their respective 
optimal conditions (P < 0.001, P < 0.001, and P < 0.01, for ST180, ST232 and ST233, 
respectively). 
 
 
Figure 4.1. Expression of luxS relative to 16S rRNA in blood and ear isolates of 
ST180, ST233 and ST232. Expression of luxS relative to 16S rRNA in the indicated 
clinical isolates grown either at pH 7.4 or 6.8, with or without addition of 100 μM Fe(III). 
Data are the mean ± standard deviation (SD) for three independent experiments (*, P < 
0.05; **, P < 0.01; ***, P < 0.001; 2-tailed Student’s t-test). 
 
  To further confirm the role of luxS in biofilm formation by serotype 3 strains, luxS was 
deleted in the ear isolates mentioned above and the mutants were then tested for biofilm 
forming ability in C+Y media at pH 6.8 (see Section 2.10). Viable counts of the dispersed 
biofilms revealed a significant reduction in biofilm formation for the luxS mutants of the 
three ear isolates compared to the wild type when grown in C+Y at pH 6.8  (P < 0.001 for 
ST180/2 and ST233/13; P < 0.01 for ST232/11) (Figure 4.2). Microscopic examination 
after crystal violet staining confirmed the results of viable counts (Figure 4.3).  
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Figure 4.2. Effect of luxS mutation on biofilm formation by ear isolates.  Effect of 
luxS mutation on biofilm formation by ear isolates, determined by viable count. Data are 
the mean ± SD for three independent experiments (**, P < 0.01; ***, P < 0.001; 2-tailed 
Student’s t-test) 
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Figure 4.3. Microscopic analysis of stained biofilms. Microscopic analysis of crystal 
violet stained biofilms formed at pH 6.8 by ear isolates (WT=wild type) and their 
respective luxS mutants (luxS-). Microscopic examination of the dispersed biofilms 
revealed a significant reduction in biofilm formation for the luxS mutants of the three ear 
isolates compared to the wild type when grown in C+Y at pH 6.8 . Scale bar: 100 μm. 
 
 
 
 
 
 
 ST180/2                        
ST232/11   
ST233/13 
 WT    luxS-   
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4.2.2. Investigation of piuA expression in relation to Fe(III), pH and isolate source. 
  Since iron has been shown to stimulate biofilm formation in the blood isolates, but 
not ear isolates, the expression level of piuA, which encodes the major pneumococcal iron 
uptake system was quantified (see Section 2.15). A significantly higher level of 
expression of piuA was observed in blood isolates grown at pH 7.4 in the presence of 
Fe(III) compared with other growth conditions (P < 0.01, P < 0.001 and P < 0.01, for 
ST180/15, ST231/1 and ST233/3, respectively) (Figure 4.4). In contrast, piuA expression 
was very low in all the ear isolates, and there was no evidence for up-regulation of piuA 
in these isolates in the presence of iron, except for a slight increase for ST233/13 at pH 
7.4 which was however insignificant. 
 
Figure 4.4. Expression of piuA relative to 16S rRNA in blood and ear isolates of 
ST180, ST233 and ST232. Expression of piuA relative to 16S rRNA in the indicated 
clinical isolates grown either at pH 7.4 or 6.8, with or without addition of 100 μM Fe(III). 
Data are the mean ± SD for three independent experiments (*, P < 0.05; **, P < 0.01; 
***, P < 0.001; 2-tailed Student’s t-test). 
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4.2.3 Investigation of transformability of serotype 3 strains. 
  Induction of the competence state has been shown to parallel biofilm formation in 
S. pneumoniae (Trappetti et al., 2011a; Trappetti et al., 2011c), and so the 
transformability of the six serotype 3 clinical isolates, as well as the reference invasive 
type 2 strain D39, was measured in planktonic cells grown at pH 7.4 and pH 6.8 (see 
Section 2.9), where each transformation reaction contained approximately 107 competent 
pneumococci. The transformability of the strains was found to be strongly influenced by 
the pH. Blood isolates exhibited a significantly greater propensity to take up external 
DNA at pH 7.4 (P < 0.001, P < 0.001 and P < 0.01 for ST180/15, ST232/1 and ST233/3, 
respectively), as did the reference strain D39. In contrast, the ear isolates showed higher 
rates of transformability at pH 6.8 (P < 0.001, P < 0.001 and P < 0.01 for ST180/2, 
ST232/11 and ST233/13, respectively) (Figure 4.5). Indeed, for the ST180 and ST232 
strains, the blood isolates were completely untransformable at pH 6.8, while the ear 
isolates were not transformable at pH 7.4. Strains of ST233 were transformable under 
both conditions tested, but a significant increase in efficiency was observed for the blood 
isolate at pH 7.4 and ear isolate at pH 6.8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
Figure 4.5. Transformability of the reference invasive strain D39 and serotype 3 
blood and ear isolates. Transformability of the reference invasive strain D39 and 
serotype 3 blood and ear isolates grown at either pH 7.4 or 6.8. Data are the total number 
of transformants (mean ± SD for three biological replicates) (**, P < 0.01; ***, P < 
0.001; 2 tailed Student’s t-test). 
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4.2.4. Capsular polysaccharide production by serotype 3 strains. 
  In order to investigate if phenotypic differences seen so far between the isolates 
within a ST were the result of differences in the amount of CPS produced, this was 
quantitated by uronic acid assay for blood isolates ST180/15, ST232/1 and ST233/3 and 
ear isolates ST180/2, ST232/11 and ST233/13 (see Section 2.12.2). As shown in Figure 
4.6, CPS production was similar across all strains. Analysis of pooled CPS production 
data for the three blood vs three ear isolates (Figure 4.7) also showed no significant 
differences in CPS production between blood and ear isolates. 
 
 
 
 
 
Figure 4.6. CPS production by ST180, ST232 and ST233 blood and ear isolates at 
pH 7.4. CPS production at pH 7.4 was determined by uronic acid assay (Section 2.12.2). 
Data are A520 (mean ± standard deviation), Significance of differences between groups 
was examined using a two-tailed Student’s T-Test: (**, P<0.01; ***, P< 0.001; 2 tailed 
Student’s t-test). 
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Figure 4.7. CPS production by pooled blood and ear isolates at pH 7.4. CPS 
production at pH 7.4 for pooled blood and ear isolates of ST180, ST232 and ST233 were 
quantitated by uronic acid assay. Data are A520 (± SD).  
  
4.2.5.  Virulence phenotypes of serotype 3 strains. 
  The virulence profile of the clinical isolates was then investigated in a murine 
nasopharyngeal inoculation model, which mimics the natural route of infection for S. 
pneumoniae (see Section 2.18). Briefly, female outbred 5–6 week old Swiss mice were 
anaesthetized and inoculated intranasally with 1×107 CFU of S. pneumoniae (confirmed 
retrospectively by viable count) in a volume of 10 μl. Groups of 15 mice were inoculated 
for each strain and five randomly selected mice from each group were euthanized by CO2 
asphyxiation at 24, 48 or 72 h post infection. Nasal wash, nasopharyngeal tissue, ear 
tissue, lung, brain and blood samples were collected and processed. Samples were serially 
diluted and plated onto blood agar plates for enumeration of viable pneumococci.  
  At all the time points examined (24, 48 and 72 h post infection), the majority of 
mice in each group infected with blood isolates (ST180/15, ST232/1 or ST233/3) showed 
bacteremia, whereas no bacteremia could be detected in any of the mice in groups 
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challenged with the ear isolates (ST180/2, ST232/11 or ST233/13) (Figure 4.8C). 
Collectively, the degree of bacteremia in blood isolates was significantly greater than the 
combined ear isolate groups at all time points (P < 0.001). When individual strain pairs 
within a ST type were compared, the level of bacteremia in the ST180/15 group was 
significantly greater than the ST180/2 group at all time points (P < 0.05), while 
bacteremia levels in the ST232/1 and ST233/3 groups were significantly greater than that 
for ST232/11 and ST233/13, respectively, at 48 h (P < 0.05). The situation was reversed 
in the nasopharyngeal tissue (Figure 4.8A), where blood isolates as a whole were inferior 
to ear isolates in terms of overall colonisation levels at 48 and 72 h (P < 0.001 in both 
cases). Comparing the individual ST types, ST232/11 colonized the nasopharyngeal 
tissue to a significantly greater extent than ST232/1 at both 48 and 72 h (P < 0.05 and P < 
0.01, respectively), while ST180/2 and ST233/13 exhibited significantly higher 
colonisation at 72 h than the corresponding ST-matched blood isolate (P < 0.01 and P < 
0.05, respectively). Bacteria were detected in ear tissue samples only in groups 
challenged with the ear isolates, and this difference was statistically significant (P < 0.05) 
at both 48 and 72 h (Figure 4.8B). Interestingly, at 24 h post-infection, pneumococci 
could not be detected in the lungs of any of the mice challenged with blood isolates, in 
spite of significant bacteremia in the majority of animals in each ST group (Figure 4.8F). 
Moreover, only 4 of the 15 mice challenged with blood isolates had evidence of 
pneumococci in the lungs at either 48 or 72 h. In contrast, no bacteria could be detected in 
the lungs of any of the mice challenged with the ear isolates. Similar findings were 
observed in brain tissue (Figure 4.8E). It is also interesting to note that pneumococci 
could not be detected in nasopharyngeal washes of any mice 24 h post infection (Figure 
4.8D). At 48 h, less than half of the mice had pneumococci in nasal wash fluid, with 
fewer again at 72 h. 
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Figure 4.8A-C. Virulence phenotypes of blood and ear isolates. Groups of 15 mice 
were infected intranasally with 107 CFU of the indicated strain. At the indicated times, 5 
mice from each group were euthanised and numbers of pneumococci in the indicated 
tissues were quantitated. (A) nasopharyngeal tissue; (B) ear; (C) blood. Viable counts are 
shown for each mouse at each site; horizontal bars indicate the median value for each 
group/time point. Blood isolates are represented by solid symbols; ear isolates are 
represented by open symbols. Differences between groups were analyzed by 1-tailed 
Mann-Whitney U test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).  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Figure 4.8D-F. Virulence phenotypes of blood and ear isolates (Continued). (D) 
Nasal wash; (E) brain; (F) lung. Viable counts are shown for each mouse at each site; 
horizontal bars indicate the median value for each group/time point. Blood isolates are 
represented by solid symbols; ear isolates are represented by open symbols. Differences 
between groups were analyzed by 1-tailed Mann-Whitney U test (*, P < 0.05).  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4.3 Discussion 
  S. pneumoniae is a diverse and adaptable pathogen, capable of surviving in a 
range of niches within its human host. Previous studies from our laboratory have 
identified changes in in vivo transcriptional profile within a given strain that either 
facilitate survival in distinct host niches (nasopharynx, lungs, blood and brain), and/or aid 
progression from one niche to another (LeMessurier et al., 2006; Mahdi et al., 2008; 
Mahdi et al., 2012; Ogunniyi et al., 2012). However, genetic differences between strains 
may also result in pneumococci with inherent tropism for one niche over another. Studies 
in animal models suggest that both capsular and non-capsular loci contribute to these 
differences in in vivo phenotype (Kelly et al., 1994; McAllister et al., 2011), but 
interpretation of molecular epidemiological analyses of human isolates is complicated by 
the vast genetic diversity of strains. In Chapter 3, phenotypic differences between clinical 
isolates from either sepsis or OM (n = 12 and 13, respectively) belonging to serotype 3, 
an important cause of bothsystemic and localized pneumococcal infections, were 
investigated. It was demonstrated that while the blood isolates were more capable of 
forming biofilms at pH 7.4 than ear isolates, especially with 100 μM Fe(III), the ear 
isolates were more capable of forming biofilms at pH 6.8, and at this pH, Fe(III) was 
inhibitory (see Section 3.3). 
   In this Chapter, more detailed phenotypic comparisons of matched pairs of 
isolates from either the blood or ear belonging to three dominant MLST types (ST180, 
ST232 and ST233) were conducted. It was previously reported that the LuxS quorum 
sensing system is a central regulator of biofilm formation in the invasive type 2 S. 
pneumoniae strain D39 (Trappetti et al., 2011c), and in the present study, there was again 
a close parallel between expression of the luxS gene and biofilm formation at the 
permissive pH for the respective groups. The observed increased luxS expression in both 
isolate types also concurred with recent studies demonstrating that luxS was responsible 
for the regulation of pneumococcal biofilms in both human respiratory epithelial cells 
(HREC) and on abiotic surfaces (Vidal et al., 2013) . Although the level of luxS 
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expression in each of the ear isolates at pH 6.8 in the absence of Fe(III) was significantly 
greater than that under the other environmental conditions, they were still significantly 
lower than the blood isolates of the corresponding ST type under optimal conditions. The 
apparently lesser importance of luxS in biofilm formation in the ear isolates compared to 
the blood isolates is not understood and warrants further investigation. Given that luxS 
has been demonstrated to be important in virulence (Stroeher et al., 2003) it will be 
helpful to  further examine this phenomenon in other clonally related pneumococci of 
different serotypes/serogroups. This may allow further understanding of the role of luxS 
in the virulence of pneumococci isolated from different clinical sites or environments.  
  Despite the decreased luxS expression observed in the ear isolates compared to the 
blood isolates, the significant reduction of biofilm formation observed through the 
mutagenesis of luxS  in the ear isolates, as demonstrated by microscopy and biofilm 
assays, concurred with findings of Trappetti et al. (2011c) for D39, and validated the 
important role of luxS in biofilm formation. The link between the luxS system and genetic 
competence previously observed in D39 also held for the type 3 isolates, with maximal 
transformation efficiencies observed under the same environmental conditions that were 
most permissive for biofilm formation. This observation parallels those of Marks et al. 
(2012) who demonstrated high transformation efficiency of pneumococci in a novel 
biofilm model in vitro, which mimicked specific environmental conditions of the 
nasopharynx including lower temperature, limited nutrient availability and epithelial cell 
interaction.  
  The stimulatory effect of Fe(III) on biofilm formation by the blood isolates at pH 
7.4 was matched by upregulated expression of piuA, which encodes the major 
pneumococcal iron transporter. In contrast, piuA expression was negligible in blood 
isolates at the non-permissive pH 6.8 or in the absence of Fe(III), and in the ear isolates 
under any of the conditions tested. These observations further support an association 
between isolate source and the optimum pH and Fe(III) level for biofilm formation. 
115 
 
The consistent and stark phenotypic distinction between blood and ear isolates in terms of 
preferred pH and requirement for Fe (III) for optimal biofilm formation suggests that 
there are fundamental differences between S. pneumoniae strains belonging to the same 
clonal lineage that enable adaptation to the distinct host niches from whence they were 
isolated. This adaptation to the human niche was closely mimicked by the behavior of the 
various strains in a mouse intranasal challenge model. All three blood isolates were poor 
colonizers of the nasopharynx, yet were able to readily spread directly to the blood in 
most animals, largely bypassing the lungs. Moreover, none of the blood isolates ever 
spread to the ear compartment. Conversely, the ear isolates were able to stably colonize 
the nasopharyngeal tissue of the vast majority of animals, but never spread to the blood, 
brain or lungs. Nearly half of the animals challenged with OM isolates had pneumococci 
in the ear compartment by 72 h.  While the absence of ear isolates from a specific tissue 
might suggest that this site is bypassed during disease progression, it is also possible that 
bacteria were actually present in these sites at early times, but were cleared by host 
immune responses by 24 h. Therefore, examining host immune response gene expression 
patterns in mice challenged with either blood or ear isolates may provide further insights 
into the underlying mechanisms of tissue tropism.  
  The low numbers of pneumococci recovered in these studies from the nasal wash 
fraction despite high numbers of pneumococci present in the nasal tissue (Figure 4.8D), 
implies that colonizing pneumococci were very tightly adhered to the nasopharyngeal 
epithelium, perhaps even penetrating the mucosa. In future studies it would therefore be 
desirable to perform in vitro adherence and invasion assays of blood and ear isolates on 
Detroit 562 (human nasopharyngeal) cells.  
  The antiphagocytic polysaccharide capsule surrounding S. pneumoniae is a major 
virulence factor and within a serotype, capsule thickness is directly related to virulence 
(Kadioglu et al., 2008). However, this cannot account for the differences in virulence 
phenotype between type 3 blood and ear isolates, as quantitation of CPS levels revealed 
no significant differences between strains from one niche vs the other. Thus, unless 
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relative CPS production by the various strains in vivo differs markedly from relative in 
vitro levels, non-capsular factors are largely responsible for the distinct virulence 
phenotypes.  
  The fact that strains belong to the same serotype and ST does not rule out genetic 
differences as the basis for distinct virulence profiles, particularly since clonally related 
stains may have acquired distinct accessory regions by horizontal gene transfer, or 
undergone minor DNA changes (e.g. point mutations or small insertions or deletions) 
outside of the housekeeping genes that determine MLST. Another possible mechanism 
for the distinct phenotypes may be differences in transcription patterns of otherwise 
similar genomes, or epigenetic effects. Manso et al. (2014) reported that switching of 
pneumococci between opacity phase variants that favour asymptomatic carriage vs 
invasive disease was impacted by genetic rearrangements in a Type I restriction-
modification system (SpnD39III) which is ubiquitous in pneumococci. By utilizing 
single-molecule real-time (SMRT) methylomics, they demonstrated that the 
rearrangements gave rise to six alternative specificities with distinct methylation patterns. 
These SpnD39III variants exhibited distinct gene expression profiles and resulted in 
distinct virulence phenotypes in experimental infection; in vivo selection for switching 
between SpnD39III variants was also demonstrated.  
  This study has clearly shown that stable adaptation of pneumococci to distinct 
host niches occurs within clonal lineages (for journal publication of this study please refer 
to Appendix A). Thus, molecular epidemiological studies aimed at associating MLST 
type with potential to cause invasive versus non-invasive disease should be interpreted 
with considerable caution. It is now clear that accessory regions outside the core 
pneumococcal genome are major determinants of virulence phenotype in both humans 
and animal models. Identification of multiple ST-matched pairs of S. pneumoniae 
serotype 3 strains with distinct human tissue tropism and virulence profile in mice 
provides a unique opportunity to identify accessory regions or polymorphisms within the 
core genome common to isolates from one niche versus the other by genome sequence 
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analysis. This, in turn, will permit direct testing of the role of identified regions in 
pathogenesis by targeted mutagenesis.  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Chapter 5:    Influence of isolate source on virulence of 
serotype 14 S. pneumoniae 
 
5.1 Introduction 
In Chapter 3, the influence of isolate source on biofilm formation between 
clonally related serotype 3 and serotype 14 blood and ear isolates was found to be 
markedly distinct. While isolate source influenced biofilm formation capacity in ST-
matched serotype 3 isolates, this was not observed for similarly matched serotype 14 
isolate. Further investigations of the ST-matched serotype 3 blood and ear isolates in 
Chapter 4 demonstrated that the isolates differed markedly in both in vitro and in vivo 
phenotypes, according to clinical site of isolation, suggesting stable niche adaptation 
within a clonal lineage (see also Trappetti et al. (2013)).  
 Apart from the aforementioned studies of serotype 3 isolates, the relationship, if 
any, between clinical isolate source and pneumococcal virulence phenotype has not been 
fully investigated. Serotype 14 is a representative serotype with high invasive disease 
potential (Brueggemann et al., 2003; Kronenberg et al., 2006; Sleeman et al., 2006), 
which along with serotypes 6B, 19F, 18C, 9V and 23F is responsible for over 78% of 
invasive infections in small children (Butler et al., 1995; Sniadack et al., 1995). In an 
experimental rabbit meningitis model, more severe inflammatory responses were 
observed after challenge with strains belonging to serotypes 6B, 14 and 23F, compared to 
the other tested serotypes (Engelhard et al., 1997). Serotype 14 S. pneumoniae is one of 
the commonest etiologic agents of pneumonia in Latin America, the UK and Spain 
(Bewick et al., 2012; Burgos et al., 2013; Gentile et al., 2012) and OM in children under 
5 years old (Rodgers et al., 2009).  Serotype 14 is also one of the most highly prevalent S. 
pneumoniae serotypes in the world (Butler et al., 1995; Kalin, 1998; Robbins et al., 1983) 
including both carriage and invasive disease isolates (Sandgren et al., 2004). This 
serotype also exhibits high rates of antimicrobial resistance and biofilm formation 
capacity (Hall-Stoodley et al., 2008).  
 The work described in this chapter aimed to examine the influence of isolate 
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source on virulence of clonally related serotype 14 blood and ear isolates. A total of 10 (5 
each for ST15 and ST130) blood and ear isolates previously investigated in Chapter 3 
(see Section 3.2.3.2) were selected for this analysis. 
 
5.2 Results 
5.2.1 Effect of isolate source and ST type on expression of luxS. 
Serotype 14 has been reported to exhibit high biofilm formation capacity in other 
studies (Camilli et al., 2011; Tapiainen et al., 2010). However, it has since been 
determined in Chapter 3 (see Figure 3.2.4) that biofilm phenotypes differed according to 
ST; biofilm formation by ST15 isolates was significantly higher than for ST130 isolates 
and unlike the situation with serotype 3 strains, was independent of isolate source. The 
pneumococcus utilizes autoinducer-2 (AI-2), the product of the LuxS enzyme, as a 
signaling molecule to induce biofilm formation (Trappetti et al., 2011c; Vidal et al., 
2013). Transcription levels of the luxS gene were therefore investigated to determine 
whether this might account for differences in biofilm formation capacity between ST15 
and ST130 isolates. Strains were grown at pH 7.4 without Fe(III) supplementation (see 
Section 2.1), in accordance to the optimal conditions observed for biofilm formation for 
these strains (see Section 3.2.4 and Figure 3.23); RNA was extracted and expression of 
luxS was assayed by quantitative real time RT-PCR (see Sections 2.14 and 2.15).   
 Figure 5.1 shows that luxS was transcribed at a significantly higher level (~1.5-
fold) in the ST15 strains compared to the ST130 strains (P < 0.01). The increased luxS 
expression observed in ST15 showed a direct correlation with the relative biofilm 
formation capacities of ST15 and ST130 isolates, as shown in Chapter 3 (see Figure 
3.24). However, no significant differences were observed in luxS expression between 
blood and ear isolates within either ST.  
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Figure 5.1. Effect of isolate source and ST type on luxS expression. Transcription of 
luxS relative to 16S rRNA of ST15 and ST130 blood (n=3 for each ST) and ear ( n=2 for 
each ST) isolates, was measured by qRT-PCR, as described in Section 2.9.2. Data are 
means ± SEM of quadruplicate assays. Pooled data are presented for blood and ear 
isolates within each ST. The significance of differences between STs was determined 
using Student’s two-tailed t-test (**, P < 0.01).  
 
5.2.2. Virulence phenotype of ST130 blood and ear isolates.  
The two dominant STs identified for the serotype 14 isolates examined in Chapter 
3 were then investigated for virulence phenotype. Firstly, low biofilm forming ST130 
strains were examined in the mouse intranasal challenge model (see Section 2.18). 
Briefly, 3 groups of 5-6 outbred 6-week old female Swiss mice were each challenged 
intranasally with one blood (ST130/4524) or one ear isolate (ST130/76547) (see Section 
2.18). CFU counts of the respective strains were then quantitated from the nasopharynx, 
lungs, blood, brain and ear tissues at 24 h, 48 h and 72 h post challenge.  
 Blood and ear isolates colonized the nasopharynx of mice at similar levels (104 - 
106 CFU) at all time points (Fig. 5.2A). At 24 h post infection, bacterial loads in the lungs 
were similar for blood and ear isolates, with bacteria detected in only 2/5 mice in both 
cases, and at levels below 103 CFU. At the later time points, no bacteria were detected in 
the lungs (Fig. 5.2B).  Bacterial loads in the brain were also similar for the blood and ear 
isolates at all time points, and increased from 1/5 mice infected at 24 h in both cases, to 
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4/6 and 4/5 mice infected at 72 h for the blood and ear isolate, respectively (Fig. 5.2C). 
Interestingly, there was a significant difference in infection rate for the ear niche between 
the blood isolate ST130/4524 and the ear isolate ST130/76547 at 24 h (0/5 vs 4/5, 
respectively; P < 0.05). However, the infection rates were similar for the two strains at 48 
h and 72 h (Fisher Exact test), with all mice showing infected ears at the latter time with a 
median bacterial load of approximately 103 CFU in both cases (Fig. 5.2D).  Neither of the 
strains were detected in the blood of any of the mice at any time point (data not 
presented).  
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Figure 5.2. Comparative virulence of ST130 blood (ST130/4524) and ear 
(ST130/76547) isolates. Blood isolates are represented by round filled black symbols 
while ear isolates are represented by square filled black symbols. The horizontal bars 
denote the median CFU for each group; the dotted horizontal line indicates the lower 
limit of detection and symbols on the line denote no bacteria detected. No significant 
differences in infection rates were found (Fisher-Exact Test). 
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5.2.3 Virulence phenotype of ST15 blood and ear isolates. 
The virulence profiles of the five ST15 strains (were also examined in the same 
challenge model. Group sizes at each time point (n) were 16 for one blood (ST15/4495) 
and one ear isolate (ST15/9-47) (both selected at random), while n = 5 at each time point 
for the remaining strains. Numbers of the respective strains in various host niches 
(nasopharynx, lungs, blood, brain and ear) were quantitated at 24 h and 72 h post-
challenge (Figure 5.3). None of the strains were detected in the blood of any of the mice 
at either time point (data not presented). The three blood (ST15/4495, ST15/4534 and 
ST15/4559) and two ear isolates (ST15/9-47 and ST15/51742) all exhibited a similar 
capacity to colonize the nasopharynx at both 24 h and 72 h post-infection, with GM 
bacterial load in this niche in the range 104-105 CFU (Figure 5.3A). There were no 
significant differences in either infection rate or GM bacterial load. However, significant 
differences were observed between blood and ear isolates in the other host niches. Neither 
of the ear isolates was detectable in the lungs of any of the infected mice at either time 
point. In contrast, the blood isolate ST15/4495 was present in the lungs of 14/16 mice at 
24 h and 8/16 at 72 h post challenge (P < 0.0001 and P = 0.0032, respectively; Fisher 
Exact test). A similar trend was seen for the other two blood isolates (ST15/4534 and 
ST15/4559), with 50% of lungs colonized at 72 h (Figure 5.3B). The opposite tropism 
was observed in the brain. None of the three ST15 blood isolates were detected in the 
brains of any of the mice at either time point. However, the ear isolate ST15/9-47 was 
detected in the brains of 15/16 mice and 11/16 mice at 24 h and 72 h, respectively (P < 
0.0001 in both cases). The other ear isolate (ST15/51742) was present in the brains of 5/5 
and 3/5 mice at 24 h and 72 h, respectively (P < 0.01 relative to any of the blood isolates 
at 24 h) (Figure 5.3C). In the infected mice, bacterial loads in the brain were in the range 
of 103-105 CFU. All five ST15 isolates were able to spread to the ear compartment after 
intranasal challenge, but the proportion of mice whose ears were infected with the ear 
isolate ST15/9-47 was significantly greater than that for mice challenged with the blood 
isolate ST15/4495 (16/16 versus 7/16 and 15/16 versus 8/16 at 24 h and 72 h, 
respectively; P = 0.0008 and P = 0.0155, respectively) (Figure 5.3D). The GM bacterial 
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load in the ears for ST15/9-47 was also significantly greater than that for ST15/4495 at 
both 24 h and 72 h (P = 0.0015 and P = 0.0020, respectively). Similar trends were also 
seen in the mice challenged with the other ST15 ear isolate and the two other blood 
isolates. Collectively, these results show once again that pneumococci of the same 
serotype and ST may exhibit distinct in vivo phenotypes in accordance with clinical site 
of isolation.  
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Figure 5.3. Comparative virulence of ST15 blood (ST15/4495, ST15/4534 and 
ST15/4559) and ST15 ear (ST15/9-47 and ST15/51742) isolates. Blood isolates are 
represented by hollow grey symbols while ear isolates are represented by filled black 
symbols. The horizontal bars denote the median CFU for each group; the dotted 
horizontal line indicates the lower limit of detection and symbols on the line denote no 
bacteria detected. Differences in infection rate (number of infected versus uninfected 
mice) were analyzed using the Fisher Exact test: **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001. 
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5.2.4  In vivo competition analysis of ST15 blood and ear isolates. 
The distinct in vivo tropism observed for the ST15 ear and blood isolates could be 
due to differences in bacterial virulence factors, expressed either on the bacterial surface 
or released into the environment. It could also be attributable to differences in the nature 
of the host innate immune responses elicited by the respective strains, whereby the 
presence of a strain with superior virulence characteristics in a given niche may enhance 
the virulence of a “passenger” strain. To explore this, in vivo competition experiments 
were carried out (see Section 2.19) in which two groups of mice were challenged 
intranasally with equal numbers of ST15/4495 and ST15/9-47, and the relative numbers 
of each strain determined in various host niches at 24 h and 72 h post-challenge. In order 
to distinguish the strains, erythromycin-resistant derivatives of each strain were 
constructed by transformation with the plasmid pAL3 (see Section 2.8).  Two competition 
experiments were performed with 5 mice per group for each time point. In one 
experiment, mice were challenged with equal numbers of ST15/4495 and ST15/9-
47:pAL3; in the other, mice were challenged with equal numbers of ST15/4495:pAL3 
and ST15/9-47. Tissue samples were 
plated on blood agar (BA) with or without erythromycin to enable calculation of the ratio 
of sensitive to resistant organisms, and hence the competitive index (CI). Data pooled 
from both experiments are shown in Figure 5.4. 
 In spite of the similar capacities of ST15/4495 and ST15/9-47 to colonize the 
murine nasopharynx when challenged in isolation (Figure 5.2), the ear isolate had a 
significant competitive advantage over the blood isolate in the mixed infection model in 
the nasopharynx at 24 h (P < 0.001) and at 72 h (P < 0.0001), by which time the median 
CI was approximately 105 (Figure 5.4B). The ear isolate also predominated in both the 
ear and brain compartments at both time points (P < 0.0001 for brain at 24 h and 72 h and 
ear at 24h; P < 0.05 for ear at 72 h). Moreover, whereas small numbers of the blood 
isolate were present along with the dominant ear isolate in the ears of all the infected 
mice, the blood isolate was never detected in brain tissue of any of the mice at either time 
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point. These findings are understandable, given that access to both the brain and the ear 
compartments occur via the nasopharynx, where the ear isolate is present at a 105-fold 
excess over the blood isolate. A distinct scenario occurred in the lungs. Only 6/10 mice 
had detectable pneumococci in the lungs at either time point, and in these mice, neither 
strain had a significant competitive advantage overall (Figure 5.4). This is in spite of the 
fact that when challenged in isolation, only the blood isolate was able to persist in the 
lungs at either 24 h or 72 h (Figure 5.2B). In the competition experiment, the ear isolate 
outcompeted the blood isolate in 4/6 infected mice, whereas the blood isolate 
outcompeted the ear isolate in 2/6 mice (Figure 5.4). The intranasal challenge inoculum 
(approximately 106 CFU; as determined by CFU counts of the inoculum post-challenge) 
is instilled into the nares under general anesthesia and a proportion of the dose is 
aspirated directly into the lungs during the challenge.   When instilled on its own, ST15/9-
47 organisms entering  the lung  during challenge are cleared within 24 h, whereas when 
ST15/4495 is instilled on its own, the blood isolate is able to resist innate defenses and 
persist in the lung. However, in the co-infection model, significant numbers of the ear 
isolate are present in a proportion of the mice at both 24 h and 72 h. These findings 
indicate that the presence of the blood isolate ST15/4495, at least during the immediate 
post-challenge period, is necessary for persistence of the ear isolate ST15/9-47 in the lung 
compartment.  
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Figure 5.4. In vivo competition between ST15/9-47 (ear isolate) and ST15/4495 
(blood isolate). Data shown are pooled from two competition experiments performed 
with 5 mice per group for each time point (24 h and 72 h post challenge). In one 
experiment, mice were challenged with equal numbers (5 × 107 CFU each) of ST15/4495 
and ST15/9-47:pAL3 (hollow symbols); in the other experiment, mice were challenged 
with equal numbers of ST15/4495:pAL3 and ST15/9-47 (solid symbols). The competitive 
index (CI) has been shown as log CI for each tissue for each mouse. The horizontal dotted 
lines denote the geometric mean CI for each tissue. Statistical differences between the 
geometric mean CI and a hypothetical value of 0 (ratio of 1:1) in each niche were 
analyzed using the two-tailed Student's t-test: ns, not significant; *, P< 0.05; ***, P< 
0.001; ****, P < 0.0001.  
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5.2.5  In vitro adherence and invasion of ST15/9-47 (ear isolate) and ST15/4495 
(blood isolate).  
To further explore the basis for the enhanced nasopharyngeal colonisation fitness 
of ST15/9-47, the adherence phenotype of all the ST15 isolates was assessed in vitro 
using Detroit 562 (human nasopharyngeal) cells (Table 5.1). There were significant 
differences in total in vitro adherence between several of the strains. Two of the blood 
isolates (ST15/4495 and ST15/4534) were significantly less adherent than the ear isolate 
ST15/9-47 (P < 0.01 and P < 0.001, respectively). The other ear isolate (ST15/51742) 
was even more adherent than ST15/9-47 (P < 0.05). The adherence of the third blood 
isolate (ST15/4559) was not significantly different from ST15/9-47, but it was 
significantly less adherent than the second ear isolate ST15/51742 (P < 0.01). The 
capacity of the ear isolate ST15/9-47 and the blood isolate ST15/4495 to invade Detroit 
562 cells was also investigated (Table 5.1), but no significant difference was observed.  
 
5.2.6 Expression of host immune response genes in infected tissues. 
Although only the blood isolates are detectable in the lungs of infected mice at 24 
h, ear isolates are delivered into the lungs during challenge, but are cleared by host innate 
defenses by 24 h. In a pilot experiment, similar bacterial loads were present in the lungs 
of mice challenged with either ST15/4495 or ST15/9-47 at 6 h post challenge (107-108 
CFU in both cases). Differences in host responses during the immediate post-challenge 
period, which may have influenced bacterial clearance from the lungs, were therefore 
investigated. 
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Table 5.1 Adherence to and invasion of Detroit 562 cells. 
Strain Source Adherencea 
(CFU/well ± SEM) 
Invasion 
(CFU/well ± SEM) 
ST15/9-47 Ear 7.88 ± 0.78 × 105 3.50 ± 0.65 × 103 
ST15/51742 Ear 1.19 ± 0.10 × 106 * Not tested 
ST15/4495 Blood 3.75 ± 0.56 × 105 ** 3.95 ± 0.28 × 103 
ST15/4534 Blood 2.85 ± 0.27 × 105 *** Not tested 
ST15/4559 Blood 7.50 ± 0.59 × 105 Not tested 
a Significant differences in adherence relative to that for ST15/9-47 are indicated as 
follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student’s t-test, two-tailed). (Credit: 
Adrienne Paton (see also Amin et al. (2015)). 
 
Mice were challenged with either the blood isolate (ST15/4495) or the ear isolate 
(ST15/9-47), or were sham-infected (anesthetized and inoculated with 30 μl SB). Total 
RNA was isolated from lungs and nasopharyngeal tissue 6 h after challenge. Expression 
of 84 key immune response genes was then quantitated using RT-PCR arrays (see 
Sections 2.14 - 2.16). 
 When compared to levels in sham-infected samples, a total of 35 genes were 
induced in the lungs, as judged by a significant increase in mRNA level following 
challenge with at least one of the two ST15 strains (Table 5.2). Overall, the pattern of 
gene expression indicated a generally pro-inflammatory response in the lungs at 6 h post-
challenge; genes encoding a number of pro-inflammatory cytokines were up-regulated, 
including IL1α, IL1β, IL23a, IL6 and TNFα. Other genes involved in regulating the 
immune response were also increased in expression. These included the chemokines 
CCL12, a murine homolog of (human) CCL2, and CXCL10, which is known to be 
induced by IFNγ, a pro-inflammatory cytokine that also showed increased expression 
following pneumococcal challenge. The chemokine receptor CCR5 was also elevated at 
the mRNA level. Genes encoding elements involved in pathogen recognition and 
signaling during immune responses were differentially expressed in challenged samples 
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compared to sham-infected samples, such as Myd88, the Toll-like receptors (TLRs) 3, 6 
and 7, Nod2, Ddx58, Jak2 and Nfkbia. Other up-regulated genes included those encoding 
the integrin CD11b (Itgam), and its associated adhesion molecule ICAM1, the 
inflammasome component NLRP3, and granulocyte-macrophage colony stimulating 
factor (GM-CSF; Csf2).  Som e strain -strain differences were observed, with 8 genes 
showing significant differential expression in lungs following challenge with ST15/4495 
compared to challenge with ST15/9-47 (Table 5.3). Of these, 6 genes were up-regulated 
by both strains when compared to resting samples, but to a significantly greater degree 
following challenge with ST15/4495. These included those encoding the pro-
inflammatory cytokines TNFα and IL6, the type I interferon IFNβ, the co-stimulatory 
molecule CD40, the transcription factor Tbet (Tbx21) and the chemokine CCL12. The 
remaining 2 genes, Apcs and Il2, were found to be up-regulated only following challenge 
with ST15/9-47. 
 Since the nasopharynx is the first host environment to which the bacteria are 
exposed during infection, we examined whether the blood isolate (ST15/4495) and the ear 
isolate (ST15/9-47) also elicited differential induction of innate immune response genes 
in this niche at 6 h post infection. However, no significant differences in expression were 
detected for any of the 84 genes analyzed between sham-infected mice and those 
challenged with either strain. 
 
Table 5.2. Genes differentially expressed in infected relative to sham-infected lungs.a 
 
ST15/4495 vs. 
sham-infected  
ST15/9-47 vs. 
sham-infected  
Gene Fold change Significance Fold change Significance 
Apcs ns ns 5.15 ** 
C5ar1 14 * 8.47 ** 
Ccl12 36.61 * 15.56 ** 
Ccr5 10.68 * 5.97 ** 
Cd14 ns ns 61.12 ** 
Cd40 6.21 * 2.55 * 
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Cd86 3.51 * 2.51 ** 
Csf2 ns ns 19.34 * 
Cxcl10 ns ns 310.55 ** 
Ddx58 ns ns 2.36 * 
Icam1 7.91 * 5.13 * 
Ifna2 ns ns 2.50 * 
Ifnb1 96.15 *** ns ns 
Ifng 17.2 ** 12.25 *** 
Il10 ns ns 17.09 * 
Il1a 29.81 ** 16.64 *** 
Il1b 88.28 * 52.60 ** 
Il1r1 2.1 * ns ns 
Il2 ns ns 4.95 ** 
Il23a 40.9 **   
Il6 ns ns 312.35 ** 
Irf7 4.01 * 3.80 * 
Itgam 3.73 **   
Jak2 3.29 ** 4.41 * 
Mx1 152.64 *   
Myd88 12.3 * 5.22 * 
Nfkbia ns ns 20.34 * 
Nlrp3 36.61 *** ns ns 
Nod2 9 ** ns ns 
Slc11a1 4.26 * 5.25 * 
Tbx21 2.4 ** ns ns 
Tlr3 4.8 ** ns ns 
Tlr6 ns ns 3.84 ** 
Tlr7 ns ns 4.80 ** 
Tnf 119.21 ** 50.78 * 
a Data are fold-difference in gene expression for the indicated comparison. Genes up-
regulated significantly after infection with both ear and blood isolates are highlighted in 
bold type. Statistical significance is indicated as follows: *, P < 0.05; **, P < 0.01; ***, P 
< 0.001, ns, not significant (Student's t-test, two-tailed). 
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Table 5.3.  Genes differentially induced after infection with ST15/9-47 versus 
ST15/4495. 
 
Gene 
ST15/4495 vs sham-
infected 
ST15/9-47 vs sham-
infected ST15/9-47 vs ST15/4495 
fold-
change significance 
fold-
change significance fold-change significance 
Apcs -1.10 ns 5.15 ** 5.67 ** 
Il2 -1.09 ns 4.95 ** 5.40 * 
Ccl12 36.61 * 15.56 ** -2.35 * 
Cd40 6.21 * 2.55 * -2.43 * 
Ifnb1 96.15 *** 17.84 ns -5.39 *** 
Il6 1842.35 (P = 0.06) 312.35 ** -5.90 * 
Tnf 119.21 ** 50.78 * -2.35 * 
Tbx21 2.4 ** 1.02 ** -2.36 **** 
Statistical significance is indicated as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001, 
****, P < 0.0001, ns, not significant (Student's t-test, two-tailed).  
 
5.2.7 Cellular and histopathological responses to lung infection. 
Blood, bronchoalveolar lavage (BAL) fluid and lung tissue from mice infected 
with either ST15/9-47 or ST15/4495, or sham-infected mice, were also investigated for 
cellular recruitment and histopathological changes (see Section 2.10.4).  At 6 h post-
infection, there were very few cells in the BAL and there were no significant differences 
in the numbers of BAL neutrophils (Ly-6G-positive cells) or monocyte/macrophages 
(F4/80-positive cells) between sham-infected mice and those infected with either ST15/9-
47 or ST15/4495, as determined by flow cytometry (result not shown). However, similar 
FACS analysis of blood leukocytes showed significantly higher numbers of neutrophils 
(Figure 5.5A), but not monocyte/macrophages (Figure 5.5B), in ST15/4495-infected mice 
relative to either sham-infected or ST15/9-47-infected mice at 6 h (P < 0.05 in both cases 
for neutrophils). A similar increase in blood neutrophil count in ST15/4495-infected mice 
relative to either sham-infected or ST15/9-47-infected mice at 6 h was also evident from 
differential cell counts of blood films (P < 0.05 and P < 0.01, respectively) (Figure 5.5C). 
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Histological examination of HE-stained lung sections at 6 h (see Section 2.10.4) revealed 
early signs of tissue damage, most notably in ST15/4495-infected mice, including 
congested capillaries, thickened alveolar walls, swollen cuboidal epithelial cells of the 
bronchioles and presence of secretions in the alveolar and bronchiolar spaces (Figure 
5.6A). These features were used to develop an 8-point scoring system for 
histopathological changes (Figure 5.6B). The mean aggregate score (± SE) for 
ST15/4495-infected mice (2.8 ± 1.3) was higher than that for either ST15/9-47-infected 
mice (1.4 ± 0.57), or sham-infected mice (0.5 ± 0.33), but this trend did not reach 
statistical significance. Finally, lung sections were examined for cellular infiltration by 
immunofluorescence microscopy after staining with anti-Ly-6G (Figure 5.7). This 
revealed patchy neutrophil infiltration in 2/5 mice infected with the blood isolate 
ST15/4495 and 1/5 mice infected with the ear isolate ST15/9-47, compared with 0/5 for 
the control mice. No differences in staining for the monocyte/macrophage marker were 
seen between groups.  
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Figure 5.5. Peripheral blood leukocyte counts. Leukocytes isolated from peripheral 
blood collected at 6 h from control (sham-infected) mice, or those infected with the blood 
isolate (ST15/4495) or the ear isolate (ST15/9-47), were examined by FACS after 
staining with anti- Ly-6G (A) or anti F4/80 (B). Data are the product of geometric mean 
fluorescence intensity and the total number of positive cells (GMFIn) for the respective 
marker (± SE). Alternatively, blood films were subjected to differential cell count and 
neutrophil numbers are expressed as a percentage of total leukocytes (mean ± SE) (C). 
Statistical significance is indicated as follows: *, P < 0.05; **, P < 0.01 (Student's paired, 
two-tailed t test). (Credit: Hui Wang (see also Amin et al. (2015)) 
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Figure 5.6. Lung histopathology. HE-stained lung sections from control (sham-infected) 
mice, or those infected with the blood isolate (ST15/4495) or the ear isolate (ST15/9-47) 
at 6 h were examined by light microscopy. Representative sections from each group are 
shown (A); scale bar = 0.1 mm. Slides were also scored (blind) according the following 
8-point scheme: congested capillaries (fine arrows, scored 0-2); thickened alveolar wall 
(arrow heads, scored  0-2); swollen cuboidal epithelial cells of the bronchioles (thick 
arrows, scored 0-2); secretions in the alveolar and bronchiole space (hollow arrow, score 
0-2). Data were examined with Student's unpaired two-tailed t test and are presented as 
mean ± SE for each group (B). (Credit: Hui Wang  (Amin et al., 2015)) 
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Figure 5.7. Neutrophil infiltration. Lung tissue from infected or control mice was fixed, 
sectioned and labelled with rat anti mouse Ly-6G or F4/80, followed by Alexa-488 
conjugated anti-rat IgG and examined by fluorescence microscopy. Scale bar = 50 μm. 
(Credit : Hui Wang  (see also Amin et al. (2015)). Patchy neutrophil infiltration was 
observed in 2/5 mice infected with the blood isolate ST15/4495 and 1/5 mice infected 
with the ear isolate ST15/9-47, compared with 0/5 for the control mice 
 
5.3 Discussion 
 In Chapter 4 multiple examples of serotype 3 strains belonging to the same ST, 
which consistently and reproducibly exhibited distinct virulence and biofilm phenotypes 
that directly correlated with the original site of isolation from human patients (i.e. ear vs. 
blood) were described (see also Trappetti et al. (2013)). This suggested that at least in 
serotype 3, pneumococci exhibit stable niche adaptation within a clonal lineage. In this 
Chapter, ST-matched blood and ear isolates belonging to serotype 14, a common cause of 
OM as well as invasive disease (Brueggemann et al., 2003) were investigated for a 
correlation between isolate source and virulence-related phenotypes.  
 Previous studies in this laboratory and elsewhere show an association between 
luxS expression and biofilm formation in D39 and serotype 3 strains (Trappetti et al., 
2011c; Trappetti et al., 2013; Vidal et al., 2011; Vidal et al., 2013). In this Chapter, the 
expression of luxS was significantly higher in ST15 than ST130 strains, which is 
consistent with the significantly higher biofilm formation capacity of the ST15 isolates at 
pH 7.4 (see Figure 3.24).  Thus, the overall association between luxS expression and 
 
Control                      Blood isolate                  Ear isolate 
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biofilm formation also appears to hold for these serotype 14 strains. However, unlike the 
findings for the serotype 3 ST180, ST232 and ST233 lineages (see Figure 4.1), there was 
no significant difference in luxS expression between blood and ear isolates within either 
ST15 or ST130 (Figure 5.1). Thus, differential luxS expression cannot account for the 
significantly higher biofilm formation exhibited by ST130 ear isolates relative to ST130 
blood isolates at pH 7.4 (Fig. 3.24).   
 Examination of the virulence phenotype of the low biofilm forming ST130/4524 
blood isolate and ST130/76547 ear isolate in the mouse intranasal challenge model 
showed that although the ear isolate appeared to translocate more quickly to the ear 
compartment than the blood isolate, in general, isolate source did not appear to be 
associated with the overall virulence phenotype of ST130 strains.  However, only one ST-
matched pair of isolates was examined, which is not sufficient for a conclusive 
observation. Analysis of additional ST130 blood and ear isolates in the collection is 
clearly warranted to gain further insight into the influence of isolate source on the 
virulence of ST130 strains. 
ST15 was the other dominant ST in the serotype 14 collection analyzed in Chapter 
3 and was represented amongst clinical isolates from cases of sepsis as well as OM. ST15 
blood and ear isolates were able to colonize the murine nasopharynx to roughly similar 
extents. However, the blood isolate (ST15/4495) was significantly better at 
colonisation/persistence in the lung, while the ear isolate (ST15/9-47) was significantly 
better able to penetrate and persist in the brain and ears. Similar preferential tropism for 
the brain and ear was observed for the other ST15 ear isolate (ST15/51742), while the 
two other ST15 blood isolates (ST15/4534 and ST15/4559) colonized the lungs in a 
proportion of infected mice. Significantly, neither of the ear isolates were detected in the 
lungs of any of the mice at either 24 or 72 h, while none of the three blood isolates were 
ever detected in the brain. Furthermore, none of the ST15 blood or ear isolates were 
detected in the blood at any time during the experiment. This is consistent with the long-
known fact that mice exhibit a high degree of innate resistance to sepsis after challenge 
with serotype 14 S. pneumoniae strains (Kadioglu & Andrew 2005; Mizrachi-Nebenzahl 
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et al., 2003).  However, these findings also suggest that the very high rate of meningitis 
that occurs after intranasal challenge with either of the ST15 ear isolates was not a 
consequence of hematogenous spread. Likely alternative routes for translocation of 
pneumococci from the nasopharynx to the brain include direct invasion by retrograde 
axonal transport along olfactory neurons into the CNS (van Ginkel et al., 2004).  
Collectively, the above findings provide robust evidence for the existence of 
distinct pathogenic profiles for serotype 14 S. pneumoniae strains belonging to the same 
ST (in this case ST15). A previous study by Silva et al. (2006) has shown modest 
differences in bacterial loads in the blood of mice 6 h after intraperitoneal challenge with 
three serotype 14 blood isolates belonging to ST124, although the bacteremia was 
transient and subclinical. However, the present study demonstrated highly significant 
differences in virulence and pathogenic profile between isolates belonging to the same 
serotype and clonal lineage as well as a close correlation between pathogenic profile in 
mice and the original site of isolation from human cases of pneumococcal disease.  This 
extends the observation that was previously reported for serotype 3 strains belonging to 
ST180, ST232 and ST233 (Chapter 4). Thus, stable niche adaptation within a clonal 
lineage appears to be a more general phenomenon.  
 Apart from the differences in biofilm formation capacity observed in Chapter 3, 
differences in virulence profiles between the ST130 and ST15 strains were also observed. 
While ST130 strains exhibited generally similar virulence profiles between blood and ear 
isolates, ST15 clinical isolates showed exclusive translocation of bacteria to specific 
tissues in accordance with isolate source. It has been previously reported that clinical 
strains of the same serotype can exhibit different disease phenotypes in accordance with 
ST (Hanage et al., 2005; Silva et al., 2006). In serotype 14 strains, ST 156 was strongly 
associated with invasive disease;  STs 482, 191, 124, and 138 were also more 
significantly associated with invasive disease relative to STs 485 and 62 which were more 
associated with carriage (Hanage et al., 2005). In another study, serotype 14 isolates were 
found to include clones exclusively found in carriers (ST230), as well as those solely 
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associated with invasive disease (ST307) (Sandgren et al., 2004). In serotype 14 strains 
the prevalence of ST types known to cause invasive disease also differs geographically, 
with the most prevalent being ST156 in Finland (Hanage et al., 2005), ST15 in England 
and ST230 in Denmark (Camilli et al., 2011).  
  Notwithstanding the above, the in vivo competition experiments of ST15 isolates 
in the present study yielded some unexpected findings. Firstly, although the ear and blood 
isolates are able to colonize the nasopharynx to similar levels when administered 
individually, the ear isolate ST15/9-47 massively out-competed the blood isolate 
ST15/4495 in this niche in the co-infection model. The reason for this is not clear, 
although production of bacteriocins by ST15/9-47 is one possibility. Regardless of 
underlying mechanism, it accounts for the dominance of ST15/9-47 in the brain and ear in 
the co-infection model, since these host niches are presumably accessed via the 
nasopharynx, where the ear isolate already enjoyed a 105-fold numeric advantage. On the 
other hand, the data from the individual challenge experiments might cause one to predict 
that the blood isolate ST15/4495 would enjoy a competitive advantage in the lungs, but 
this was not the case, with neither strain predominating, a fact that mitigates against the 
bacteriocin hypothesis mentioned above. Similar numbers of ear and blood isolates were 
delivered into the lungs during challenge under general anesthesia, and bacterial loads in 
lung tissue at 6 h post challenge were similar. However, in the individual challenge 
studies, ST15/9-47 was completely cleared from the lungs of all mice by 24 h, while 
ST15/4495 was able to persist. There are two possible explanations for this. ST15/4495 
may secrete a (yet to be defined) virulence factor that can act in trans and support 
survival of ST15/9-47 in the mixed infection model. Alternatively, differences in host 
innate immune responses elicited by the blood and ear isolates could account for the 
distinct pathogenic profiles. Clearly, host responses triggered (or inhibited) by ST15/4495 
enable this strain to persist in the lung environment. However, this may create a host 
microenvironment that also enables persistence of co-administered strains such as 
ST15/9-47, which would otherwise have been cleared.  
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  To establish if the host immune response plays a role in the distinct pathogenic 
profiles of the ST15 blood or ear isolates, the transcriptional responses of 84 genes 
representing the major pathways involved in the innate and adaptive immune response to 
microbial pathogens were examined. Unsurprisingly, infection with either strain induced 
a variety of pro- inflammatory genes. Differentially expressed genes included those 
encoding the cytokines IL6 and TNFα that are involved in the classical activated 
macrophage response to infection (Mosser, DM 2003). IL6 is induced in response to 
pathogen-associated molecular patterns (PAMPS) and has previously been shown to be 
protective in a model of pneumococcal pneumonia (van der Poll et al., 1997). TNFα is a 
key player in induction of pro-inflammatory responses and is rapidly produced in 
response to injury or infection. It is primarily produced by cells of monocytic origin, such 
as macrophages, which in turn are highly responsive to this cytokine. Along with IL1β, it 
is also known to induce up regulation of expression of adhesion molecules such as 
ICAM1 on endothelial cells, promoting recruitment of leukocytes such as neutrophils to 
sites of infection (Collins et al., 1995; Mackay et al., 1993). Through the induction of 
CCR2 ligands, including CCL12, IFNβ is involved in the recruitment of “inflammatory” 
Ly6C high monocytes from the circulation (Lee et al., 2009), and these cells then 
differentiate into macrophages within the infected tissue. Type I interferons have also 
been shown to have varying roles in the response to pneumococcal infection, with a 
recent study from our laboratory demonstrating a role for these cytokines in the 
development of invasive pneumococcal disease (Hughes et al., 2014).  
 CD40 is expressed on a range of leukocyte subsets, including macrophages, where 
its expression is induced by various cytokines including IFNγ and GM-CSF (Alderson et 
al., 1993). It is involved in macrophage activation and can, in conjunction with either 
IFNγ or TNFα, induce production of antimicrobials such as nitric oxide (Portillo et al., 
2012). Tbx21 encodes the transcription factor T-bet, which is a hallmark of Th1 cells 
during adaptive immune responses. However, it is also known to be expressed by a 
variety of other cell types, including dendritic cells (DCs), natural killer (NK) cells and 
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other innate lymphoid cells (ILCs) (Lazarevic et al., 2013). It has also recently been 
shown to be expressed by respiratory epithelium during pneumococcal infection (Woo et 
al., 2014). 
 Serum amyloid P, the protein encoded by Apcs, is known to play a role in 
complement activation, and has been shown to be involved specifically in complement 
deposition on pneumococcus, improving phagocyte efficiency and aiding clearance of the 
pathogen (Yuste et al., 2007), while IL2 is believed to be involved in proliferation and 
activation of natural killer (NK) cells and other innate lymphoid cells (ILCs), as well as 
proliferation and differentiation of T cells during the adaptive immune response 
(Gasteiger & Rudensky, 2014). 
  The strain-specific differences observed provide important clues as to how the 
immune response may vary, yielding very different patterns of infection from two 
clonally related strains. Six of the eight genes that were differentially expressed in 
response to infection with ST15/4495 relative to ST15/9-47 are up regulated in response 
to both strains relative to sham-infected lungs, but are induced more strongly in response 
to ST15/4495. This suggests that while both strains induce a broadly similar response, 
one of the distinguishing features between the two is the strength of the response induced 
at a similar bacterial load. This response included increased expression of genes encoding 
CCL12, IL6, TNFα, IL1β and CD40, which points to an overall stronger macrophage 
response to the blood isolate than to the ear isolate. BAL fluid collected at 6 h post-
infection contained very few cells and there were no significant differences between 
sham-infected mice and those infected with either of the isolates. However, mice infected 
with the blood isolate ST15/4495 exhibited significant neutropenia relative to sham-
infected or ST15/9-47-infected mice at this early time point. Histopathological 
examination was also suggestive of increased lung damage in mice infected with 
ST15/4495. The above findings have parallels with a previous study from this laboratory, 
which compared host transcriptional responses to highly invasive and non-invasive S. 
pneumoniae strains belonging to serotype 1 in a similar intranasal challenge model. A 
total of 29 genes of the 84 on the array showed significant up-regulation, of which 22 
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were also up-regulated in the present study. Both type 1 strains were present in roughly 
equal numbers in the lung at 6 h, but the invasive strain triggered a much stronger type I 
interferon response, which facilitated invasion of the pleural cavity followed by the blood 
(Hughes et al., 2014). In the present study we identified two genes (Apcs and Il2) that 
were only significantly up regulated in mice challenged with the ear isolate ST15/9-47 
when compared to sham-infected mice; infection with the blood isolate had a negligible 
effect on their expression. Therefore, it is tempting to speculate that the expression of 
Apcs and Il2 might contribute to the clearance of the ear isolate from the lungs. In 
particular, serum amyloid P, the protein encoded by Apcs, is known to play a role in 
complement deposition on the pneumococcus, improving phagocyte efficiency and aiding 
clearance of the pathogen (Yuste et al., 2007).  
 In this study, we have provided further evidence that S. pneumoniae strains belonging 
to the same serotype and ST can elicit distinct host innate immune responses and cause 
different types of disease (for journal publication of this study please refer to Appendix 
B). Future comparative genomic and transcriptomic analyses of these ST-matched strain 
pairs with distinct virulence phenotypes should facilitate identification of specific 
bacterial determinants that contribute to tissue tropism. Indeed, RNA sequencing has 
since been carried out on ST15 isolates grown in vitro, and will be discussed further in 
Chapter 6. However, in vivo transcriptomic analysis of the blood and ear isolates 
themselves (rather than the host) during early lung infection may allow a more thorough 
understanding of differences between these strains that impact on virulence phenotype.  
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Chapter 6: Transcriptomic analysis of clonally 
related blood and ear isolates of Serotypes 3 and 14 
 
6.1 Introduction 
The evolution of different lineages is an important survival mechanism for the 
pneumococcus and has become an immense challenge in the control and treatment of 
pneumococcal diseases. In Chapter 5 it was observed that the serotype 14 blood isolate 
ST15/4495 showed a distinct virulence phenotype compared to ear isolate ST15/9-47. 
Further investigations of clonally related blood isolates ST15/4534, ST15/4559 and ear 
isolate ST15/51742 showed similar trends (see Section 5.2.3). Differential immune 
response gene expression patterns were also seen between mice infected with the 
ST15/4495 blood and ST15/9-47 ear isolates. In Chapter 4 it was also shown that 
serotype 3 blood and ear isolates from ST180 and ST233 also exhibited distinct virulence 
phenotypes in mice in accordance with clinical site of isolation.  
The availability of high throughput methods to sequence and analyse whole 
genomes is becoming increasingly useful for probing pneumococcal genetic diversity. An 
extension to genome sequencing are transcriptome profiling approaches, which probe and 
quantitate the complete set of transcripts in the cell, including mRNAs, non-coding RNAs 
and small RNAs, at specific developmental stages or physiological conditions (Wang et 
al., 2009). Two main technologies are currently used to quantify and probe the 
transcriptome: hybridization-based microarray analysis and the sequencing-based RNA-
Seq. Whilst microarray technology is high throughput and relatively inexpensive, its main 
drawbacks include the requirement for prior knowledge of the genome sequence, 
difficulties in detecting small RNA species or those in low abundance, as well as issues 
with cross-hybridization. RNA-Seq has several advantages, most importantly the capacity 
to detect unknown transcripts, and sequence variations, thereby providing much more in-
depth information. It also has very low background signals, a large dynamic range of 
detection at low or very high level gene expression, high levels of reproducibility and 
requires less RNA sample (Croucher & Thomson 2010; McClure et al., 2013; Pruitt et 
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al., 2005). A further advantage is that if there are differences in genome sequence 
between two strains being compared (e.g. presence or absence of an AR) these will be 
apparent from the respective transcriptome if the genes in question are actually being 
expressed, thereby reducing the importance of separate genome sequence analysis.   
The differences in virulence phenotype within ST lineages in accordance with 
isolation site observed for the serotype 3 and 14 strains in Chapters 4 and 5 suggests the 
possibility of differences in transcriptional profile between otherwise closely related 
isolates. Therefore, the aim of the work described in this chapter was to utilize RNA-Seq 
to compare the transcriptomes of the clonally related serotype 3 and 14 blood and ear 
isolates. 
 
6.2 Results 
6.2.1 Transcriptomic analysis of serotype 14 ST15 clinical isolates 
For transcriptomic analysis of ST15 strains a total of 5 blood (ST15/4495, 
ST15/4534 and ST15/4559) and ear (ST15/9-47 and ST15/51742) isolates investigated 
previously in Chapter 5 were selected. Bacterial strains from frozen stock were firstly 
grown in serum broth in triplicates to a final OD600 of 0.2 and RNA was extracted using 
the Qiagen RNAEasy Mini Kit as per the manufacturer’s instructions (see Section 2.14). 
The quantity and integrity of the RNA samples were then determined (see Section 2.18). 
RNA samples with a RIN (RNA Integrity Number) of ≥ 8.0 and a total amount of ≥3 μg 
were then sent to the Australian Genome and Research Facility (AGRF Melbourne, 
Australia) for ribosomal RNA removal using the Illumina Ribo-zero rRNA (Bacteria) 
removal kit, cDNA library preparation and RNA-Sequencing using the Illumina Hi-Seq 
2500 sequencing platform. The number of reads produced for each of the blood 
(ST15/4495, ST15/4534 and ST15/4559)  and ear (ST15/9-47 and ST15/51742) isolates 
were 26,885,011, 49,113,015, 49,936,770, 47,846,137 and 47,819,885, respectively. The 
per base sequence quality for the 5 samples was reported by AGRF to be excellent, with 
>97% bases above Q30 across all samples.  
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Differential gene expression analysis was performed using the publicly available serotype 
14 ST15 CGSP14 genome (NC_010582.1) (Ding et al., 2009) as a reference. Initial 
analysis to compare the group of blood isolates with the ear isolates was carried out by 
AGRF using the EDGE-pro (Estimated Degree of Gene Expression in PROkaryotes) 
pipeline (Magoc, Wood & Salzberg 2013) and R/Bioconductor-based voom and limma 
packages (Ritchie et al., 2015). In addition to AGRF’s data analysis, differential gene 
expression analysis was also carried out using the R/Bioconductor DESeq (v.3.2) package 
(Anders & Huber, 2010) to validate AGRF's analysis, as well as to carry out differential 
gene expression analysis between single isolates. Firstly, sequenced reads were aligned to 
the CGSP14 reference genome using Bowtie2 (v2.0.0.0-beta6) (Langmead & Salzberg, 
2012). SAMtools (v 0.0.18) (Li et al., 2009) and BEDTools (v2.24.0) (Quinlan & Hall, 
2010) were then used to obtain read counts for each transcript.  DESeq analysis was 
subsequently performed using this data. DESeq analysis applies P-value adjustments 
(Padj) on the analysed data which account for the false discovery rate (FDR) using the 
Benjamini-Hochberg method (Glueck et al., 2008). An FDR-adjusted P-value of 0.05 
implies that that 5% of the tests found to be statistically significant (e.g. by P-value) will 
be false positives. A significant differential expression in DESeq refers to all Padj values 
of < 1. The Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database resource 
(http://www.genome.jp/kegg/genes.html)  were used as appropriate.  
6.2.1.1 Transcriptomic analysis of ST15 blood and ear isolates. 
Alignment of the reads of five transcriptomes of ST15 serotype 14 blood 
(ST15/4495, ST15/4534, ST15/4559) and ear isolates (ST15/9-47 and ST15/51742) 
against the reference genome revealed a total of 2276 coding sequence (CDS) transcripts 
sequenced for every isolate. However, when the transcriptomes of the five ST15 clinical 
strains were grouped according to isolation site (ear vs blood) and compared by AGRF, 
no significant differences in gene expression were observed between the two groups. 
DESeq analysis subsequently carried out confirmed the lack of significant differences in 
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gene expression between the two groups as analysed by AGRF, as adjusted P-values 
(Padj) were determined to be 1 for all genes. 
As part of the aforementioned analysis, single isolates were then compared 
separately using DESeq. Comparison of these isolates showed variable numbers of 
significantly differentially expressed genes between isolates with an average of 88 genes. 
Ear isolate ST15/9-47 compared against blood isolate ST15/4534 showed the highest 
number of differences (125 genes), while ear isolate ST15/9-47 compared against blood 
isolate ST15/4559 showed the lowest number of significantly differentially expressed 
genes (52 genes). Table 6.1 summarises the number of significantly differentially 
expressed genes for single strain-strain comparisons. 
 
Table 6.1. Significantly differentiated genes identified by DESeq analysis of single 
blood and ear isolates. 
DESeq analysis of isolate pairs Differentially expressed genes (n)a 
ST15/9-47 (ear) vs ST15/4495 (blood) 69 
ST15/51742 (ear) vs ST15/4495 (blood) 116 
ST15/9-47 (ear) vs ST15/4534 (blood) 125 
ST15/51742 (ear) vs ST15/4534 (blood) 76 
ST15/9-47 (ear) vs ST15/4559 (blood) 52 
ST15/51742 (ear) vs ST15/4559 (blood) 76 
ST15/9-47 (ear) vs ST15/51742(ear) 97 
ST15/4495 (blood) vs ST15/4534 (blood) 77 
ST15/4495 (blood) vs ST15/4559 (blood) 103 
ST15/4534 (blood) vs ST15/4559 (blood) 94 
a Number of significantly differentially expressed genes (Padj < 0.05) based on P value 
adjusted for multiple testing using Benjamini-Hochberg method in the DESeq analysis 
software package. 
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Significant differences in gene expressions observed between isolates from the 
same source (blood vs blood; ear vs ear) as well as between sources (ear vs blood) 
suggests a high background of transcriptional differences that are unrelated to isolate 
source or virulence profile. Therefore, further investigations on common genes that are 
differentially expressed between multiple ear vs multiple blood isolates were carried out 
to determine commonality in gene expressions within the isolate groups. To probe for 
significantly differentially expressed genes common to both ear isolates, parallel 
comparison of the two ear isolates ST15/9-47 and ST15/51742 was carried out against 
single blood isolates. As shown in Table 6.2, 51 significantly differentially expressed 
genes were found to be common in the two ear isolates when compared with blood isolate 
ST15/4495. As shown in Table 6.2, 27 genes were found to be significantly upregulated 
and 24 genes significantly downregulated in both of the ear isolates when compared with 
blood isolate ST15/4495. 
 
Table 6.2. Common differentially expressed genes in ear isolates ST15/9-47 and 
ST15/51742 relative to blood isolate ST15/4495. 
 ST15/9-47 vs ST15/4495 ST15/51742 vs ST15/4495 
GENE ID Fold changea 
Statistical 
significance 
(Padj ≤0.05)b 
Fold 
change 
Statistical 
significance 
(Padj ≤0.05) 
SPCG_0013 
(comX1) 52.59 ** 36.98 ** 
SPCG_0044 
(comA)c 53.54 ** 19.17 *** 
SPCG_0045 
(comB)c 55.89 ** 16.44 ** 
SPCG_0087 
(ABC transporter, 
permease protein) 
0.01 ** 0.01 **** 
SPCG_0088 
(ABC transporter, 
permease protein) 
0.02 ** 0.01 **** 
SPCG_0089 
(ABC transporter 
substrate-binding 
0.02 ** 0.01 **** 
149 
 
protein) 
SPCG_0104 
(Hypothetical Protein) 58.80 ** 51.51 **** 
SPCG_0172 
(rRNA methylase) 0.01 **** 0.01 **** 
SPCG_0189 
(ribE) 0.04 * 0.05 *** 
SPCG_0190 
(ribA) 0.03 * 0.05 **** 
SPCG_0191 
(ribC) 0.04 * 0.05 *** 
SPCG_0192 
(ribD) 0.04 * 0.06 *** 
SPCG_0323 
(kdgA) 0.01 ** 0.02 **** 
SPCG_0324 
(carbohydrate kinase) 0.01 ** 0.02 **** 
SPCG_0325 
(Hypothetical Protein) 0.01 ** 0.02 **** 
SPCG_0326 
(gno) 0.01 ** 0.03 **** 
SPCG_0327 
(PTS system N-
acetylgalactosamine-
specific IIA component) 
0.01 *** 0.01 **** 
SPCG_0328 
(glucuronyl hydrolase) 0.006 *** 0.014 **** 
SPCG_0329 
(PTS system, N-
acetylgalactosamine-
specific IIB component) 
0.008 *** 0.011 **** 
SPCG_0330 
(PTS system, N-
acetylgalactosamine-
specific IIC component) 
0.007 *** 0.014 **** 
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SPCG_0331 
(PTS system, N-
acetylgalactosamine-
specific IID 
component) 
0.01 *** 0.015 **** 
SPCG_0332 
(preprotein 
translocase) 
0.01 ** 0.017 **** 
SPCG_0333 
(Hypothetical 
Protein) 
0.01 ** 0.021 **** 
SPCG_0413 
(phaB) 53.38 ** 33.41 **** 
SPCG_0417 
(fabK) 29.26 * 26.1 **** 
SPCG_0423 
(accC) 17.92 * 18.96 **** 
SPCG_0424 
(accD) 17.66 * 18.72 **** 
SPCG_0791 
(degenerate 
transposase) 
36.36 * 35.14 ** 
SPCG_0807 
(degenerate 
transposase) 
37.96 ** 28.69 **** 
SPCG_0819 
(hypothetical protein) 151.61 *** 150.80 **** 
SPCG_0888 
(hypothetical protein) 37.73 * 23.09 ** 
SPCG_0957 
(IS3-Spn1) 21.53 * 12.55 ** 
SPCG_0961 
(hypothetical protein) 37.29 * 37.58 **** 
SPCG_1267 
(hypothetical protein) 40.19 ** 29.35 **** 
SPCG_1274 
(site-specific 
recombinase) 
1040.20 **** 1040.20 **** 
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SPCG_1322 
(hypothetical protein) 0.01 **** 0.01 **** 
SPCG_1323 
(erythromycin 
ribosome methylase) 
0.01 **** 0.01 **** 
SPCG_1326 
(omega2 protein) 0.01 **** 0.01 **** 
SPCG_1327 
(rRNA methylase) 0.01 **** 0.01 **** 
SPCG_1602 
(hypothetical protein) 18.32 * 18.39 *** 
SPCG_1603 
(hypothetical protein) 130.59 *** 107.98 **** 
SPCG_1629 
(hypothetical protein) 29.50 * 27.68 *** 
SPCG_1856 
(dexS) 25.78 * 42.17 **** 
SPCG_1857 
(treP) 34.45 * 57.91 **** 
SPCG_1949 
(hypothetical 
protein)c 
22.23 * 9.13 • 
SPCG_1950 
(ABC transporter, 
ATP-binding 
protein)c 
28.72 * 11.48 ** 
SPCG_1951 
(immunity protein, 
putative)c 
30.42 * 12.78 *** 
SPCG_1952 
(hypothetical protein) 39.75 ** 15.37 *** 
SPCG_2118 
(arginine deiminase) 0.03 * 0.01 **** 
SPCG_2119 
(arcB) 0.04 * 0.02 **** 
SPCG_2202 
(comD)c 
 
21.05 * 8.71 ** 
a Genes up-regulated greater than 2-fold are highlighted in bold type. 
b Statistical significance is indicated as follows: *, Padj < 0.05; **, Padj < 0.01; ***, Padj 
< 0.001; ****, Padj < 0.0001 (padj value that corresponds to p-value adjusted for 
multiple testing using Benjamini-Hochberg method in the DESeq analysis software). 
c Common genes in blood isolates ST15/4495 and ST15/4534 differentially expressed 
against the two ear isolates are highlighted in yellow. 
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 As shown in Table 6.3 below, parallel comparisons of ST15/9-47 and ST15/51742 
showed 45 common significantly differentially expressed genes when the two ear isolates 
were compared with blood isolate ST15/4534, with 15 genes upregulated and 27 genes 
downregulated in the two ear isolates. However, expression of SPCG_2152 (glpF), 
SPCG_2153 (hypothetical protein) and SPCG_2154 (glpK) was observed to be 
upregulated in ST15/9-47, while the reverse was observed in ST15/51742. 
 
Table 6.3. Common differentially expressed genes in ear isolates ST15/9-47 and 
ST15/51742 relative to blood isolate ST15/4534 
 ST15/9-47 VS ST15/4534 ST15/51742 VS ST15/4534 
GENE ID Fold changea 
Statistical 
significance 
(Padj ≤0.05)b 
Fold change 
Statistical 
significance (Padj 
≤0.05) 
SPCG_0044 
(comA)c 14.35 **** 5.19 **** 
SPCG_0045 
(comB)c 16.13 **** 4.79 **** 
SPCG_0046 
(purC) 0.33 ** 0.07 **** 
SPCG_0047 
(purL) 0.06 **** 0.03 **** 
SPCG_0048 
(purF) 0.06 **** 0.04 **** 
SPCG_0049 
(purM) 0.07 **** 0.04 **** 
SPCG_0050 
(purN) 0.08 **** 0.04 **** 
SPCG_0051 
(vanZ) 0.11 **** 0.08 **** 
SPCG_0052 
(purH) 0.13 **** 0.14 **** 
SPCG_0053 
(purD) 0.04 **** 0.09 **** 
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SPCG_0054 
(hypothetical 
protein) 
0.03 **** 0.08 ** 
SPCG_0055 
(purE) 0.04 **** 0.10 **** 
SPCG_0056 
(purK) 0.05 **** 0.14 **** 
SPCG_0057 
(hypothetical 
protein) 
0.41 ** 0.38 * 
SPCG_ 153 
(lipoprotein; 
K02073 D-
methionine 
transport system 
substrate-binding 
protein) 
0.22 **** 0.19 **** 
SPCG_0154 
(hypothetical 
protein) 
0.28 **** 0.28 *** 
SPCG_0300 
(xanthine/uracil 
permease family 
protein) 
0.11 **** 0.01 **** 
SPCG_0301 
(hypothetical 
protein) 
0.12 **** 0.10 **** 
SPCG_0426 
(hypothetical 
protein) 
6.32 **** 2.63 * 
SPCG_0462 
(hypothetical 
protein) 
0.46 ** 0.39 * 
SPCG_0463 
(hypothetical 
protein) 
0.45 ** 0.41 * 
SPCG_0491 
(dnaJ) 2.21 *** 4.51 **** 
SPCG_0551 
(metE) 0.11 **** 0.10 **** 
SPCG_0552 
(metF) 0.11 **** 0.10 **** 
SPCG_0641 
(hypothetical 
protein) 
3.92 *** 4.40 ** 
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SPCG_0642 
(ABC transporter, 
ATP-binding 
protein) 
4.42 * 6.01 * 
SPCG_0841 
(Type I 
restriction-
modification 
system, S subunit) 
0.10 **** 0.15 *** 
SPCG_1073 
(hypothetical 
protein) 
0.16 **** 0.18 **** 
SPCG_1509 
(patB) 0.32 **** 0.33 ** 
SPCG_1510 
(metB) 0.32 **** 0.33 ** 
SPCG_1569 
(oxlT) 0.15 **** 0.20 **** 
SPCG_1689 
(hypothetical 
protein) 
8.34 **** 3.03 ** 
SPCG_1690 
(ABC transporter) 9.29 **** 3.40 *** 
SPCG_1821(xpt) 0.12 **** 0.07 **** 
SPCG_1822 
(xanthine 
permease) 
0.11 **** 0.08 **** 
SPCG_1949 
(hypothetical 
protein)c 
12.40 **** 5.15 **** 
SPCG_1950 
(ABC 
transporter)c 
13.38 **** 5.40 **** 
SPCG_1951 
(immunity protein, 
putative)c 
13.50 **** 5.73 **** 
SPCG_1952 
(hypothetical 
protein) 
19.84 **** 7.75 **** 
SPCG_2152 
(glpF)d 3.78 **** 0.30 ** 
SPCG_2153 
(hypothetical 
protein)d 
3.52 **** 0.28 *** 
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SPCG_2154 
(glpK)d 3.51 **** 0.29 *** 
SPCG_2201 
(comE) 11.80 **** 5.03 **** 
SPCG_2202 
(comD)c 11.46 **** 4.79 **** 
SPCG_2203 
(comC) 12.01 **** 4.54 **** 
a Genes up-regulated greater than 2-fold are highlighted in bold type. 
b  Statistical significance is indicated as follows: *, Padj< 0.05: **, Padj< 0.01; ***, 
Padj< 0.001; ****, Padj< 0.0001 (padj value that corresponds to p-value adjusted for 
multiple testing using Benjamini-Hochberg method in the DESeq analysis software). 
c Common genes in blood isolate ST15/4495 and ST15/4534 differentially expressed 
against the two ear isolates are highlighted in yellow. 
d Common genes in blood isolate ST15/4534 and ST15/4559 differentially expressed 
against the two ear isolates are highlighted in green. 
 
As shown in Table 6.4 below, 3 significantly differentiated genes were found to 
be common in the two ear isolates when compared with blood isolate ST15/4559. 
However, gene expression was not similar in the two ear isolates. Similar to blood isolate 
ST15/4534 the expression of SPCG_2152 (glpF), SPCG_2153 (hypothetical protein) and 
SPCG_2154 (glpK) was observed to be upregulated in ST15/9-47 while the reverse was 
observed in ST15/51742.  
 
 
Table 6.4. Common differentially expressed genes in ear isolates ST15/9-47 and 
ST15/51742 relative to blood isolate ST15/4559. 
 ST15/9-47 VS ST15/4559 ST15/51742 VS ST15/4559 
GENE ID Fold changea 
Statistical 
significance 
(Padj ≤0.05)b 
Fold 
change 
Statistical 
significance (Padj 
≤0.05) 
SPCG_2152 
(glpF)d 2.06 *** 0.16 **** 
SPCG_2153 
(HP)d 2.05 *** 0.16 **** 
SPCG_2154 
(glpK)d 2.02 *** 0.17 **** 
a Genes up-regulated greater than 2-fold change are highlighted in bold type. 
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b  Statistical significance is indicated as follows: *, Padj< 0.05: **, Padj< 0.01; ***, 
Padj< 0.001; ****, Padj< 0.0001 (padj value that corresponds to p-value adjusted for 
multiple testing using Benjamini-Hochberg method in the DESeq analysis software). 
d Common genes in blood isolate ST15/4534 and ST15/4559 differentially expressed 
against the two ear isolates are highlighted in green. 
 
 As results in Tables 6.2-6.4 showed significantly differentially expressed genes, 
which were common to both ear isolates when compared against a single blood isolate, 
further in-parallel grouped comparisons between 2 blood isolates were carried out to 
identify common significantly differentially expressed genes in the blood isolates against 
the two ear isolates. Blood isolates ST15/4495 and ST15/4534 revealed 6 common genes 
differentially expressed against the two ear isolates (highlighted in yellow in Tables 6.2 
and 6.3) while blood isolates ST15/4559 and ST15/4534 revealed 3 common genes 
(highlighted in green in Tables 6.3 and 6.4). No common significantly differentially 
expressed genes were identified in blood isolates ST15/4495 and ST15/4559 when 
compared against each of the two ear isolates. 
 
6.2.1.2  Validation of RNA-Seq data by qRT-PCR 
Independent validation of RNA-Seq data is an important component of 
transcriptomic data analysis in order to verify differential gene expression obtained from 
DESeq. qRT-PCR has been shown in many studies to show strong correlation with RNA-
Seq data (Croucher & Thomson, 2010; Hu et al., 2015; Passalacqua et al., 2009). In this 
study, two genes, nanA and spxB, which have previously been shown to be associated 
with biofilm formation (Blanchette-Cain et al., 2013; Parker et al., 2009) were found to 
be differentially expressed in ear isolate ST15/9-47 relative to blood isolates ST15/4534 
and ST15/4559 by DESeq (refer to Appendix C). These were therefore selected as targets 
for validation of the transcriptomic data obtained from RNA-Seq.  
Bacterial strains from frozen stock were firstly grown in serum broth in triplicates 
to a final OD600 of 0.2 and RNA was extracted using the Qiagen RNAEasy Mini Kit as 
per manufacturer’s instructions (Section 2.14). The quantity and integrity of the RNA 
samples were then determined (Section 2.18). qRT-PCR was performed (Section 2.15) 
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using the designated primers (Section 2.1) and the relative gene expression was analyzed 
using the 2−ΔΔCT method (Livak & Schmittgen, 2001). Quantified gene expression data for 
nanA and spxB obtained from the RNA-Seq analyses were then compared with qRT-PCR 
data (Table 6.5). It can be seen that there was close agreement between the qRT-PCR and 
RNA-Seq data wherein nanA was upregulated in ear isolate ST15/9-47 relative to both 
blood isolates, while spxB was downregulated. 
 
Table 6.5. Validation of RNA-Seq data for nanA and spxB by qRT-PCR.  
Gene 
ST15/9-47 (EAR) VS 
ST15/4559 (BLOOD)a 
ST15/9-47 (EAR)  VS 
ST15/4534 (BLOOD) 
RNA-Seq 
Fold change 
qRT-PCR 
Fold change 
RNA-Seq 
Fold change 
qRT-PCR 
Fold change 
SPCG-1665 
(nanA) 2.4 2.8 2.4 3.8 
SPCG_0679 
(spxB) 0.09 0.3 0.07 0.22 
 
 
6.2.2 Transcriptomic analysis of serotype 3 ST180 and ST232 clinical isolates 
For transcriptomic analysis of serotype 3 strains a total of 4 blood (ST180/15, 
ST232/1) and ear isolates (ST180/2, ST232/11) previously investigated in Chapter 4 were 
selected. Bacterial strains from frozen stock were firstly grown in serum broth in 
triplicates to a final OD600 of 0.2 and RNA was extracted using the Qiagen RNAEasy 
Mini Kit as per the manufacturer’s instructions (Section 2.14). The quantity and integrity 
of the RNA samples were then determined (Section 2.18). RNA samples with a RIN 
integrity of ≥ 8.0 and total yield of  ≥ 3 μg were then sent to the Australian Genome and 
Research Facility (Melbourne) for ribosomal RNA removal using the Illumina Ribo-Zero 
(Bacteria) kit, cDNA library preparation and RNA-Sequencing using the Illumina Hi-Seq 
sequencing platform. The number of reads produced for each of the blood (ST180/15, 
ST232/1) and ear (ST180/2 and ST232/11) isolates were 28,027,131, 29,125,338, 
27,193,077 and 27,916,214, respectively.  
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Differential gene expression analysis between the transcriptomes of blood and ear 
isolates was carried out by firstly aligning the sequenced reads against the serotype 3 
ST180 SPNOXC141 (NC_017592.1) (Donati et al., 2010) reference genome made 
publicly available on KEGG (http://www.genome.jp/dbget-bin/www_bget?gn:spw) using 
Bowtie2 (v2.0.0.0-beta6) (Langmead & Salzberg 2012). SAMtools (v 0.0.18) (Li et al., 
2009) and BEDTools (v2.24.0) (Quinlan & Hall 2010) were then used to obtain read 
counts for each gene. Differential analysis of the transcriptomes generated from 
BEDTools were then carried out using the R/Bioconductor based DESeq     
(http://bioconductor.org/packages/release/bioc/html/DESeq.html) software (v.3.2) 
(Anders & Huber 2010). The basic local alignment search tool (BLAST) (Altschul et al., 
1990) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database resource was 
used as appropriate.  
Ear and blood isolates from ST180 and ST232 were selected to carry out 
comparison of blood and ear transcriptomes from the same sequence type as previously 
done for serotype 14 ST15 isolates. However, visualisation of transcripts by the Artemis 
genome viewer (v 16.0.11) (Carver et al., 2012) revealed contamination of the ST180/2 
transcriptome with another unrelated strain. As ST180/2 was found to be unusable for 
analysis, only ear isolate ST232/11 was subsequently used for comparison with the blood 
isolates ST180/15 and ST232/1. 
Analysis of the ear isolate ST232/11 revealed 67 significantly differentially 
expressed genes when compared with blood isolate ST180/15 (refer Appendix D). and 7 
genes relative to blood isolate ST232/1 (refer Appendix E). As shown in Table 6.6, 6 
genes were found to be commonly upregulated in blood isolates ST232/1 and 180/15 
relative to the ear isolate ST232/11.  
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Table 6.6. Genes commonly differentially expressed in blood isolates ST232/1 and 
180/15 relative to ear isolate ST232/11. 
GENE ID ST232/11 (ear) vs ST232/1 (blood) 
ST232/11 (ear) vs ST180/15 
(blood) 
 Fold change 
Statistical 
significancea Fold change 
Statistical 
significance 
SPNOXC15940 
(trpA) 93.56 ** 7.92 *** 
SPNOXC15950 
(trpB) 90.75 ** 8.17 *** 
SPNOXC15960 
(trpF) 91.32 ** 9.05 ** 
SPNOXC15970 
(trpC) 101.20 ** 6.73 ** 
SPNOXC15980 
(trpD) 125.83 ** 11.05 **** 
SPNOXC15990 
(trpG) 193.26 ** 10.20 ** 
a  Statistical significance is indicated as follows: *, Padj < 0.05: **, Padj < 0.01; ***, 
Padj < 0.001; ****, Padj < 0.0001 (Padj = P value adjusted for multiple testing using 
Benjamini-Hochberg method in the DESeq analysis software). 
 
6.2.2.1 RNA-Seq data validation of ST180 and ST232 isolates by RT-PCR 
In order to validate the results obtained by RNA-Seq, qRT-PCR of 2 genes trpF and trpG 
from the common differentially expressed genes for blood isolates ST180/15 and 
ST232/1 against ear isolate ST232/11 (Section 2.14). qRT-PCR was performed (Section 
2.15) using appropriate primers (Section 2.1) and the relative gene expression was 
analyzed using the 2−ΔΔCT method (Livak & Schmittgen, 2001). qRT-PCR results (Table 
6.7) were then compared with RNA-Seq data (Table 6.6). However, in marked contrast to 
the RNA-Seq data, qRT-PCR analysis indicated that expression of trpF and trpG was not 
significantly different in the ear isolate relative to either of the blood isolates. Possible 
reasons for this stark discrepancy will be discussed further in Section 6.3.  
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Table 6.7. qRT-PCR validation of RNA-Seq data for trpF and trpG.  
Gene qPCR fold change qPCR fold change 
 ST232/11 vs ST232/1
 ST232/11 vs ST180/15 
SPNOXC15960 (trpF) 0.82 0.78 
SPNOXC15990 (trpG) 1.04 1.13 
 
 
6.3 Discussion 
The extreme diversity of the pneumococcus as a species has resulted in markedly 
variable capacities of a given strain to cause either localised or invasive disease. 
Molecular determinants of this variation are still poorly understood. In Chapters 4 and 5, 
distinct virulence phenotypes that correlated with isolate source were consistently 
exhibited in mice after IN challenge with ST-matched (i.e. clonally-related) serotype 3 
and 14 blood and ear isolates, suggesting stable niche adaptation by these strains. 
Transcriptomic analyses in this Chapter aimed to identify bacterial determinants which 
might contribute to these distinct virulence profiles.  
 RNA-seq analysis revealed substantial transcriptomic variation within a clonal 
lineage, as evidenced by the total number of differentially expressed genes observed 
between individual isolates of serotype 14 ST15. Somewhat unexpectedly, there was a 
similar number of differentially expressed genes whether comparisons were being made 
between ST-matched isolates from the same niche (i.e. ear vs ear; blood vs blood) or from 
different niches (ear vs blood). For the four strain-strain comparisons from the same 
niche, the number of differentially expressed genes ranged from 77 to 103 (mean 93), 
while for the six cross-niche comparisons, the range was 52-125 (mean 86) (Table 6.1). 
Thus, identification of transcriptional differences that might be associated with distinct 
virulence phenotypes is complicated by a high background of unrelated interstrain 
transcriptional variation.   
 To minimise the impact of the above variability, transcriptomic comparisons were 
made between the two ear isolates ST15/9-47 and ST15/51742 and each of the blood 
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isolates ST15/4495 and ST15/4534 to identify common differentially expressed genes 
(Tables 6.2 and 6.3). This identified 51 and 45 differentially expressed genes common to 
both ear isolates relative to ST15/4495 and ST15/4534, respectively.  
However, of these, only 6 genes were differentially expressed in both ear isolates 
relative to both blood isolates. These 6 genes were all upregulated in the ear isolates and 
included competence genes comA, comB and comD. These genes are important 
components of the competence regulon, which mediates horizontal gene transfer that 
drives pneumococcal genome plasticity. Other competence-related genes, notably comC, 
comE and comX1, were also significantly upregulated in both ear isolates relative to 
either of the two blood isolates.  The competence genes have been increasingly linked 
with virulence in recent years. For example, a study by Lau et al. (2001) reported that the 
ability of S. pneumoniae to cause pneumonia and bacteraemia in mice is attenuated in 
comB and comD mutants. ComB, and ComA are components of the ABC transporter 
required for the export of CSP (the competence stimulating peptide encoded by comC), 
while comD and comE respectively encode the histidine kinase and response regulator of 
the two-component signal transduction system that senses and responds to extracellular 
CSP.  
Several other recent studies have also confirmed the role of competence in 
increasing virulence of pneumococci (Ibrahim et al., 2004; Lin et al., 2016; Zhu et al., 
2015). Zhu et al. (2015) demonstrated the importance of 14 of the ComX-regulated late 
competence genes in virulence, as deletion of these genes attenuated pneumococcal 
fitness during host infection to the same level in both wild-type and ComX-null genetic 
backgrounds; suggesting that the constitutive baseline expression of these genes was 
important for bacterial fitness (Zhu et al., 2015). Ibrahim et al. (2004) also demonstrated 
the importance of the CiaR/H two-component system, involved in regulating 
pneumococcal virulence and competence; deletion of CiaR caused pneumococcal strains 
to become much less virulent in mouse models, less able to grow at higher temperatures, 
and more sensitive to oxidative stress. The expression of the CiaR/H-regulated HtrA, 
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implicated in the ability of the pneumococcus to colonize the nasopharynx of infant rats, 
was also reduced in a ciaR-null mutant (Ibrahim et al., 2004). 
 It is notable, however, that in the present study, higher com regulon expression 
was observed in the two ear isolates relative to the blood isolates ST15/4495 and 
ST15/4534, even though the latter were better able to cause lung infection in the mouse 
model. It should, of course, be remembered that in the present study, even the blood 
isolates are still expressing com genes, albeit to a lesser extent than the ear isolates, 
whereas the various com mutants described in previous studies would lack the respective 
transcripts altogether. A further complicating factor is that when the transcriptomes of the 
two ST15 ear isolates were compared with the third ST15 blood isolate (ST15/4559), no 
com genes were differentially expressed. Thus, differences in expression of this regulon 
cannot account for the distinct virulence profiles of ST15 blood and ear isolates. 
Moreover, it remains a possibility that the observed differences in com expression were 
fortuitous, and related to slight variations in growth phase (com expression is influenced 
by cell density, i.e. quorum sensing (Cvitkovitch et al., 2003)) at the time of RNA 
extraction for the various strains.  
Three more genes found to be commonly differentially exressed in blood isolates 
ST15/4495 and ST15/4534 relative to the two ear isolates are SPCG_1949, SPCG_1950 
and SPCG_1951. SPCG_1949 and SPCG_1951 are hypothetical and putative proteins 
with unknown functions, while SPCG_1950, is identified as an ABC transporter (ATP 
binding protein). ABC transporters are an important class of transmembrane transporters 
involved in the import and export of a wide variety of substrates, and many of these 
systems contribute to pneumococcal virulence as demonstrated in various studies 
(Kadioglu et al., 2008; Lau et al., 2001; Whalan et al., 2006). Nonetheless, the expression 
of SPCG_1950 was not found to be significantly different in the blood isolate ST15/4559 
when compared against the two ear isolates. 
The differential expression of SPCG_2152 (glpF), SPCG_2153 (hypothetical 
protein) and SPCG_2154 (glpK) was also seen in blood isolates ST15/4559 and 
ST15/4534 relative to the ear isolates.   Glycerol uptake facilitator protein (glpF) and 
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glycerol kinase (glpK) are involved as transporters in pneumococcal glycerol uptake. 
glpF has also been implicated in pneumococcal opacity variation (Saluja & Weiser 1995). 
However, the expression of glpO (glycerol oxidase), an important virulence factor 
preferentially expressed during meningitis in a mouse model (Mahdi et al., 2012), was 
not significantly upregulated in the ear isolates. This was rather surprising, as the ability 
to cause meningitis was exclusively observed in the ST15 ear isolates, as shown in 
Chapter 5 (Figure 5.3).    
Transcriptomic analysis of serotype 3 isolates revealed a high number of 
differentially expressed genes between ear isolate ST232/11 and blood isolate ST180/15. 
In contrast, only 7 genes were differentially expressed between ear isolate ST232/11 and 
blood isolate ST232/1 (see Appendix E). Interestingly, the 6 genes that were significantly 
upregulated in the ear isolate ST232/11 compared to both blood isolates ST232/1 and 
ST180/15 were all from a single operon: the tryptophan biosynthesis pathway genes trpA, 
trpB, trpC, trpD, trpF and trpG. However, it remains to be determined whether this 
differential expression of the trp operon directly contributes to the distinct virulence 
profiles of the serotype 3 ear and blood isolates.   
Although qRT-PCR was able to validate RNA-Seq differential gene expression 
analysis (DEG) of the ST15 isolates, the same was not observed for serotype 3 isolates. 
qRT-PCR analysis did not detect any significant differential expression of trpF or trpG 
between the ear isolate ST232/11 and either of the blood isolates ST232/1 or ST180/15, 
compared with approximately 94-fold and 8-fold upregulation respectively as determined 
by RNAseq analysis. One possible explanation is that the trp operon is known to be 
repressed whenever tryptophan is present in the environment (Merino et al., 2008). Thus, 
since RNAseq and qRT-PCR analyses were conducted on RNA extracted from bacterial 
cultures grown on different occasions, using different batches of serum broth as the 
growth medium, slight differences in residual tryptophan concentration in the medium at 
the time of harvest could have impacted the findings. This might also account for the 
roughly 10-fold differences in relative expression of the various trp genes observed 
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between the two blood isolates observed by RNAseq analysis (Table 6.6).  
The transcriptomic analyses of both serotype 3 and serotype 14 isolates described 
in this Chapter failed to detect any genes that were consistently differentially expressed 
between the blood and ear isolates of a given ST. This is in spite of the consistent 
differences in virulence profiles observed in mice between serotype- and ST-matched 
blood and ear isolates. A probable explanation for these seemingly discordant findings 
could be that relative expression of key virulence-related genes in vivo may be markedly 
different from that observed in in vitro cultures from which the bacterial RNA was 
extracted in the present study. Indeed, several previous studies from this laboratory have 
shown differential virulence gene expression patterns between in vitro batch culture and 
in vivo derived RNA extracts, but also between bacterial RNA extracts from distinct host 
niches (e.g. nasopharynx vs blood vs brain) (Harvey et al., 2011; Mahdi et al., 2008; 
Ogunniyi et al., 2009). These studies employed either qRT-PCR analysis of known 
virulence-related genes, or transcriptomic microarray analysis, which lacks the resolving 
power of more modern RNAseq approaches. Clearly, comparative transcriptomic 
analyses of the various serotype/ST-matched ear and blood isolates using RNA extracted 
from infected mouse tissues may provide a more meaningful indication of differential 
virulence gene expression patterns. However, the purity of bacterial RNA required for 
RNAseq analyses is somewhat greater than that needed for microarray studies. In the 
present study, total bacterial numbers in several of the key host niches under investigation 
were very low at critical times (particularly the first 24 h) of the disease process (<103-104 
CFU per mouse in some niches [e.g. see Fig. 4.8 and 5.3]). To date, bacterial RNA yields 
in extracts from these samples have not been sufficient for RNAseq analysis.  
As mentioned previously, Manso et al., (2014) have identified a type I restriction-
modification (RM) system (SpnIII) in S. pneumoniae strain D39, which can 
spontaneously rearrange to generate six SpnIII variants with distinct genomic methylation 
patterns (Manso et al., 2014). Each SpnD39III variant exhibited distinct virulence profiles 
in experimental infection and there was evidence of in vivo selection for switching 
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between SpnD39III variants. Importantly, while the relative frequencies of the six alleles 
in a given culture was relatively stable during in vitro culture, the proportions varied 
significantly upon injection into mice. This finding suggests that regulation of virulence 
by epigenetic switching occurs in vivo. Whether such epigenetic switching contributes to 
the distinct virulence profiles of the serotype/ST-matched ear and blood isolates studied 
here is uncertain. Manso et al. described a PCR-amplification/restriction fragment assay 
for accurate quantitation of SpnIII allele frequencies. This technique could be used in 
future studies to determine whether there are differences in these frequencies between the 
various paired isolates, using DNA extracted from both in vitro and in vivo cultures. The 
fact that the first step of the assay involves PCR amplification of a region of DNA 
spanning the spnIII locus should enable accurate data to be obtained even when bacterial 
CFU counts in a given tissue are very low.   
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Chapter 7: Final Discussion 
 
7.1 Introduction 
S. pneumoniae is a preeminent human respiratory pathogen responsible for 
massive global morbidity and mortality. Its ability to survive in, and adapt to, distinct 
ecological niches within the human host results in capacity to cause a wide spectrum of 
invasive and localized infections. Its extremely diverse and plastic genome makes the 
pneumococcus highly adaptable to various selective pressures (Chaguza et al., 2015). S. 
pneumoniae strains differ markedly in their capacity to cause either invasive or localized 
infections, and both serotype and genetic background influence virulence profile 
(Blomberg et al., 2009; Sandgren et al., 2005). The existence of over 93 CPS serotypes 
superimposed on over 5000 clonal lineages is a reflection of species diversity which 
underlies profound differences in disease potential. Due to this diversity, attempts to 
associate a given clonal lineage or serotype with propensity to cause disease are 
problematic. More importantly, these marked variations have frustrated attempts to 
identify specific molecular determinants of the distinct virulence phenotypes.  
Formation of biofilms is an important step in pneumococcal pathogenesis, as they 
serve as reservoirs of infection and organisms within biofilms are resistant to 
antimicrobials and host immune defences. Biofilms also significantly impact on 
pneumococcal genetic diversity, as this environment favours horizontal gene transfer 
between cells (Marks et al., 2012) and biofilm formation capacity has also been found to 
vary among clinical isolates (Moscoso et al., 2009; Allegrucci et al., 2006; Tapiainen et 
al., 2010). This study initially examined the influence of three parameters, namely isolate 
source, pH and Fe(III) supplementation, on the formation of biofilms by a group of 
clinical isolates (Section 3.2). Previous studies have identified multiple molecular 
determinants of biofilm formation in clinical isolates (Tapiainen et al., 2010; Trappetti et 
al., 2011). However, this is the first study which has explored the association between 
clinical isolate source, biofilm formation capacity and virulence phenotype. This study 
focused on blood and ear isolates (from cases of sepsis and OM, respectively), as the 
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strain collection available to us had greater numbers of isolates from these sources rather 
than, for example, from CSF, ensuring a wide selection of serotypes and STs.  
7.1.1 Biofilm formation of blood and ear clinical isolates of serotypes/serogroups 3, 
6, 9, 14 and 19. 
 The initial assessment of  blood and ear clinical isolates of serotypes/serogroups 3, 
6, 9, 14 and 19 revealed profound inconsistencies in the influence of Fe(III), pH and 
isolate type on biofilm formation capacity. However after MLST typing, distinct biofilm 
phenotypes were identified between blood and ear isolates belonging to the same 
serotype/group and ST type. The suppressive effect of Fe(III) in biofilm formation when 
the strains were grown at pH 6.8 was also demonstrated. Additionally, the importance of 
LuxS and Fe(III) for biofilm formation capacity previously reported by Trappetti et al. 
(2011) also held true in this study.  
 
7.1.2. Influence of clinical isolate source on virulence profiles of ST-matched 
serotype 3 and 14 isolates. 
 The stark differences in phenotypes observed between serotype 3 blood and ear 
isolates with respect to physiological conditions for optimal biofilm formation prompted 
questions as to whether the influence of source of clinical isolate might also be reflected 
in virulence phenotype. ST typing carried out in Chapter 3 allowed the selection of 
representative clonally related (ST-matched) blood and ear isolates from serotype 3 
(ST180, ST233 and ST232) and serotype 14 (ST15 and ST130) for investigation of the 
influence of isolate source on virulence phenotype in Chapters 4 and 5.  
 Further in vivo investigations on blood and ear isolates belonging to serotype 3 
ST180, ST232, and ST233, and serotype 14 ST15 revealed distinct pathogenic profiles. 
None of the blood isolates were found in the ear compartment after intranasal challenge, 
whereas the ear isolates were never recovered from the lung tissue at 24 h post infection. 
This showed a consistently stark distinction in virulence profiles in vivo, which clearly 
demonstrated the adaptation of the strains to their respective niches. This was further 
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supported by the exclusive detection of only serotype 14 ST15 ear isolates being 
recovered from the brain tissue over the time of the experiments.  However, the in vivo 
co-infection experiment with ST15 isolates showed that ear isolates could also persist in 
the lungs when co-infected with the blood isolate. This suggested the possibilities of  
differential host immune responses to ear versus blood isolates, or the secretion of a 
virulence factor by the blood isolate that enabled the survival of the ear isolate over the 
course of the experiment.  
 
7.1.3.  Early lung immune response of mice to infection with blood and ear isolates. 
 The investigation of early immune response in the lungs of mice challenged by 
blood and ear isolates (Section 5.2.6), revealed an unsurprising induction of 35 pro-
inflammatory genes in response to pneumococcal infection. However, strain-specific 
differences in gene expression were also observed, with 8 genes showing significant 
differential expression in lung tissue following challenge with blood isolate ST15/4495 
compared to that in mice challenged with ear isolate ST15/9-47. Six genes showed a 
significantly greater degree of upregulation following challenge with the blood isolate. 
Two more genes, Apcs and Il2, were found to be up-regulated only following challenge 
with the ear isolate.  These findings provided insight into how the host immune response 
may vary from strain to strain, resulting in distinct patterns of infection from two closely 
related strains. 
 
7.1.4.  Transcriptomic analysis of blood and ear isolate in vitro. 
 The consistent differences in pathogenic profiles of pneumococcal strains within a 
clonal lineage seen in Chapters 4 and 5 was consistent with stable niche adaptation by 
these strains in accordance with their original site of isolation. This suggested the 
existence of fundamental genomic, methylomic, transcriptomic, proteomic or 
metabolomic differences between clonally-related blood and ear isolates, which allows 
them to adapt and survive in distinct host niches. A comprehensive combined “omics” 
analysis of the various strains, preferably using in vivo-derived samples, would be 
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required to identify the underlying molecular basis for our observations. This is a major 
and costly undertaking, well beyond the scope of this thesis. Nevertheless, available 
resources were sufficient to commence transcriptomic analysis of the ST180, ST232 and 
ST15 strains using RNA-Sequencing.   
Despite the observed differences in virulence profiles between serotype- and ST-
matched blood and ear isolates, the transcriptomic analyses of both serotype 3 and 
serotype 14 isolates did not identify any genes that were consistently differentially 
expressed between the blood and ear isolates of a given ST. A probable explanation is 
that there may be differences in expression patterns of key virulence-related genes even 
between bacteria growing in different in vivo niches, let alone between in vivo niches and 
the in vitro cultures from which the bacterial RNA was extracted in the present study. 
Thus, future studies need to be focused on examining patterns of gene transcription in in 
vivo-derived bacterial RNA samples. 
Concluding remarks and future directions 
The findings of this study constitute a significant paradigm shift, in that we have 
found multiple examples of clonally-related strains that consistently and reproducibly 
exhibit distinct virulence phenotypes in mice that directly correlate with the original site 
of isolation from human patients (in this case, ear vs blood). Thus, strains within a clonal 
lineage can exhibit stable niche adaptation. Moreover, our data suggest differential 
capacity to trigger early host innate immune responses may, at least in part, underpin this 
adaptation and influence the course of disease. These findings provide a robust platform 
for future studies aimed at identifying critical bacterial and host determinants of 
pneumococcal virulence phenotype. Specific questions that can be addressed in these 
studies include the following:- 
• What bacterial features (genomic, methylomic, transcriptomic, proteomic or 
metabolomic) determine virulence/pathogenic phenotype? 
Comprehensive comparative “omics” analyses of the type 3 strains ST180/2 and 
ST180/15, and type 14 strains ST15/9-47 and ST15/4559 are currently in progress as part 
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of a nation-wide collaborative study. This will provide a comprehensive list of candidate 
genes/proteins/pathways whose level of expression or activity is associated with virulence 
phenotype. The contribution of individual components could then be tested, for example 
by mutagenesis or manipulation of expression of a candidate gene, and determining the 
impact on pathogenic profile of ear or blood isolates. Techniques for construction and 
analysis of in-frame deletion mutants of S. pneumoniae, or strains over-expressing genes 
as a consequence of ectopic expression from multi-copy plasmids, are well established in 
this laboratory. Alternatively, the course of disease induced by challenge with ear vs 
blood isolates could be followed in mice that have been immunized against one or more 
candidate proteins.   
• Which host factors/responses have the greatest influence on disease course? 
Studies in Chapter 5 identified several host genes which were differentially induced in 
mice during the early stages of infection with serotype- and ST-matched blood vs ear 
isolates. These factors can now be targeted to determine their individual contribution to 
disease progression. Experiments could include in vivo blockade by administration of 
appropriate factor-specific neutralizing monoclonal antibodies immediately before and 
after challenge with the respective strains, and determining the impact on disease 
progression. Alternatively, the pathogenic profile of ear and blood isolates could be 
compared in wild type vs gene knock-out mice (e.g. Icam-1-/-, Ifn-β1-/- and IfnAR1-/- mice 
are available in the C57BL/6 background).  
Management of pneumococcal disease is being hampered by increasing rates of 
antibiotic resistance and the limited serotype coverage and other shortcomings of existing 
vaccines. Future studies such as those outlined above, will provide important new 
information on the molecular basis for the range of pathogenic phenotypes displayed by 
S. pneumoniae strains. This will inform future development of novel vaccines capable of 
protecting against the full spectrum of pneumococcal infections, and identification of 
novel bacterial and host targets for therapeutic intervention. 
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APPENDIX C 
 
Significantly differentiated genes identified by DESeq analysis of ST15/947 ear 
isolate against blood isolates ST15/4559 and ST15/4534. 
 
Blood 
Isolate 
Gene 
Name 
Gene ID log2FoldChange     pval         padj 
ST15/4559 spxB SPCG_0679 -3.39 1.08E-46 2.35E-43 
 nanA SPCG_1665 1.26 1.12E-06 7.14E-05 
      
ST15/4534 spxB SPCG_0679 -3.66 4.05E-35 1.46E-32 
 nanA SPCG_1665 1.26 7.12E-05 0.0016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
217 
 
 
APPENDIX D  
 
67 significantly differentiated genes identified by DESeq analysis of ST 232/11 ear 
isolate against blood isolate ST180/15. 
 
 
 
Gene 
ID 
baseMean foldChange log2Fold 
Change 
pval padj 
1 18 6228.650114 0.0000854 -13.51534761 3.03E-23 5.69E-20 
2 19 3641.708552 0.00014608 -12.74095601 2.22E-16 1.39E-13 
3 20 1723.592906 0.000308696 -11.66152506 2.89E-09 0.000000905 
4 21 1299.580926 0 NA 6.54E-08 0.0000112 
5 27 1256.8718 0.000423374 -11.20577811 0.000000375 0.0000504 
6 42 1178.379932 0.000451588 -11.11270469 0.000000886 0.0000925 
7 44 791.9688466 0 NA 0.0000269 0.001684408 
8 46 783.0386341 0 NA 0.0000301 0.001765716 
9 54 1064.105323 0 NA 0.000000987 0.0000976 
10 56 1436.069843 0.001112398 -9.812110735 0.00000026 0.0000407 
11 125 6665.375848 5.686144864 2.507450855 0.001107587 0.034117299 
12 150 13983.98134 0.245080505 -2.028672364 0.001624346 0.045554426 
13 169 58105.26845 7.170871695 2.842148504 0.000000675 0.0000746 
14 207 6154.970899 0.15929277 -2.650247312 0.000792862 0.027087033 
15 279 44051.12444 5.573863105 2.47867757 0.0000155 0.001076942 
16 362 45510.01627 11.28463811 3.496288248 4.83E-09 0.00000113 
17 421 8392.212622 0.15598515 -2.68051941 0.000245293 0.009686162 
18 426 670.9535251 0.00318111 -8.296253935 0.001074907 0.033662492 
19 427 500.5619119 0 NA 0.001149558 0.034839011 
20 428 906.8372489 0.001762741 -9.147963476 0.0000609 0.003177756 
21 430 932.1559618 0.001142534 -9.773547154 0.0000281 0.001702636 
22 436 5615.285517 0.0000947 -13.365774 7.98E-22 7.49E-19 
23 448 2145.006433 0.063559746 -3.975742838 0.000922387 0.030915679 
24 477 1818.438305 0.013338292 -6.22828228 0.0000134 0.000969648 
25 518 6340.299349 6.621286774 2.727111616 0.000520374 0.019172213 
26 561 5501.730843 6.225636876 2.638221431 0.00120449 0.035924402 
27 662 652.8455359 0 NA 0.000156945 0.006702249 
28 688 12228.81068 4.374535624 2.129129877 0.001289841 0.03672138 
29 730 968.6930521 0 NA 0.00000308 0.000262891 
30 731 1705.732481 0.000311929 -11.64649273 3.46E-09 0.000000928 
31 732 680.5761958 0 NA 0.000109961 0.00480505 
32 873 894.9012961 0 NA 0.00000754 0.000589969 
33 874 617.594697 0 NA 0.000247438 0.009686162 
34 875 555.1451005 0.000959051 -10.02610513 0.001245053 0.036553977 
35 886 541.452885 0 NA 0.00066926 0.024183444 
36 895 7695.491882 5.433397777 2.44185467 0.000956964 0.031002339 
37 913 4369.160419 7.599319868 2.925870304 0.000937836 0.030915679 
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38 952 11337.73164 0.152906334 -2.709279925 0.0000786 0.003989468 
39 953 16969.1098 0.118070972 -3.082273775 0.00000214 0.000191102 
40 954 9726.296282 0.123012696 -3.023120875 0.000025 0.00162191 
41 955 8945.271328 0.131310662 -2.928944031 0.000057 0.003061955 
42 956 9293.287758 0.141664192 -2.819452958 0.0000866 0.004284108 
43 975 7434.85257 0.112722201 -3.149156405 0.0000408 0.002324363 
44 976 5793.438074 0.151010426 -2.727279936 0.000712814 0.0248051 
45 1048 4291.785365 0.113430182 -3.140123527 0.000468413 0.017602944 
46 1068 2207.828209 0.000723272 -10.43317361 1.95E-10 7.32E-08 
47 1163 17347.32352 4.962571993 2.311088032 0.000235023 0.009600162 
48 1164 13724.28108 4.590638169 2.198694724 0.000712866 0.0248051 
49 1379 5585.036336 0.062859861 -3.991717098 0.00000355 0.000290111 
50 1380 3682.609516 0.073161613 -3.772769304 0.000102902 0.004603632 
51 1459 13555.36806 7.917910418 2.985119745 0.00000876 0.000658529 
52 1460 19093.50874 8.172165258 3.030718379 0.00000203 0.000190561 
53 1461 8500.687096 9.053439622 3.178466011 0.0000194 0.001303794 
54 1462 8135.227103 6.733950818 2.751453184 0.00019446 0.008119777 
55 1463 14125.02924 11.04510562 3.46533531 0.000000359 0.0000504 
56 1464 5894.369888 10.19724472 3.350107485 0.0000473 0.002612199 
57 1465 11716.58411 11.43307188 3.515141179 0.000000635 0.0000746 
58 1636 290759.1824 4.189083986 2.066634809 0.0000981 0.004494175 
59 1663 229336.2727 4.245064977 2.085786636 0.0000899 0.004331528 
60 1677 18528.09069 11.72861848 3.551961183 6.01E-08 0.0000112 
61 1739 6003.419977 0.111366051 -3.166618586 0.0000976 0.004494175 
62 1784 24034.28075 0.23432342 -2.093426941 0.000458937 0.017598829 
63 1795 12835.97118 4.324610465 2.112570189 0.001266048 0.036598538 
64 1799 37594.80616 22.49795704 4.491722096 1.45E-12 6.83E-10 
65 1818 2996.276481 0.017705082 -5.819692642 0.000000439 0.0000549 
66 1819 4767.765706 0.022471621 -5.475752 1.59E-08 0.00000332 
67 1820 2820.632316 0.090929384 -3.459109617 0.001025532 0.032660584 
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APPENDIX E 
 
7 significantly differentiated genes identified by DESeq analysis of ST232/11 ear 
isolate against blood isolate ST232/1. 
 
 
 Gene ID baseMean foldChange log2FoldChange pval padj 
1 1458(15930) 12014.663 72.168 6.173 5.68E-05 0.015 
2 1459(15940) 16929.487 93.576 6.548 2.64E-05 0.009 
3 1460(15950) 7620.592 90.750 6.504 3.02E-05 0.009 
4 1461(15960) 7050.898 91.319 6.513 2.98E-05 0.009 
5 1462(15970) 12879.388 101.202 6.661 2.13E-05 0.009 
6 1463(15980) 5327.498 125.826 6.975 1.23E-05 0.009 
7 1464(15990) 10663.586 193.256 7.594 3.30E-06 0.006 
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